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Two classes of fluorinated derivatives were synthesized in this work to test the effects of the 
fluorinated drugs in antibacterial, antioxidant and anti-platelet activity.  These two classes 
were the 2-styrylchromones and the 2-thioimidazoles.  The 2-styrylchromones were tested for 
their antibacterial activity and the 3-hydroxypentadien-1one intermediates were tested for 
their antioxidant activity.  The 2-thioimidazoles were tested for the ability to inhibit platelet 
aggregation in vitro. 
 
A total of ten 2-styrylchromones together with their intermediates were synthesized of which 
six were new(A5a-A5f).  The two intermediates to each of the six compounds were also new 
and together with the 2-styrylchromones resulted in thirty compounds being synthesised and 
characterised.  The synthesis was based on the Baker-Venkataraman rearrangement using 
substituted cinnamic acids and hydroxyacetophenones.All the 2-styrylchromones were 
screened for their antibacterial activity using Gram-positive bacteria (Staphylococcus 
aureus,scuii and xylosus and Bacillussubtilis) and Gram-negative bacteria (Escherichia coli, 
Pseudomonas aeruginosaand Klebsiella pneumonia).  The compounds were most effective 
against B. subtilis followed by S. aureus and a single strain of E. coli (ATCC 25922).  
Difluorination on the phenyl ring was shown to enhance antibacterial activity and fluorine 
substitution at the 6-position was shown to be far superior to substitution at the 7-position.  In 
comparison to tetracycline, the activity indices of the fluorinated styrylchromones ranged 
from 0.50 to 0.75 against B. subtilis. 
 
The fluoro and methoxy analogues of (2Z, 4E)-3-hydroxy-1-(2-hydroxyphenyl)-5-(phenyl) 
penta-2, 4-dien-1-one, the intermediates to the 2-styrylchromones were tested for their ability 
to act as antioxidants since they contained a 3-hydroxy group in the backbone of their 
iv 
 
structure.   They were screened by the 2, 2-diphenyl-1-pycryl-hydrazyl (DPPH) radical 
scavenging assay and Ferric Reducing Power assay (FRAP).All the methoxylated analogues 
showedbetter activity thanthe fluorinated analogues and comparable to that of ascorbic acid. 
 
Seven fluorinated derivatives of diethyl-2-(benzylthio)-2,3-dihydro-1H-imidazole-4,5-
dicarboxylate (B6a-B6g) as well as a nitro and chloro derivative (B6h-B6i) also known as 2-
thiomidazole derivativeswere prepared in five steps from glycine, ethyl formate, diethyl 
oxalate, potassium thiocyanate and substituted benzyl bromides.  The synthesized compounds 
exhibited concentration dependent anti-platelet aggregation activity on both the thrombin and 
ADP induced platelet aggregation. The 4-nitro and 4-fluoro compounds exhibited the highest 
activity from the compounds tested, with estimatedIC50 values of 1.05 and 0.99 mM for the 
thrombin-induced and ADP-induced platelet aggregation respectively.  Three of the 
compounds, the 3,4-difluoro(B6c), 4-nitro(B6h) and 3-chloro(B6i) derivatives have 
reasonable activity in both of the assays and could have potential as broad spectrum 
antiplatelet inhibitors.  With the exception of B6c, the fluoro derivatives were not as active as 
the nitro and chloro compounds. 
 
All the reactions in this work were monitored by 1H and 13C NMR at each step and all 
compounds were characterized using 1D and 2D NMR as well as MS, IR and UV data.  All 
the synthesised compounds were fully characterised unambiguously and the respective 
carbon and proton resonances were assigned with the aid of HSQC, HMBC and NOESY 
data.  In addition, crystal structures of two 2-styrylchromones and three of its cinnamate ester 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































13C NMR  (C-13) nuclear magnetic resonance spectroscopy 
1H NMR  proton (H-1) nuclear magnetic resonance spectroscopy 
19F NMR         fluorine-19 (F-19) nuclear magnetic resonance spectroscopy 
Ac  acetate 
EtOH  ethanol 
MeOH  methanol 
aq  aqueous 
br  broad  
c  concentration 
cc  column chromatography 
CD3OD deuterated methanol 
CDCl3  deuterated chloroform 
DMSO-d6 deuterated dimethyl sulfoxide 
D2O  deuterated water 
COSY  correlated spectroscopy 
d  doublet 
dd  double of doublets 
DEPT   distortionless enhancement by polarization transfer 
DNA  deoxyribonucleic acid 
DNP  dictionary of natural products 
EIMS   electron impact mass spectroscopy 
HMBC heteronuclear multiple bond coherence 
HPLC  high pressure liquid chromatography 
HREIMS high resolution electron impact mass spectroscopy 
HSQC  heteronuclear single quantum coherence 
Hz  hertz 
IR  infrared 
m  multiplet 
Me  methyl 
Mp  melting point 
MS  mass spectroscopy 
x 
 
NOESY nuclear overhauser effect spectroscopy 
RSA   radical scavenging activity 
s  singlet 
t  triplet 
td             triplet of doublets 
TCA  trichloroacetic acid 
TGI  total growth inhibition 
TLC  thin layer chromatography 
UV  ultraviolet 
MIC  minimum inhibitory concentration 
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Chapter 1. Introduction 
1.1. An introduction to Fluorine pharmaceuticals 
Fluoride is relatively abundant (0.065%) in the earth’s crust and the most abundant of all the 
halogens. It was first isolated in 1886 by the French chemist Henry Moissan, which earned 
him the Nobel Prize in 1906. The importance of fluorinated organic molecules has grown 
over the last 50 years, particularly in the pharmaceutical and agrochemical 
industries(Sandford et al., 2000; Key et al., 1997), highlighting the active nature of research 
in this particular area.  Fluorine has unique properties since it is a very small atom with a high 
electronegativity and low polarisability (Sasaki et al., 2004; 2010).  The presence of one (or 
more) fluorine atom(s) in place of hydrogen in anorganic compound confers upon 
themproperties and reactivity which are significantly different from those of the 
hydrogenated compound because the length of the C-F bond is almost the same as the length 
of the C-H bond (1.39 and 1.09 Årespectively). 
 
The fluorinated analogues have three lone pairs around the fluorine substituent and combined 
with its high electronegativity, makes fluorinated analogues more reactive than the non-
fluorinated compounds.  Biologically important compounds in which the hydrogen or oxygen 
in C–H or C–O bonds have been replaced with fluorine haveresulted in molecules with 
special advantages. For example, fluorination increases the activity and selectivity of 
cortisone and fluorination in pyrimidines like 5-fluorouracil is effective in the treatment of 
cancer (Kirk et al., 2006). 
 
Prior to the synthesis of 5-fluorouracilin1957, which was developed into an anti-tumour drug 
Thalidomide, there were no drugs containing fluorineon the market.  Since then, the situation 
changed dramatically with over 150 fluorinated drugs beingpresent today(Hangmann et 
2 
al.,2008),representing approximately 20% of all pharmaceuticals(Kirk et al., 2006; Isanbor et 
al., 2006; Muller et al., 2007).  Apart from the pharmaceutical market, fluorine compounds 
have also found application in agrochemicals, where these compounds have an even higher 
proportionthan the pharmaceuticals (Muller et al., 2007).Presently,pharmaceutical research 
involving fluorinated molecules is routine(Park et al., 2001) and some fluorinated drugs are 
among the most popular, for example, the anti-depressant fluoxetine (Prozac), the anti-





























Prozac Ciprobay  
Figure1-1Examples of some popular fluorine drugs 
 
1.1.1 Nomenclature 
Organic fluorine compoundsare named according to the rules of theInternational Union for 
Pure and Applied Chemistry (IUPAC).However, for highly fluorinated molecules with 
several carbon atoms, this nomenclature can be confusing.  The term “perfluoro” may be used 
when all hydrogen atoms bonded to the carbon skeleton in a particular substituent have been 
replaced by fluorine. This does not apply to functional groups with hydrogen (e.g., CHO or 
3 
COOH). Fluorine on aromatic or aliphatic moieties, like other halides are termed fluoro, for 
example 4-fluoronitrobenzene contains a fluorine at C-4 and 2, 2-difluoropentane contains 
two fluorine atoms at C-2 of the pentane chain.  The methyl and methoxy functional groups 
where fluorine has replaced all of the hydrogens is termed trifluoromethyl (-CF3) and 
trifluoromethoxy (-OCF3).  Likewise, an acetate group where fluorine has replaced hydrogen 
is termed trifluoroacetate (CF3COO-). 
 
1.1.2 Electronic effect of fluorine 
The C-F bond is the strongest single bond in organic chemistry, in comparison to C-C, C-H, 
C-O and C-Cl bonds(Table 1-1) (Park et al., 2001;O' Hagan et al., 2008).This can be 
explained by the high electronegativity of the fluorine atom which strongly attracts the 
covalent electron density, rendering the C-F bond highly polarised.  The electron density is 
displaced towards the fluorine. Thus, the high strength of the bond is due to an electrostatic 
attraction between Cδ+ and Fδ- rather than a normal covalent bond with electron sharing (Park 
et al., 2001). 
 
Table 1-1Dissociation energies of various C-X bonds (O' Hagan et al., 2008) 
Bond  Dissociation 
energy  
(kcalmol-1) 
C-F  105.4 






1.1.3 Steric influence of fluorine 
The fluorine atom is smaller than oxygen, nitrogen and chlorine with a Van der Waals radius 
of 1.47 Å (O = 1.52; N = 1.55 and Cl = 1.75 Å) (Bondi et al., 1964) and has been found to be 
a good substituent to replace hydrogen (1.20 Å) in organic molecules (O' Hagan et al., 
2008).The substitution of fluorine for hydrogen does not result in steric hindrance at all 
(Wodzinska et al., 2008) and in crystal structures, hydrogen and fluorine are often 
interchangeable. Thus, despite the difference in size, fluorine is a good hydrogen mimic and 
has been widely used in this regard in medicinal chemistry (O' Hagan et al., 1997). Replacing 
hydrogen with fluorine allows modification of the electronic environment without altering the 
steric environment of the molecule.  There is however some evidence that replacing a 
hydrogen atom with fluorine can induce a change in the geometry of the molecule (Liu et al., 
2008). 
 
An example of the effect that fluorine can have on adjacent functional groups is illustrated by 
the pKa of amines and carboxylic acids. Ethylamine has a pKa of 10.58 but 1-
fluoroethylamine has a pKa of 9.19, 1,1-difluoroethylamine a pKa of 7.45 and 1,1,1-
trifluoroethylamine has a pKa of 5.40.  When hydrogen is replaced with fluorine the molecule 
becomes more acidic.  This is due to its inductive withdrawal effects which weaken the N-H 
bond. The same effect is seen in carboxylic acids (CH3COOH has a pKa of 4.76; 
CH2FCOOH 2.60; CHF2COOH 1.40 and CF3COOH 0.51). 
 
The CF3 group though is not a good CH3 mimic. CF3 is far bigger than CH3 and experimental 
evidence indicates that it is actually closer to an isopropyl group and sometimes acts more 
like tert-butyl in terms of steric impact (Riggi et al., 1995). 
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1.1.4 Hydrogen bonding to fluorine 
Fluorine is highly electronegative and the C-F bond highly polarised with three lone pairs 
being present around the fluoro substituent.  This makes fluorine an ideal hydrogen bond 
acceptor.  However H····F contacts are rare as revealed by structures deposited in the 
Cambridge Structural Database (Dunitz et al., 1997) and fluorine forms hydrogen bonds only 
in the absence of a better acceptor (Abraham et al., 1989).  
 
1.1.5 The chemical properties of fluorinated compounds 
The influence of fluorine is greatest in highly fluorinated and perfluorinated compounds and 
these compounds have a high thermal stability and chemical resistance and are 
physiologically inert (Sandford et al., 2000).  This makes them suitable inmany applications 
for which hydrocarbonsare not. Properties that are exploited commercially include high 
thermal and chemical stability, low surface tension, and good dielectric properties.  This can 
be seen in fluoropolymers, perfluorinated oils and inert fluids (Boday et al., 2012).  These 
differences from hydrocarbon based organic moleculesis due to the very small inter-and intra-
molecular forces for perfluoro-carbon molecules. However, the partially fluorinated 
molecules arequite polar and have appreciable molecular interactions owing to strong 
electrostatic bond dipole interactions. Organic molecules which are fluoro substituted are 
affected by both electron withdrawal by induction and electron donation by resonance since 
fluorine can do both. 
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1.1.6 Fluorine and lipophilicity 
To crosslipid membranes, a drug needs to be sufficiently lipophilic and therefore this 
property is important in medicinal chemistry. However, if a drug is too lipophilic, this would 
reduce its water solubility and its bioavailability and therefore the right proportion of 
lipophilicity is needed in order for a drug to be successful. Selective fluorinationis a good 
way to introduce lipophilicity into a molecule and the introduction of one or more fluorine 
atoms can increase the lipophilicity in an incremental manner.An Increase in lipophilicity 
results in a concurrent increase in hydrophobicity. Aromatic fluorination is known to always 
increase the liphophilicity of molecules (Filler et al., 2009; Boiko et al., 2010). 
 
1.1.7 Effects of fluorine on Biological activity 
In the area of medicinal chemistry, incorporation of fluorine into organic compounds have 
had an exceptional impact.  Fluorinated compounds have been used as antivirals (Filler et al., 
2009), antibacterials (Hardy et al., 1987), in the treatment of HIV (Marquez et al., 1990), 
malaria (Simpson et al., 2000), obesity (Vermes et al., 2000), mental illness (Park et al., 
1994), cancer (Klijn et al., 2001; Feldman et al., 2001), Alzheimer's disease (Zhang et al., 
2005) and as herbicides and insecticides(Key et al., 1997). The incorporation of fluorine into 
a biologically active compound alters the electronic, lipophilic and steric parameters and can 
critically increase the intrinsic activity, the chemical and metabolic stability, and 
bioavailability (Dinoiu et al., 2006).  
 
Fluorinated compounds find pharmaceutical applications as steroids.For example 9α-fluoro-
11-β-hydroxycorticoids exhibited anti-inflammatory activity (Fried et al., 1954); broad 
spectrum antibiotics such as ciprofloxacin and temafloxacin(Filler et al., 2009); antifungal 
agents such asfluconazole and voricon-azole (Kuznetsovaet al., 2008; Sabo et al., 2000), 
7 
effective in the treatment of dermal and vaginal infections; anticancer agents such as 
tamoxifen, an estrogenantagonist used in the treatment of hormone dependent breast cancer 
(Klijn et al., 2001)., fludarbine, a purine antimetabolite, effective in the treatment of B-
Cellchronic lymphocytic leukemia (Isanbor et al., 2006; Rummel et al., 1999) and flutamide, 
an anti-androgen used in the treatment of prostate cancer (Feldman et al., 2001); antimalarials 
such as mefloquin(Simpson et al., 2000); haloperidol, an antipsychotic drug used in the 
treatment of schizophrenia and acute psychotic states (Park et al., 1994); fluoxetine and 
citalopram, antidepressant drugs (Hiemke et al., 2000); and cardioprotective effects showed 


















































Figure 1-2Examples of fluorinated drugs 
 
Two other fields where fluorine molecules have been widely used are in aneasthesia and 
Positron Emission Tomography (PET).  Inhalation anesthetics are almost entirely dependent 
on fluorine chemistry.  Fluoroxene (CF3CF2OCH=CH2), isoflurane (CF3CClOCHF2), 
sevoflurane ((CF3)2CHOCH2F) and desfluorane (CF3CHFOCHF2) have almost 
revolutionized the field of anesthesiology because of their low blood-gas partition 
coefficients and their minimal levels of metabolism, which minimize side effects and 






















Figure 1-2 continued...Examples of fluorinated drugs 
 
Positron Emission Tomography (PET) is non invasive nuclear medical imaging technique 
that makes use of 18F isotope tracers. 18F is used since it has a longer half-life compared to the 
other commonly used radionuclides. PET scans show biological processes, providing 
information on metabolic processes (Persur, 2008).  The fluorinated compound 2-deoxy-2-
[18F] fluoro-D-glucose or [18F] FDG is the most frequently used radiopharmaceutical. 
1.2. Introduction to 2-styrylchromones 
Chromones are one of the most abundant classes of naturally occurring compounds found 
especially in plants. They are oxygen-containing heterocyclic compounds with a 
benzoannelated γ-pyrone ring, the parent compound being chromone (Figure 1-3) (Douglas et 
al., 2003). The 2-styrylchromones (Figure 1-3) are a new class of flavonoids, structurally 
10 
related to the flavones (2-phenylchromones) and characterized by the attachment of a styryl 
group to the C2-position instead of a phenyl group as in the flavonoids. 
 
Chromone derivatives are relatively non-toxic and some are beneficial in our diets, for 
example the flavonoids, where polyhydroxy flavonoids are known antioxidants contained in a 
wide variety of fruit and vegetables and in red wine.These antioxidants are known to fight off 
damaging free radicals which cause harm to normal cells.  Chromone derivatives also find 
application as drugs on the market such asnedocromil for the treatment of asthma (Barnes et 








1          2            3 
Chromone                          Flavone                       2-styrylchromones 
 
Figure 1-3 The basic structure of a chromone, flavone and 2-styrylchromone 
 
 
Unlike the flavonoids, 2-styrylchromones are not that common in nature, with 
hormothamnione(4)and 6-desmethoxyhormothamnione(5) (Figure 1-4) being the first and to 
the best of our knowledge the only naturally occurring styrylchromones which were isolated 
from the marine blue green algae, cryptophyte, Chrysophaeumtaylori and which 
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Figure 1-4Natural 2-styrylchromones 
 
 
The biological activities of 2-styrylchromones have recently been reviewed by Gomes et al. 
(2010).  The 2-styrylchromones were shown to be A3 adenosine receptor antagonists (Karton 
et al., 1996), have hepatoprotective activity (Fernandes et al., 2003), be potent antioxidants 
(Filipe et al., 2004), have anti allergic properties (Doria, et al., 1979), antiviral activity 
(Desideri, et al., 2000),  anticancer activity (Marinho et al., 2008; Momoi et al., 2005; 
Gerwick et al., 1987) and  to display xanthine oxidase inhibition to treat for example gout, 
hypertension and hepatitis linked to xanthine oxidase actitivity (Fernandes, 2002). 
 
1.2.1 Synthesis 
The synthesis of 2-styrylchromones was reviewed by Silva et al. (2004).  They can be 
synthesised by two basic methods, the aldol condensation and the Baker-
Venkataramanrearrangment.  Both these methods make use of 2'-hydroxyacetophenones, 
with the aldol condensation making use ofcinnamaldehydes (Pinto et al., 1996; 2004; Silva et 
al., 1994; 1996; 1998; 2004) and the Baker-Venkataraman rearrangement using cinnamoyl 
chlorides (Pinto et al., 1996; 1998; 1999; 2000; Reddy et al., 1996; Santos et al., 2003). 
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Both methods result in 2,4-pentadien-1-ones as the intermediate, with the Baker-
Venkataraman rearrangment having a 3-hydroxyl group, which makes these intermediates 
susceptible to cyclisation with acid.  For the cyclisation step, halogens such as I2 and Br2 with 
DMSO are used for both intermediates, whereas acids such as hydrochloric acid and p-
toluenesulphonic acid is used only for the 3-hydroxy intermediate that results from the Baker-
Venkataraman rearrangement.  This makes the Baker-Venkataraman rearrangement a more 
desirable synthetic route as it precludes the use of I2 or Br2 and the cyclisation can be carried 
out using the relatively mild p-toluene sulphonic acid. 
 
1.2.1.1 Aldol condensation / Oxidative cyclisation. 
This method involves the base catalyzed aldol reaction of cinnamaldehydes (6) with 2-
hydroxyacetophenones (7) to produce a 2'-hydroxycinnamylideneacetophenone (8) 
intermediate.This reaction is carried out with a strong base such as sodium hydroxide in 
methanol at room temperature, which is followed by oxidative cyclisation of 8 into (E)-2-
styrylchromones (9) (Silva et al., 1998; Santos et al., 2003).More attention has been devoted 
in the literature to the oxidative reagents for the cyclisation. These reagents are anhydrous 
potassium carbonate (Pinto et al., 1996), DMSO with either I2 or Br2 in catalytic 
amounts(Pinto et al., 1994; 1999; Silva et al., 1994; 1996),ethanolicsulphuric acid (Reddy et 
al., 1996).A catalytic amount of iodine with DMSO was reported as the most successful 
oxidative cyclisation reagent (Silva et al., 2004) and the reaction is normally refluxed for 30 
minutes to 2 hours respectively (Scheme 1-1Error! Reference source not found.)(Silva et 
al., 1998).  This particular reaction also results in halogenation of the most activated position 




It was also reported that reacting the 6'-benzyloxy-2'-hydroxycinammylideneacetophenone 















Reagents and conditions: (i) NaOH-H2O, MeOH, rt. (ii) I2 (cat.) or Br2 (cat.), DMSO, reflux, 
30 min. 
 
Scheme 1-1Aldol condensation and oxidative cyclisation leading to the synthesis of 2-
styrylchromones 
1.2.1.2 Baker-Venkataraman rearrangement 
The Baker-Venkataraman rearrangement is one of the most common methods used to 
synthesize flavonoids.  In forming the 2-styrylchromones, it begins with the O-acylation of 2-
hydroxyacetophenones (10) followed by a base catalyzed rearrangement of the formed esters 
(12) into 5-aryl-3-hydroxy-1-(2-hydroxyaryl)-2,4-pentadiene-1-ones (13). The third and last 
step of the synthesis is thecyclodehydration of the -hydroxyketones into the desired 2-
styrylchromones (14)(Scheme 1-2) (Priceet al., 1993). 
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This reaction was reduced to two steps by Reddy et al. (1996)  producing (13) from (10)and 
(11), using potassium carbonate in acetone and refluxing for 12 hours, which probably works 
via the same mechanism as the three step reaction without producing the esterified 
intermediate.  A one step reaction involving the synthesis was reported by the same group 
using the same reagents, but with thiopheneacroyl chlorides instead of cinnamoylchlorides 
and refluxing for 16 hours (Miya et al., 1998; 2012).A second step was necessary to 
hydrolyse the ester from the undesired position, but the styrylchromone was produced in one 
step with a longer reaction time (Scheme 1-3).  
 
Instead of using cinnamoyl chlorides, cinnamic acid anhydrides (20) were also reported to be 






























Reagents and Conditions: (i) DCC, 4-Pyrrolidinopyridine, CH2Cl2, rt. X=OH;  (ii) K2CO3, 
acetone, reflux, 12 h, X=Cl;  (iii) a. H2SO4, reflux, 3h; b. p-toluenesulfonic acid or I2, DMSO, 
90-100 °C, 2-3 h;  (iv)NaOH or KOH 
 
Scheme 1-2The Baker-Venkataraman rearrangement for the synthesis of 2-styrylchromones 
(Price et al., 1993; Reddy et al., 1996) 
 
1.2.2 Reactivity. 
Due to the conjugated unsaturated system of the styrylchromone moiety and the 2-ene-4-one 
moiety in the 2-styrylchromone backbone, they have been shown to participate in pericyclic 
reactions as dienes and dienophiles forming xanthones and polyaromatic compounds and in 
reactions with azo compounds forming azoles and with thiourea or diamino imines forming 





























R = H, OH




Scheme 1-3One step synthesis of 2-styrylchromones (Miya et al., 1998) 
 
1.2.2.1 Styrylchromones as dienes and dienophiles 
Using daylight with chloroform as the solvent, styrylchromones were converted to xanthones 
by an intramolecular Diels-Alder reaction followed by an oxidative process, with aE to 
Zisomerisation occurring prior to this (Scheme 1-5) (Silva et al., 1996).  Xanthones were also 
reported to be formed with pyrrolidine enamines via a [4+2] cycloaddition reaction (Scheme 
1-6) (Kelkar et al., 2000).  The pyrolidine enamines were formed in situ with the 
corresponding ketones as a solvent and a catalytic amount of pyrrolidine.  The 
styrylchromone 25 was completely converted to the xanthone, probably via the intermediate 
27 since this was isolated in some of the reactions, which gets converted to the xanthone via 
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migration of the exocyclic double bond and subsequent oxidation (Kelkar et al., 2000).  
Somewhat surprisingly, with 2-butanone as the solvent, the expected 1,2-dimethylxanthones 
were not formed directly as was the case with acetone forming 1-methylxanthones.  The 
subsequent migration of the double bond and oxidative aromatisation did not occur.  
However, the 1-methylidene-2-methyltetrahydroxanthones (30) were easily converted to the 


























R1 = H, Me, OMe
R2 = H, Me
R3 = H, Me, OMe
 
Reagents and conditions: (i) Ba(OH)2/ DMSO, hυ,40 °C, 40 sec.;  (ii) PTSA, hυ, 40 °C, 60 
sec. 
 
Scheme 1-4: The synthesis of 2-styrylchromones using microwave reactions with anhydrides 



























Scheme 1-5IntramolecularDiels Alder reaction of 2-styrylchromones to produce 






























The reaction of 2-styrylchromones (23) with ortho-benzoquinodimethanes (32) generated in 
situwith 1,3-dihydrobenzo[c]thiophene 2,2-dioxideproducedcycloadducts (33) which could 
be dehydrogenated to 2-[2-(3-arylnaphthyl)] chromones (34). They were also prepared in a 
one pot synthesis with ortho-benzoquinodibromomethane (35) generated in situ from 
α,α,α',α'-tetrabromo-o-xylene (Scheme 1-7) (Silva et al., 1999a).  
 
1.2.2.2 2-Styrylchromone reactions with azo compounds 
2-Styrylchromones react with diazomethane, behaving as dipolarophiles, producing 
pyrazolines (37) via the intermediate 36with 38 occurring as a minor component of the 
reaction (Scheme 1-8) (Pinto et al., 1998).   They can also form 1,2,3-triazoles, either in a one 
pot synthesis with sodium azide or from the brominated compounds 39 and 41 with sodium 
azide (Silva et al., 1999;  2004) (Scheme 1-9). 
 
1.2.2.3 Styrylchromone reactions with hydrazine 
It was shown that the chromones can react with hydrazine hydrate togive 5(3)-(2-
hydroxyphenyl) pyrazoles (Takagi et al., 1986).In the reaction of 2-styrylchromones (44) 
with methyl hydrazine, only the styrylpyrazole (46) was formed but with hydrazine hydrate 
an additional two compounds, 47 and 48 were formed together with the expected 
styrylpyrazole (45) (Pinto et al., 1997) (Scheme 1-10). 
 
1.2.2.4 Styrylchromone reactions with diamino imines and thioureas 
The styrylchromones (49) were shown to react with thiourea and guanidine to produce the 

























R= H, CH3; R1= H, CH3, OCH3, Cl. 
(i) 1,2,4-Trichlorobenzene; (ii) (a) NBS, benzoylperoxide, CCl4or (b) Et3N;(iii) DMF. 
Scheme 1-7 Diels Alder reactions of 2-styrylchromones with ortho-benzoquinodimethanes 











































































R= H, Me, Cl,
Br
 















































R = H, CH3; R1 = H, Me, OCH3, C(CH3)3 



















50 51  
R = H, CH3, OCH3; (i) H2NC (NH) NH2.HCl; (ii) H2NCSNH2 
 
Scheme 1-11 The reaction of 2-stryrylchromones with thiourea and guanidine (Karale et al., 
2003) 
 
1.2.3 Biological activity of 2-styrylchromones 
The biological activities of 2-styrylchromones have recently been reviewed by Gomes et al. 
(2010).  The 2-styrylchromones were shown to be A3 adenosine receptor antagonists (Karton 
et al., 1996), have hepatoprotective activity (Fernandes et al., 2003), be potent antioxidants 
(Filipe et al., 2004), have anti allergic properties (Doria et al., 1979), antiviral activity 
(Desideri et al., 2000),  anticancer activity (Marinho et al., 2008;Momoi et al., 2005, Gerwick 
et al., 1987 ) and shown to display xanthine oxidase inhibition to treat for example gout, 
hypertension and hepatitis linked to xanthine oxidase activity(Fernandes et al., 2002).   
 
1.2.3.1 Antioxidant activity 
The polyhydroxylated 2-styrylchromones were found to be potent hepatoprotectors against 
pro-oxidant hepatotoxicity exerted by tert butyl hydroperoxide in freshly isolated rat 
hepatocytes, with the best activity being shown withtwo hydroxyl groups present on the 
benzene ring and with one or two hydroxyl groups on the benzopyronering (Fernandes et al., 
23 
2003).The polyhydroxylated 2-styrylchromones were also shown to be good antioxidants, 
capable of scavenging activity against reactive oxygen and reactive nitrogen species (ROS 
and RNS).The most potent activity was shown by 5,7-dihydroxy and 7-hydroxy substitution 
in the A-ring (Gomes et al., 2007).Polyhdroxylated styrylchromones with two hydroxyl 
groups on the styryl moiety and an additional hydroxyl group at C-5 on the benzopyrone ring 
were shown to have an even betterinhibitory effect on the Cu2+- induced  peroxidation of  
low-density lipoproteins  (LDL) than the flavonoid quercetin (Filipe et al., 2004). 
 
1.2.3.2 Antiviral (rhinovirus and norovirus) activity 
Human rhinoviruses (HRVs) are the most frequent cause of the common cold and responsible 
for several chronic conditions, such as asthma and sinusitis(Wimalasundera et al., 1997), 
whereas Human noroviruses (NoV) are responsible for acute gastroenteritis (Rocha-Pereira et 
al., 2010).The 6-fluoro-2-styrylchromone and its 3-hydroxy and 3-methoxy derivatives were 
shown to be effective against serotype 1Bof the HRV (Desideri et al. 2000; 2003; Conti et al., 
2005) and 5-hydroxy-2-styrylchromone and 4'-methoxy-2-styrylchromonewith an estimated 




The highly oxygenated hormothamnione(Figure 1-4) witha methyl group at C-3 and methoxy 
groups at the 6, 7 and 8 positions and hydroxy groups at C-5, C-3' and C-5' showed potent 
cytotoxicity against the P388 lymphocytic leukemia and HL-60 human promyelocytic 
leukemia cells by inhibiting RNA synthesis, while its 6-desmethoxy analogue with a 
hydrogen at C-6 instead of the methoxy group showed good cytotoxicity to 9 KB cells 
(Gerwick et al., 1986; 1989). The 4'-methoxy-2-styrylchromone and the 3',4',5'-trimethoxy-2-
24 
styrylchromone (Figure 1-5) showed good cytotoxic activity against four human tumor cell 
lines (squamous cell carcinoma HSC-2, HSC-3,submandibular gland carcinoma 









Figure 1-53', 4’, 5’-trimethoxy-2-styrylchromone 
 
 
1.2.3.4 Anti-inflammatory activity 
Cyclooxygenases (COXs) are the key enzymes in the biosynthesis of prostaglandins involved 
in inflammatory responses. The 3',4’-dihydroxy and 4'-hydroxy 2-styrylchromone 
compounds showed COX-1 and COX-2 as well as LTB4 inhibition making them potential 
anti-inflammatory compounds (Gomes et al., 2009). 
 
Several 2-styrylchromone-6-carboxylic acids displayed anti-allergic activity when 
administered orally to rats in the passive cutaneous anaphylaxis test (Doria et al., 1979).  
 
The 2-styrylchromonols and 2-styrylfuranochromones have been described as A3 adenosine 
receptor antagonists which have the potential for the treatment of allergic, inflammatory and 
possibly ischemic disorders with the 2-styryl analogue (52) (Figure 1-6) of the natural 







Figure 1-62-styrylfuranochromone with A3 adenosine receptor antagonist activity 
 
1.2.4 Structural elucidation of 2-styrylchromones 
The 2-styrylchromones are highly conjugated molecules and the ultraviolet (UV) spectrum 
contains characteristic absorption bands in the region 262-345 nm corresponding to an , , 
, - unsaturated conjugated carbonyl system (Rao et al., 2011).  Due to the delocalisation of 
electrons in this unsaturated carbonyl system, the carbonyl stretching frequency in the IR 
spectrum occurs at 1620-1650 cm-1 exhibiting more single bond character.  The CH 
stretching bands of the olefinic bonds are observed between 1580-1620 cm-1 (Desideri et al., 
2003). 
 
The 1H NMR spectra of the 2-styrylchromones contain aromatic and olefinic resonances 
between  6.1 and  7.8.  In many cases, the H-3 resonance can be seen as a singlet between  
6.10 - 6.25 for the benzyloxy 2-styrylchromones and more downfield at between  6.20 - 6.50 
for the hydroxy 2-styrylchromones.  The H and H proton resonances of the styryl moiety 
occur between  6.50 - 7.18 for the H proton resonances and more downfield between  
7.36-7.74 for the H proton resonances.  These resonances occur as doublets with a large 
coupling constant of approximately 16 Hz for the trans olefinic protons and  in many cases 
overlap with the aromatic resonances which resonate between  6.20 to  7.80 (Santos et al., 
2003). 
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The basic 2-styrylchromone nucleus contains seventeen carbon atoms and their resonances in 
the 13C NMR spectrum are mainly concentrated in the region  100-140.   The carbonyl 
resonance is easily detected at δ 176-183 due to the unsaturated carbonyl system.  The C 
resonance is also distinguishable at  136 - 139 as is the C-2 resonances at  160 -163, 
however this overlaps with the oxygenated aromatic resonances.  Other aromatic proton 
resonances can be seen at  100-130 (Santos et al., 2003).    
 
 
1.3. Introduction to imidazole-2-thiones 
Imidazole-2-thiones are planar five membered cyclic compounds consisting of three carbon 
and two nitrogen atoms in the ring and an exocyclic sulphur bond.  They are based on the 
parent compound, imidazole, a basic molecule, which readily forms salts with acids (Turner 
et al., 1949) and found in a number of biological important molecules including purine, 
histamine and histidine.  They are therefore important components of nucleic acids and 
proteins, histidine playing an important role in the structure and binding of hemoglobin 
(Bhatnagar et al., 2011). 
 
Imidazole-2-thiones can exist in two tautomeric forms, a thione (53) and a thiol (54) (Figure 
1-7).  Ionization of the compounds occurs in the thione form in the crystalline state and in 
solution (Jayaram et al., 2008).  The length of the C-N bond is 1.345 Å, very close to the 










53 54  
Figure 1-7 Tautomeric forms of imidazole-2-thiones. 
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These compounds are weak organic bases, readily protonated when dissolved in acids. 
Having both nitrogen and sulfur atoms in their core structure, they belong to the so-called 
"ambifunctional nucleophilic compounds" and are readily involved in reactions with 
electrophilic agents.  The ambidentate anion of compounds with a thioamide group, generated 
by proton abstraction results in a triatomic functionality with the negative charge being 
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Figure 1-8 Ambifunctional nucleophilic compounds 
 
The interaction of imidazole-2-thione with electrophilic reagents normally involves the 
readily polarized and highly nucleophilic sulphur atom. In the case of polar electrophiles, 




Recent reviews by Dawood et al. (2010) and Savjani et al. (2011) containthe different 
synthetic procedures and starting materials that have been used to synthesise the imidazole-2-
thiones, which can be substituted at almost all positions on the imidazole-2-thione skeleton.  
They can be formed from -bromoketones with substituted hydrazines and potassium 
thiocyanate (Lagoja et al., 2003), from-hydroxyketones, thiourea and ammonium 
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thiocyanate (Maduskuie et al., 1995), from benzil and thiourea (Muccioli et al., 2006) and 
from phenylglycine methyl ester with phenyl or alkyl isothiocynate (Muccioli et al., 2006) to 
name a few.  The imidazole-2-thiones are extremely reactive and can be alkylated and 
arylated at both sulphur and nitrogen using a variety of reagents (Trzhtsinskayaand 
Abramova, 1991) added to activate double bonds such as 2-cyanoethene (Bagrii et al., 1978; 
Trzhtsinskaya et al., 1992), acetylene (Skvortsova et al., 1974), aliphatic and alicyclic ketones 
and acetophenones (Hozien et al., 2000). 
 
1.3.1.1 Synthesis with -bromoketones, substituted hydrazines and potassium 
thiocyanate  
The N-substituted 1-amino-2,3-dihydro-1H-imidazole-2-thiones (58)were synthesized in 
good yields in a one-step reaction  from easily available starting materials like hydrazines 
(55), R-bromoketones(56), and potassium thiocyanate(57)in the presence of acetic acid at 


















hydrazines R-bromoketones potassium thiocyanate 1-amino-2,3-dihydro-1H-imidazole-2-thiones
55 56 57 58
 
Scheme 1-12Reaction with-bromoketones, substituted hydrazines and potassium 





1.3.1.2 Synthesis from-hydroxyketones and thiourea, and from diketones and 
ammonium thiocyanate  
 
The 4,5-disubstituted-2-mercaptoimidazole(59)was synthesized by a condensation reaction 
with the α-hydroxy ketone(60)and thioureainthe presence of N,N-dimethylformamide or 
hexanol.  The diketone (61) reacted with ammonium thiocyanate and n-hexanol also gave the 


























Scheme 1-13 Condensation reaction with α-hydroxy ketone and thiourea, and diketones and 
ammonium thiocyanate 
 
1.3.1.3 Synthesis from benzil and thiourea 
A 5-disubstituted-4-keto derivative of 2-thioimidazole (63) was synthesized using microwave 
reactions with benzil (64) and thiourea (65) (Scheme 1-14). The advantages of this reaction 
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Reagents and conditions: (a) DMSO/aq KOH, nine microwaves pulses (750 W) 
Scheme 1-14 Microwave assisted reaction of benzil and thiourea (Muccioli et al., 2006) 
 
1.3.1.4 Synthesis from phenylglycine methyl ester with phenyl or alkyl isothiocynate 
The 3-substituted-4-keto-5-phenyl-2-thioimidazoles (66) were synthesized with 
phenylglycinemethyl ester(67) with the desired phenyl or alkyl isothiocyanates(68)in the 
presence of pyridine, leading first to a 3-substituted (thio)urido-phenyl aceticacid which is 
then cyclised by refluxing under acidic conditions (Scheme 1-15)(Muccioli et al., 2006). 















Scheme 1-15Reaction withphenylglycine methyl ester and phenyl or alkyl isothiocynate 
(Muccioli et al., 2006) 
 
1.3.1.5 Synthesis from methyl or phenyl isothiocyanate and -amino acids via 2-
thiohydantoins  
The 2-thioimidazoles can be formed from methyl or phenyl isothiocyanates and  amino 
acids forming thiohydantoic acid (69) which is cyclized to the 2-thiohydantoins (70) with 
acid.  The 2-thiohydantoins arethen reduced by borohydrides to 4-hydroxyimidazolidine-2-
thiones (71), which form imidazole-2-thiones (72) by the elimination of water with acid 




















































Scheme 1-16 Synthesis with methyl or phenyl isothiocyanate and α-amino acids via a 2-
thiohydantoin intermediate (Scott et al., 1968) 
 
1.3.1.6 Preparation from imidazolium salts and elemental sulphur 
Imidazolium salts (73) reacted with elemental sulphur, potassium tert butoxide and sodium 
hydride produced the 2-thioimidazoles (74) in good yields (Sauerbrey et al., 2012).  They 
were subsequently phosphanylated with diorganochlorophosphane at C-4 on the 2-








1) 1/8 S8, 2h, rt
2) KOt-Bu, NaH
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Scheme 1-17Preparation of thioimidazole-2-thiones using imidazolium salts and elemental 
sulphur (Sauerbrey et al., 2012) 
 
 
1.3.1.7 Preparation by intramolecular vinylic substitution 
A series of 1, 3, 4-trisubstituted imidazole-2-thiones (76) were prepared by the intramolecular 
vinylic substitution reaction with N, N’-trisubstituted thiones (77) with a vinylic bromide 
moiety and potassium carbonate in dimethyl formamide (DMF) (Shen et al., 2009) (Scheme 
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Scheme 1-18 Preparation by an intramolecular vinylic substitution reaction (Shen et al., 
2009) 
 
1.3.2 Reactions of imidazole-2-thiones 
A literature search on Scifinder Scholar (2012) shows that the imidazole-2-thiones are 
extremely reactive and can be alkylated and arylated at both sulphur and nitrogen using a 
variety of reagents (Trzhtsinskayaand Abramova, 1991), added to activated double bonds 
such as 2-cyanoethene (Bagrii and Vasilenko, 1978; Trzhtsinskaya et al., 1992), acetylene 
(Skvortsova et al., 1974), and aliphatic and alicyclic ketones and acetophenones (Hozien et 
al., 2000).However, apart from the reaction with acetylene, most of the other references were 
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only available as abstracts despite several attempts at obtaining them and the details for these 
are not commented on in this work.   
 
For the reaction with acetylene, 2-mercaptobenzimidazole (78) was reacted with acetylene 
and potassium hydroxide to produce the S-vinyl product (79).  Reaction with acetylene using 
metal catalysts such as cuprous chloride and cadmium acetate produced the divinyl product 





















Scheme 1-19 Reactions of imidazole-2-thiones with acetylene (Skvortsova et al., 1974) 
 
1.3.3 Biological activity of imidazole-2-thiones 
The imidazole-2-thiones have also shown a wide range of biological activities, having 
antiulcer(Tsuji et al., 1989), anti-inflammatory(Buhler et al., 2011; Selig et al., 2011; Tsuji et 
al., 1989; Makita et al., 2000), antiarthritic, analgesic (Sharpe et al., 1985), antihyperthyroid 
(Doerge et al., 1993), anti-hypercholesterolemic (Billheimer et al., 1990; Maduskuie et al., 
1995), antibacterial, antifungal(Saeed et al., 2007) and anti-HIV activity (Yasser et al., 2003) 
as well asbeing platelet aggregation inhibitors (Hayashi et al., 1989).  The related 4-nitro-5-
thioimidazole derivatives have also showed antitumour activity (Iradyan et al., 1988). 
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1.3.3.1 Antiulcer, anti-inflammatory, antiarthritic and analgesic activity 
The tri- and tetra-substituted imidazole-2-thione derivatives (81) and their corresponding 
sulphoxides (82) (Figure 1-9) were tested for anti-inflammatory activity using the p38 
MAPK assaywhere thesulphides were shown to have a higher affinity for the enzyme than the 
sulphoxides (Buhler et al., 2011).   In a related study, observing the steric effects of the S-
substituted methyl group, it was shown that a loss of steric hindrance increased the inhibitory 
potency of the compounds to the enzyme up to two-fold when compared to the 



















R1 = acyl or fluorobenzylacyl
R2 = methyl or H  
Figure 1-9Tri- and tetrasubstituted thioimidazole-2-thiones and their sulphoxide derivatives 
 
The 4,5-dipyridyl-S-substituted ether(83)(Figure 1-10)was shown toexhibit activity on human 










Figure 1-10 A 4,5-dipyridyl-S-substituted ether of imidazole-2-thione 
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A series of 4,5-diaryl-2-(alkyloxy substituted thio)imidazole derivatives with chloro, fluoro 
or methoxy substitution on the phenyl groups and alkyl, alkenyl, fluoralkyl and thioethers and 
esters substituted on the sulphur were tested for both their anti-inflammatory and analgesic 
activity.  The best analgesic and anti arthritic activity was seen when sulphur was substituted 
with fluoroalkyl groups and when the phenyl groups at C-4 and C-5 were para 
substituted.The derivative tiflamizole (84) (Figure 1-11) was eight times more potent than 
indomethacinin the rat adjuvant induced arthritis assay and with its high efficacy, could be 









Figure 1-11 Tiflamizole 
 
The diphenyl thioimidazole (85) (Figure 1-12) with a methylpyridinyl group attached to the 








Figure 1-12Dipehnyl-S-methylpyridinyl thioimidazole-2-thiones 
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1.3.3.2 Antihyperthyroid, antihypertensiveand anti-hypercholesterolemic activity 
N-substituted imidazolylethanols (86)(Figure 1-13)synthesized from their corresponding 
diphenylimidazoles with β-halo alcohols (Cl, Br) were shown to have antihypertensive 







R = H, Me, Ph, p-C6H4NO2 




Figure 1-13 Imidazolylethanols 
 
A series of N-substituted imidazoline-2-thiones and benzimidazoline-2-thione (87-91) (Figure 
1-14) derivatives were synthesized and tested to treat hyperthyroidism.  The 1,3-disubstituted 
thiourea derivative (90) was the most potent and could represent a new class of potential 
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Figure 1-14Imidazole-2-thiones and their benzo derivatives tested for antihyperthyroid 
activity 
 
The 4,5-diaryl-2-substituted thioimidazoles(92)where R1 and R2 are H, F, Cl, CF3 or alkyl 
and R3 is H, CH3 or ethyl with A being an alkylene group of 7-20 carbon atoms was 
synthesized along with their sulphoxide derivatives (Figure 1-15).  These compounds were 
shown to inhibit the intestinal absorption of cholesterol thereby having the potential to inhibit 









R1 = and R2 = H, F, Cl, CF3 or alkyl
R3 = H, CH3 or CH2CH3
A = alkylene groups of 7-20 carbon atoms
n = 0, 1, 2
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Figure 1-15Anti-hypercholesterolemic imidazole-2-thiones 
 
Kruse et al. (1987) reported the dopamine β-hydroxylase activity of 52 thione analogues, 
identifying compounds which could be used for cardiovascular disorders related to 
hypertension.  Among these, the N-substituted alkyl phenyl groups with hydroxyl, nitro and 
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Figure 1-16N-substituted thioimidazole-2-thione dopamine β-hydroxylase inhibitors 
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The 2-thioimidazoles substituted with an alkyl imidazole at the sulphur atom were seen to 
inhibitdiet-induced elevation of plasma cholesterol in rats.Among the compounds that were 











Figure 1-17Plasma cholesterol inhibiting 2-thioimidazole 
 
1.3.3.3 Antibacterial, antifungal and anti-HIV activity  
The imidazolyl ethanols (86) (Figure 1-13) mentioned for their antihypertensive properties 
above also showed fungicidal and bactericidal activities (Povstyanoi et al., 1979).  The 
N,N,4'-trisubstituted imidazole-2-thiones with chloro, bromo, methyl and methoxy 
substitution at various positions were screened for their antibacterial activity against 
Escherichia coli, Pseudomonas areuginosa, Staphylococcus aureus, and Bacillus subtilis.  
The chloro derivative (99) (Figure 1-18) showed the broadest spectrum of activity being 
active against all of the strains tested (Saeed et al., 2007).   The same set of compounds was 
also tested for antifungal activity against Trichophyton longifusus, Candida albicans, 
Aspergillus flavus, Microsporum canis, Fusariumsolani, and C. glabrata.  The results 
showed that only the chloro and bromo substituted compounds exhibited slight activity 









Figure 1-18Antibacterial N,N,4'-trisubstituted imidazole-2-thiones 
 
The 4,5,N-substituted 2-methylsulfanyl 1H-imidazoles with alkyl or benzyl ethers at the N 
and benzyl, cyclohexamethyl, ethyl and isopropyl groups at C-4 and C-5 (100 and 101) 
(Figure 1-19) were tested for their anti-HIV activity in MT4 cell cultures infected with wild 
type HIV-1 (strain IIIB).  Compounds with an isopropyl group at C-4 (101f-g) showed the 
















100 101  
100,101 R1 R2 R3 101 R1 R2 R3 
a Ph Et Me e Ph i-Pr Me 
b Ph Et Ph f Ph i-Pr Ph 
c C6H5 Et Me g C6H5 i-Pr Me 
d C6H5 Et Ph h C6H5 i-Pr Ph 
Figure 1-19 Anti-HIV alkylated imidazole-2-thiones 
 
1.3.3.4 Platelet aggregation inhibition 
A series of 4,5-diphenyl S-benzylated esters were tested for their blood platelet anti 
aggregation activity where compound (102)(Figure 1-20) showed the best activity (Meanwell 












Figure 1-20 4,5-Diphenyl S-benzylated ester with blood platelet aggregation inhibiting 
activity 
 
Hayashi et al. (1989) synthesized substituted imidazole derivatives (103)(Figure 1-21) with S-











R1 and R2 = H, phenyl or substituted phenyl  
Figure 1-21S-substituted pyridinyl methyl imidazole-2-thiones with blood platelet 
antiagglutination activity 
 
1.3.3.5 Enzyme inhibitors 
The 4,5-diphenylimidazole-2-thione (104)(Figure 1-22)showed -glucosidase and -amylase 
inhibitory activity (Balba et al., 2011).  Glycosidase inhibitors have the potential to be used in 
the treatment of diabetes, HIV and metastatic cancer while amylase inhibitors are used for the 










Figure 1-224,5-Diphenylimidazole-2-thione with -glucosidase and -amylase inhibitory 
activity 
 
1.3.3.6 Antitumour activity of related 5-thio(sulfo)imidazoles 
The S-substituted derivatives of 4-nitro-5-thio(sulfo)imidazole were tested for their antitumor 
activity in a threonine dependent strain of E.coli P-678 and a lysine dependent strain of 
Actinomyces rimosus 222 by testing the frequency of mutations in the test cultures and on the 
mutations induced by UV rays.  Compounds 105-110 (Figure 1-23) showed the best 
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Figure 1-235-Thio (sulfo) imidazoles with antitumour activity 
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1.3.4 Structural elucidationof diethyl-2-(benzylthio)-2,3-dihydro-1H-imidazole-4,5-
dicarboxylates 
The 1H-NMR spectra of these compoundsshow characteristic resonances for the benzyl 
proton between δ 4.27-4.62 with the N-H resonance of the imidazole moiety being variably 
observed between δ 5.88-11.32 and the aromatic resonances of the benzyl group being 
observed between  7.00- 7.50. The two ethoxy groups show the typical pattern of triplets 
and quartets for the methyl and methylene groups respectively at δ 1.28-1.37 and δ 4.28-4.37. 
 
The 13C-NMR spectra also has characteristic resonances, especially C-2 of the imidazole ring 
and the benzylic carbon, C-7'', which appears at  144 and  37-38 consistently.  The 
aromatic carbon resonances appear at  115-140 with the C-1'' carbon resonance bonded to 
the benzylic carbon appearing consistently at  138-140.  The carbon resonances for the two 
ethyl ester groups at positions 4 and 5 appear as equivalent resonances at  157-163, 61-62 
and 14-15 for the carbonyl, the methylene and the methyl resonances respectively.  The C-4/5 
resonances are not easily detected in the 13C NMR spectrum, but appear at  127-129 
detectable. 
 
1.4. Aims and objectives 
This project was funded in part by the Fluorine Expansion Initiative (FEI) of South Africa 
and part of FEIs plan and our broad objective was to increase the capacity of the local South 
African fluorine pharmaceutical market.  Our aim was to develop fluorinated 
pharmaceuticals, which can be developed into drugs that could be marketed in South Africa.  
To this end, we chose the 2-styrylchromone and 2-thioimidazole nucleus and aimed to 
investigate the potential of inserting fluorine into these molecules by using fluorine 
precursors in the synthesis. 
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We synthesized the 2-styrylchromones with the specific aim of testing these compounds for 
antibacterial and antioxidant activity since these screens are readily available at UKZN in the 
School of Biological and Conservation Sciences.  The 2-thioimidazoles were synthesized 
with the aim of testing these compounds for antiplatelet activity in conjunction with our 
collaborators in the Department of Biochemistry and Microbiology at the University of 
Zululand in South Africa. 
 
1.4.1 Specific aims and objectives 
The objectives were two fold, (i) to synthesize the two classes of compounds mentioned 
above and (ii) to test these compounds in bioassays aimed at antibacterial and antioxidant 
activity in the case of the 2-styrylchromones and antiplatelet activity in the case of the 2-
thioimidazoles. 
 
To achieve these, we had the following specific objectives: 
1. To synthesize novel target molecules using known procedures modified to suit our 
starting materials. 
2. To characterize the synthesized compounds using spectroscopic and other structure 
determination techniques such as X-ray crystallography. 
3. To test the synthesized compounds in standard known bioassays and compare the 




1.5 References  
44 
Abraham M.H., Grellier P.L., Prior D.V., Duce P.P., Hydrogen Bonding.Part 7, A Scaleof 
Solute Hydrogen-bond Basicity using log K Values for Complexation in Tetrachloromethane, 
Journal of the Chemical Society, Perkin  Transactions II, 1989, 521-529. 
Abramov N.D., Trzhtsinskaya V.B., Structure and properties of imidazole-2-thiones (review), 
Chemistry of Heterocyclic Compounds, 1988, 24, 1309-1321. 
Arduengo A.J., III, 2008, US Pat. Appl. Publ., US 2008171883/A1. 
Bagrii A.K.,Vasilenko E.T., Study of the cyanethylation of aryl derivatives of 2-
thioimidazole, FarmatsevtichniiZhurnal (Kiev), 1978, 4, 33-36. 
Barnes P.J., Drugs for asthma, British Journal of Pharmacology, 2006, 147, S297–S303. 
Beecher G.R., Overview of Dietary Flavonoids: Nomenclature, Occurrence and Intake, 
Journal of Nutrition, 2003, 133, 3248‐3325. 
Balba M., El-Hady N., Taha N., Rezki N., El Ashry H. S., Inhibition of α-glucosidase and α-
amylase by diaryl derivatives of imidazole-thione and 1,2,4-triazole-thiol, European Journal 
of Medicinal Chemistry, 2011, 46, 2596-2601. 
Bhatnagar A., Sharma P.K., Kumar N., A Review on “Imidazoles”: Their Chemistry and 
Pharmacological Potentials, International Journal of PharmTech Research, 2011,3, 268-282. 
Billheimer J.T., Gillies P.J., Wilkerson W.W., Anti hypercholesterolemic 4,5-diaryl-2-
substituted thioimidazoles, 1990, US Patent 4900744. 
Boday D.J., The State of Fluoropolymers, ACS Symposium Series, 2012, 1106, 1–7. 
Bondi A., Van der Waals Volumes and Radii, Journal of Physical Chemistry, 1964, 68, 441-
451. 
Boiko V.N., Aromatic and heterocyclic perfluoroalkylsulfides, Methods of preparation, 
Beilstein Journal of Organic Chemistry, 2010, 6, 880–921. 
Bridge A.W., Wlilliam A., Harris N.V., Lythgoe D.J.,Smith C., PCT Int. Appl. WO 9110662, 
1992;Chemical Abstracts, 115, 207994. 
Buhler S., Goettert M., Schollmeyer D., Albrecht W.,Laufer S.A., Chiral sulfoxides as 
metabolites of 2-thioimidazole-based p38α mitogen-activated protein kinase inhibitors: 
45 
Enantio selective synthesis and biological evaluation, Journal of Medicinal Chemistry, 2011, 
54, 3283-3297. 
Conti  C., Mastromarino P., Goldoni P., Portalone  G., Desideri N., Synthesis and anti-
rhinovirus properties of fluorosubstitutedflavonoids, Antiviral Chemistry & Chemotherapy, 
2005, 16, 267–276. 
Cumper C.W.N.,  Pickering D.G., Electric dipole moments of some imidazolin-2(3H)-ones, 
benzimidazol- 2(3H)-ones, and analogous thiones, Journal of the Chemical Society, Perkin 
Transactions 2, 1972, 14, 2045-2048. 
Dawood K.M., Wahab-Abdel B.F., Synthesis, reactions, and biological activity of 4,5-
diarylimidazole-2-thiones, Chemistry of Heterocyclic Compounds, 2010, 46,  255-278. 
Desideri N., Conti C., Mastromarino P., MastropaoloF., Synthesis and anti-rhinovirus activity 
of 2-styrylchromones, Antiviral Chemistry and Chemotherapy, 2000, 11, 373-381. 
Desideri N., Mastromarino P., Conti C., Synthesis and evaluation of antirhinovirus activityof 
3-hydroxy and 3-methoxy 2-styrylchromones, Antiviral Chemistry and Chemotherapy, 2003, 
14, 195 –203. 
Dinoiu V., Fluorine chemistry: Past, present and future, Revue Roumaine de Chimie, 2006, 
51, 1141–1152. 
Doria G., Romeo C., Forgione A., Sberze P., Tibolla N., Corno M.L, Cruzzola G. and Cadelli 
G., Antiallergic agents. III. Substituted trans-2-ethenyl-4-oxo-4H-1-benzopyran-6-carboxylic 
acids, Journal of Medicinal Chemistry, 1979, 14, 347–351. 
Doerge D.R., Decker C.J., Takazawall R.S., Chemical and enzymatic oxidation of 
benzimidazoline-2-thiones: A dichotomy in the mechanism of peroxidase inhibition, 
Biochemistry, 1993, 32, 58-65. 
Douglas H.A., Bourne T.G., Smythe M.L., The combinatorial synthesis of bicyclic privileged 
structures or privileged substructures, Chemical Reviews, 2003, 103, 893-930. 
Dunitz J.D., Taylor R., Organic fluorine hardly ever accepts hydrogen bonds,European 
Journal of Chemistry, 1997, 3,89-98. 
46 
Feldman B.J., Feldman D., The development of androgen-independent prostate cancer, 
Nature, 2001, 1, 34-45. 
Fernandes E., Carvalho M., Carvalho F., Silva A.M.S., Santos C.M.M., Pinto D.C.G.A., 
Cavaleiro J.A.S. and Bastos M.L., Hepatoprotective activity of polyhydroxylated 2-
styrylchromones against tert-butylhydroperoxide induced toxicity in freshly isolated rat 
hepatocytes, Archives of Toxicology, 2003, 77, 500–505. 
Fernandes E.R., Carvalho F., Silva A.M.S., Santos C.M.M., Pinto D.C.G.A., Cavaleiro 
J.A.S., Bastos M.L., 2-Styrylchromones as novel inhibitors of xanthine oxidase.A structure–
activity study, Journal of Enzyme Inhibition and Medicinal Chemistry, 2002, 17, 45–48. 
Filler R., Saha R., Fluorine in medicinal chemistry: a century of progress and a 60-year 
retrospective of selected highlights, Future medicinal chemistry, 2009, 1, 777-791. 
Filipe P., Silva A.M.S.,  Morliene P., Brito C.M., Patterson L.K., Hug G.L., Silva J.N.,  . 
CavaleiroJ.A.S., Maziere J.C., Freitas J.P.,  Santus R., Polyhydroxylated 2-styrylchromones 
as potent antioxidants, Biochemical Pharmacology, 2004, 67, 2207-2218. 
Fried J., Sabo E.F., 9α-Fluoroderivatiesof cortisone and hydrocortisone, Journal of American 
Chemical Society, 1954, 76, 1455-1456. 
Gerwick W.H., 6-Desmethoxyhormothamnione, a new cytotoxic styrylchromone from the 
marine cryptophytes Chrysophaeumtaylori, Journal of Natural Products, 1989, 52, 252-256. 
Gerwick W.H., Lopez A., Van Duyne G.D., Clardy J., Ortiz W. and Baez A., 
Hormothamnione, a novel cytotoxic styrylchromone from the marine cyanophyte 
hormothamnion enteromorphoides grunow, Tetrahedron Letters,1986, 27, 1979. 
Goel S., Ritu., Makrandi J.K., Microwave assisted synthesis of 1-(2-hydroxyphenyl)-5-
phenyl pent-4-ene-1,3-diones and their conversion to 2-styryl chromones,Indian Journal of  
Chemistry, 2006, 45, 1278-1281. 
Gomes A., Fernandes E., Silva A.M.S., Santos C.M.M., Pinto D.C.G.A., Cavaleiro J.A.S.,  
Lima J.L.F.C., 2-Styrylchromones: Novel strong scavengers of reactive oxygen and nitrogen 
species, Bioorganic and Medicinal Chemistry, 2007, 15,  6027–6036. 
Gomes A., Freitas M., Fernandes E. and Lima J.L.F.C., Biological Activity of 2-                                    
Styrylchromones, Mini-Reviews in Medicinal Chemistry, 2010, 10, 1-7. 
47 
Gomes A., Fernandes E., Silva A.M.S.,Pinto D.C.G.A.,Santos C.M.M., Cavaleiro J.A.S., 
Lima J.L.F.C., Anti-inflammatory potential of 2-styrylchromones regarding their interference 
with arachidonic acid metabolic pathways, Biochemical Pharmacology, 2009, 78, 171–177. 
Hangmann W. K., The many roles for fluorine in medicinal chemistry, Journal of Medicinal 
Chemistry, 2008, 51, 4359-4369. 
O'Hagan D., Understanding organofluorine chemistry,An introduction to the C–F 
bond,Chemical Society Review,2008, 37, 308-319. 
O'Hagan D., Rzepa H.S., Some influences of fluorine in bioorganic chemistry, Chemical 
Communications, 1997, 645-652. 
Hardy D.J., Swanson R.N.,  Hensey D.M., Ramer N.R., Bower R.R., Hanson C.W., Chu 
D.T.W., FernandesP.B., Comparative antibacterial activities of Temafloxacin hydrochloride 
(A-62254) and two reference fluoroquinolones, Antimicrobial Agents and Chemotherapy, 
1987,31, 1768-1774. 
Hayashi M., Sadakazu Y., Katsuo H.,  Kaoru S., Substituted imidazole derivative, Jpn. Kokai 
Tokkyo Koho JP 62187469; Chemical Abstracts, 1989, 108, 21896. 
Hiemke C., Hartter S., Pharmacokinetics of selective serotonin reuptake inhibitors, 
Pharmacology and Therapeutics,2000, 85, 11–28. 
Hozien Z.A., El-Wareth A.O.S.A., El-Sherief H.A.H., Mahmoud A.M., An efficient route for 
synthesis of 5,6-diphenylimidazo-[2,1-b]thiazoles as antibacterial agents,Journal of 
Heterocyclic Chemistry, 2000, 37, 943-949. 
Iradyan M.A., Ayvazyan A.K., Mirzoyan V.S., Paronikyan G.M.,Sarkisyan T.P., Stepanyan 
G.M., ArsenyanF.G., Garibdzhanyan B.T., Synthesis and biological activity of 4-nitro-5-
thioimidazole derivatives, Pharmaceutical Chemistry Journal, 1988, 403-408. 
Isanbor C., O’Hagan D., Fluorine in medicinal chemistry: A review of anti-cancer agents, 
Journal of Fluorine Chemistry, 2006, 127, 303-319. 
Jayaram P. N., Roy G., Mugesh G., Effect of thione–thiol tautomerism on the inhibition of 
lactoperoxidase by anti-thyroid drugs and their analogues, Journal of Chemical Sciences, 
2008, 120, 143–154. 
48 
Karton Y., Jiang J., Ji X., Melman, N., Olah M.E., Stiles G.L.,Jacobson K.A., Synthesis and 
biological activities of flavonoid derivatives as A3 adenosine receptor antagonists, Journal of 
Medicinal Chemistry, 1996, 39, 2293–2301. 
Karale B. K., Gill C. H., Shingare M. S.,Synthesis of styrylpyrimidines, Indian Journal of  
Heterocyclic Chemistry, 2003, 12, 267-270. 
Kelkar A.S., Letcher R.M., Cheung K.K., Chiu K.F., Brown G.D., Synthesis of C-ring 
substituted xanthones from the [4 +2]cycloaddition reaction of vinylchromones and acyclic 
enamines, Journal of the Chemical Society, Perkin Transactions-1, 2000, 3732-3741. 
Key B.D., Howell R.D., Criddle C.S., Fluorinated organics in the biosphere, Environmental 
Science and Technology, 1997, 31, 2445-2454. 
Kirk K.L., Fluorine in medicinal chemistry: Recent therapeutic applications of fluorinated 
small molecules, Journal of Fluorine Chemistry, 2006, 127, 1013-1029. 
Kruse L.I., Kaiser C., DeWolf Jr W.E., Frazee J.S., Ross S.T., Wawro J., Wise M., Flaim 
K.E., Sawyer J.L., EricksonR.W., Ezekie M., Ohlstein E.H., Berkowitz B.A., Multisubstrate 
Inhibitors of Dopamine β-Hydroxylase. 2. Structure-Activity Relationships at the 
phenethylamine binding site, Journal of Medicinal Chemistry, 1987, 30, 486-494. 
Kuznetsova L.V., Pepe A., Ungureanu I.M., Pera P.,Bernacki R.J., Ojima I., Syntheses and 
structure–activity relationships of novel 30-difluoromethyl and 30-trifluoromethyl-taxoids, 
Journal of Fluorine Chemistry, 2008, 129,  817–828. 
Klijn J.G.M., Blamey R.W., Boccardo F., Tominaga T., Duchateau L., Sylvester R., 
Combined Tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus 
LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis offour 
randomized trials, Journal of Clinical Oncology, 2001, 19, 343-353. 
Lagoja I.M., Pannecouque C., Aerschot A.V., Witvrouw M., Debyser Z., Balzarini J., 
Herdewijn P.,  De Clercq E., N-aminoimidazole derivatives inhibiting retroviral replication 
via a yet unidentified mode of action, Journal of Medicinal Chemistry,2003, 46, 1546-1553. 
Liu P., Sharon A., Chu C. K., Fluorinated nucleosides: synthesis and biological implication, 
Journal of Fluorine Chemistry, 2008,129, 743–766. 
49 
Maduskuie T.P., Wilde R.G., Billheimer J.T., Cromley D.A., Germain S., Gillies P.J., Higley 
C.A., Johnson A.L.,Pennev P., ShimshickE.J., Wexler R.R., Design, synthesis, and structure-
activity relationship studies for a new imidazole series of J774 macrophage specific Acyl-
CoA:CholesterolAcyltransferase (ACAT) Inhibitors, Journal of  Medicinal Chemistry,1995, 
38, 1067-1083. 
Makita A., Isobe Y.,Tomizawa H., Chiba S.,  Sasaki M., Preparation of 3-nitrogen-containing 
5-membered heterocyclylthio-1,2-propanediols and cytosolic phospholipase A2 
inhibitors,Jpn. Kokai Tokkyo Koho JP 2000038380, Chemical Abstracts, 2000, 132, 137387. 
Marquez V.E., Tseng C.K., Mitsuya H., Aoki S., Kelley J.A., Ford JrH., RothJ.S., Broder S., 
Johns D.G., Driscoll J.S., Acid-stable 2’-fluoropurine dideoxynucleosides as active 
agentsagainst HIV, Journal of  Medicinal Chemistry, 1990, 33, 978-985. 
Marinho J., Pedro M., Pinto D.C.G.A., Silva A.M.S., Cavaleiro J.A.S., Sunkel C.E. and 
Nascimento M.S.J.,4-methoxy-2-styrylchromone a novel microtubule-stabilizing antimitotic 
agent, Biochemical Pharmacology, 2008, 75, 826-835. 
Meanwell N., Imidazole carboxylic acids and esters and inhibition of blood platelet 
aggregation therewith, 1991, US patent 5011851. 
Miya M.B., Ramadas S.,  Krupadanam G.L.D., A facile synthesis of 2-(2'-vinylthiophene) 
chromones by modified Baker Vankataraman transformation, Indian Journal of Chemistry, 
1998, 37B, 579-582. 
Miya M.B., RaoJ.Y., Krupadanam D.G.L., Photochemical synthesis of 9-methoxy-5-
thiophenyl-12H-benzo[a] xanthenes-12-one, Indian Journal of Chemistry, 2012, 51B, 895-
898. 
Momoi K., Sugita Y., Ishihara M., Satoh K., Kikuchi H., Hashimoto K., Yokoe I., Nishikawa 
H., Fujisawa S., Sakagami H., Cytotoxic activity of styrylchromones against human tumour 
cell lines, In vivo, 2005, 19, 157-164. 
Muccioli G.G., Fazio N., ScribaG.K.E.,Poppitz W., Cannata F., PoupaertJ.H., Wouters J., 
Lambert D.M., Substituted 2-thioxoimidazolidin-4-ones and imidazolidine-2,4-diones as fatty 
acid amide hydrolase inhibitor templates,Journal of Medicinal Chemistry, 2006,49, 417-425. 
50 
Muller K., Faeh C., Diederich F., Fluorine in pharmaceuticals: Lookingbeyond intuition, 
Science, 2007, 317, 1881-1886. 
Park B.K., Kitteringham N.R., O’Neill P.M., Metabolism of fluorine-containing drugs. 
AnnualReview of Pharmacology and Toxicology, 2001, 41, 443-470. 
Park B.K., Kitteringham N.R., Effects of fluorine substitution on drugmetabolism—
pharmacological and toxicological implications (Review), Drug Metabolism, 1994, 26,605–
643. 
Pinto D.C.G.A., Silva A.M.S., Cavaleiro J.A.S., A convenient synthesis of new (E)-5-
hydroxy-2-styrylchromones by modifications of the BakerVenkataraman method, New  
Journal of  Chemistry,2000,24, 85-92. 
Pinto D.C.G.A., Silva A.M.S., Cavaleiro J.A.S., Foces-Foces C., Llamas-Sainz A.L., 
JagerovicN., Elguero J., Synthesis and molecular structure of 3-(2-benzyloxy-6-
hydroxyphenyl)-5-styrylpyrazoles.  Reactions of 2-styrylchromones and hydrazine hydrate, 
Tetrahedron, 1999, 55, 10187-10200. 
Pinto D.C.G.A., Silva A.M.S., Cavaleiro J.A.S., Synthesis of 6, 8-(dibromo or diiodo)-5-
hydroxy-2-(phenyl or styryl)chromones, Tetrahedron Letters,  1994, 35, 9459-9460. 
Pinto  D.C.G.A., Silva A.M.S., Cavaleiro J.A.S., Syntheses of 5-hydroxy-2-(phenyl or styryl) 
chromones and of some halo derivatives, Journal of Heterocyclic  Chemistry, 1996, 33, 1887-
1893. 
Pinto D.C.G.A., Silva A.M.S., Almeida L.M.P.M., Cavaleiro J.A.S., Levai A. and Patonay 
T., Synthesis of 4-aryl-3-(2-chromonyl)-2-pyrazolines by the 1,3-dipolar cycloaddition of 2-
styrylchromones with diazomethane, Journal of  Heterocyclic  Chemistry, 1998, 35, 217-224. 
Pinto D.C.G.A., Silva A.M.S., Cavaleiro J.A.S., Aconvenient synthesis of 3-cinnamoyl-5-
hydroxy-2-styryl-chromones by a modified Baker-Venkataraman transformation, 
Heterocyclic  Communications, 1996, 2, 145-148. 
Povstyanoi M.V., Priimenko B. A., Kochergin P. M., Synthesis and biological activity of 2-
mercaptoimidazole derivatives, Khimiko-Farmatsevticheskii Zhurnal, 1978, 12, 59-62. 
Price W.A., Silva A.M.S., Cavaleiro J.A.S., 2-Styrlchromones: Biological action, synthesis 
and reactivity, Heterocycles, 1993, 36, 2601-2612. 
51 
Rao C.S., Naresh K., Jyotsna C., Sait S.S., Synthesis of substituted 2-styrylchromones from 
7-hydroxy-2-styrylchromones, Research Journal of Pharmaceutical, Biological and Chemical 
Sciences, 2011, 2,487-494. 
Reddy B.P., KrupadanamG.L., The synthesis of 8-allyl-2-styrylchromones by the modified 
Baker-Venkataraman transformation,Journal of Heterocyclic Chemistry, 1996, 33, 1561-
1565. 
Riggi I.D., Virgili A., de Moragas M., and Jaime C., Restrictedrotation and NOE transfer: A 
conformational study of some substituted (9-Anthry1)carbinolderivatives, Journal of  Organic  
Chemistry, 1995, 60,27-31. 
Rocha-Pereira J., Cunha R., Pinto D.C.G.A., Silva A.M.S., Nascimento M.S.J., (E)-2-
Styrylchromones as potential anti-norovirus agents, Bioorganic & Medicinal Chemistry, 
2010, 18, 4195–4201. 
Rummel M.J., Kafer G., Pfreundschuh M., Jager E., Reinhardt U.,  Mitrou P.S., Hoelzer1 D., 
Bergmann L., Fludarabine and epirubicin in the treatment of chronic lymphocyticleukaemia: 
A German multicenter phase II study, Annals of Oncology, 1999, 10, 183-188. 
Sabo J.A., Abdel-Rahman S.M., Voriconazole: A new triazole antifungal, The Annals of 
Pharmacotherapy, 2000, 34, 1032-1043. 
Saeed A., Batool M., Synthesis and bioactivity of some new 1-tolyl-3-aryl-4-
methylimidazole-2-thiones, Medicinal Chemistry Research, 2007, 16, 143-154. 
Sandford G., Organofluorine Chemistry, Philosophical Transactions: Mathematical, Physical 
and Engineering Sciences, 2000, 358, 455-471. 
Santos C.M.M., Silva A.M.S., Cavaleiro J.A.S., Synthesis of new hydroxy-2-
styrylchromones, European Journal of Organic Chemistry, 2003, 4575-4585. 
Sasaki Y., Satake H., Tsukimori N., Nanbu N., Takehara M., and Ue M., Physical and 
electrolytic properties of difluorinated dimethyle carbonate, Journal of Fluorine Chemistry, 
2004, 125, 1205-1209. 
Sasaki Y., Satake H., Tsukimori N., Nanbu N., Takehara M., and Ue M., Physical and 
electrolytic properties of partially fluorinated methyl propyl carbonate and its application to  
lithium batteries, Electrochemistry,  2010, 78,  467-470. 
52 
Savjani J.K., Gajjar A.K., Pharmaceutical importance and synthetic strategies for 
imidazolidine-2-thione and imidazole-2-thione derivatives, Pakistan Journal of Biological 
Sciences, 2011, 14, 1076-1089. 
Sauerbrey S., Majhi P. K., Schnakenburg G., ArduengoIII A.J.and Streubel R., Synthesis, 
structure and reactivity of 4-phosphanylated 1,3-dialkyl-imidazole-2-thiones, Dalton 
Transactions, 2012, 41, 5368-5376. 
Scott J.E., Henderson G., A new route to the imidazole-2-thiones from 2-thiohydantoins, 
Biochemical Journal, 1968, 109, 209-215. 
Selig R., Schattel V., Goettert M., Schollmeyer D., Albrechtc W. and Laufer F., 
Conformational effects on potency of thioimidazoles and dihydrothiazolines, Medicinal 
Chemistry Communications, 2011, 2, 261-269. 
Shen S., Lei M., Wong Y., Tong M., Teo P.L., Chiba S. andNarasaka K., 
Intramolecularnucleophilic substitution at a sp2 carbon: synthesisof substituted thiazoles and 
imidazole-2-thiones, Tetrahedron Letters, 2009, 50, 3161–3163. 
Sharpe T.R., Cherkofsky S.C., Hewes W.E., Smith D.H., Gregory W.A., Haber S.B., 
Leadbetter M.R. and Whitney J.G., Preparation and antiarthritic and analgesic activity of 4,5-
diaryl-2-(substitutedthio) -1 H-imidazoles and their sulfoxides and sulfones,Journal of  
Medicinal Chemistry, 1985, 28, 1188-1194. 
Silva A.M.S., Silva A.M.G., Tome A.C., Cavaleiro J.A.S., New syntheses of flavones from 
Diels–Alder reactions of 2-styrylchromones with ortho-benzoquinodimethanes, European 
Journal of Organic Chemistry,1999, Issue-1, 135-139. 
Silva A.M.S., Pinto D.C.G.A., Cavaleiro J.A.S., Levai A., Patonay T., Synthesis and 
reactivity of styrylchromones, ARKIVOC, 2004, (vii), 106-123. 
Silva A.M.S., Pinto D.C.G.A.,  Cavaleiro J.A.S., 5-Hydroxy-2-(phenyl or styryl) chromones: 
One-pot synthesis and C-6, C-8 13C NMR assignments,Tetrahedron Letters, 1994, 35, 5899-
5902. 
Silva A.M.S., Pinto D.C.G.A., Tavares H.R., Cavaleiro J.A.S., Jimeno, M.L., Elguero J., 
Novel (E)- and (Z)-2-styrylchromones from (E,E)-29-hydroxycinnamylideneacetophenones – 
53 
Xanthones from daylight photooxidative cyclization of (E)-2-styrylchromones, European 
Journalof Organic Chemistry, 1998, Issue 9,2031-2038. 
Silva  A.M.S., Tavares H.R., Cavaleiro J.A.S., Synthesis of xanthones by daylight photo 
oxidative cyclization of (E)-2-styrylchromones, Heterocyclic Communications, 1996, 2, 251-
254. 
Silva A.M.S., Vieira J.S., Brito C.M., Cavaleiro J.A.S., Patony T., Levai A., Elguero J., 
Bromination and azidation reactions of 2-styrylchromones. New syntheses of4(5)-aryl-5(4)-
(2-chromonyl)-1,2,3-triazoles, Monatshefte fur Chemie, 2004, 135, 293-308. 
Simpson J.A.,Watkins E.R., Price R.N., Aarons L., Kyle D.E., White N.J., Mefloquine 
pharmacokinetic-pharmacodynamic models: Implications for dosing and resistance, 
Antimicrobial Agents and Chemotherapy, 2000, 44, 3414–3424. 
Skvortsova G.G., Abramova N.D., Trzhtsinskaya B.V., Synthesis and some properties of N, 
S-divinyl-2-mercapto benzimidazole, Chemistry of Heterocyclic Compounds, 1974, 10, 
1217-1220. 
Svetlik J., Turecek F., Goljer I., Condensation of (2-Bromo-1-
phenylethy1idene)malononitrile with substituted thioureas: An unusual ring size effect, 
Journal of Organic Chemistry, 1990, 55, 4740-4744. 
Takagi K., Tanaka M., Mrakami Y., Morita H. and Aotsuka T., Synthesis of new 3(5)-(2-
hydroxyphenyl)pyrazoles as potential analgesic agents and platelet aggregation inhibitors, 
European Journal of Medicinal Chemistry, 1986, 21, 65-69. 
Tsuji M., Inoue T.,IkesueK., FujimotoN., Koichi I., Noriyuki F., Noda, K., Jpn. Kokai 
Tokkyo Koho, 1989, JP 01040467; Chemical Abstracts, 1990, 111, 97243. 
Trzhtsinskaya B.V., Abramova N.D., Imidazole-2-thiones: synthesis, structure, properties, 
Journal of Sulfur Chemistry, 1991, 10, 389-430. 
Trzhtsinskaya B.V., Aleksandrova A.E., Abramova N.D., Andriyankova L.V., Vinogradova 
T.I., Shchegoleva R.A., Synthesis and tuberculostatic activity of imidazole-2-thione 
derivatives, Khimiko-FarmatsevticheskiiZhurnal, 1992, 4, 57-60. 
Turner R.A., Studies of imidazole compounds. II. The structure of certain simple imidazole 
derivatives, Journal of Organic Chemistry, 1949, 71, 3472-3476. 
54 
Vermes A., Guchelaar H.-J., Dankert J., Flucytosine:a review of its pharmacology, clinical 
indications, pharmacokinetics, toxicity and drug interactions,  Journal of Antimicrobial 
Chemotherapy, 2000, 46, 171-179. 
Voitychuk O.I., Strutynskyi R.B., Moibenko O.O., Shuba Y.M., Effects of fluorine-
containing opener of ATP-sensitivepotassium channels, pinacidil-derivative flocalin, on 
cardiacvoltage-gated sodium and calcium channels, Naunyn-Schmiedeberg's Archives of 
Pharmacology, 2012, 385, 1095–1102. 
Wimalasundera S.S., Katz D.R. and Chain B.M., Characterization of the T cell response to 
human rhinovirus in children: Implications for understanding the immunopathology of the 
common cold, Concise Communications, 1997, 176, 745-842. 
Wodzinska J., Kluger R., pKa-dependent formation of amides in water from an acyl 
phosphate monoester and amines, Journal of Organic Chemistry, 2008, 73, 4753–4754. 
Yasser M.L., El-Badawi M.A., El-Barbary A.A., Pedersen E.B., Nielsen C., Synthesis of 2-
methylsulfanyl-1H-imidazoles as novel non-nucleoside reverse transcriptase inhibitors 
(NNRTIs), Archiv der Pharmazie, 2003, 336, 175–180.  
Zhang W.,  Oya S., Kung M-P., Hou C., Maier D.L., Kung H.F., F-18 Polyethylene glycol 
stilbenes as PET imaging agents targeting Ah aggregates in the brain, Nuclear Medicine and 
Biology, 2005, 32, 799–809. 
  
55 
Chapter 2. Synthesis, Crystal Structure and Evaluation of Novel 
Fluorinated 2-Styrylchromones as Antibacterial Agents 
 
Mehbub I.K Momina, Deresh Ramjugernathb, Hafizah Cheniac and Neil Koorbanallya* 
 
aSchool of Chemistry& Physics,  University of KwaZulu-Natal, Private Bag X54001, 
Durban, 4000, South Africa. 
bSchool of Chemical Engineering, University of KwaZulu-Natal, Howard college, Durban,  
South Africa. 
cSchool of Biological sciences, Genetics, and Microbiology,  University of KwaZulu-Natal, 
Private Bag X54001, Durban, 4000, South Africa. 






A range of fluorinated 2-styrylchromones (5a-g) of which six are new (5a-f) were prepared in 
three steps using the Baker-Venkataraman rearrangement together with two 
methoxyderivatives (5h-i) and a methylenedioxy derivative (5j), and screened for their 
antibacterial activity using Gram-positive bacteria (Staphylococcus aureus,Scuii and Xylosus 
as well as Bacillussubtilis) and Gram-negative bacteria (Escherichia coli, Pseudomonas 
aeruginosaand Klebsiella pneumonie).The compounds were most effective against B. subtilis 
followed by S. aureus and a single strain of E. coli (ATCC 25922).  Difluorination of the 
phenyl ring was shown to enhance antibacterial activity and fluorine substitution at the 6-
position was shown to be much superior to substitution at the 7-position.  In comparison to 
tetracycline, the activity indices of the fluorinated styrylchromones ranged from 0.50 to 0.75 
against B. subtilis.  The crystal structure of 6-fluorostyrylchromone is also presented and the 
molecule was shown to be planar. 
 





Fluorinated compounds have a wide range of medical applications such as anti-inflammatory, 
antiviral, anti-HIV, antibacterial, anticancer, antimalarial, antidepressants, antipsychotics, 
anaesthetics and steroids (Park et al., 2001; Kirk and Filler, 1996).   Introducing fluorine 
atoms into drug molecules can also alter the rate and route of drug metabolism (Park et al., 
2001) and stereoelectronic factors associated with the fluorine atom can lead to changes in 
the biological action of molecules in comparison to its analogues substituted with hydroxy 
groups or hydrogen atoms (O’ Hagan and Rzepa, 1997).  The substitution of fluorine for 
hydrogen or hydroxy groups can lead to changes in the mechanism of the drug as well as 
enzyme inhibition (O’ Hagan and Rzepa, 1997).  The small size of the fluorine atom, the 
enhanced lipophilicity it imparts to the molecules and the electronegativity of the atom often 
results in improved therapeutic drugs (Kirk and Filler, 1996).  As part of an ongoing study on 
fluorinated pharmaceutical compounds, we have chosen to explore the antibacterial effects of 
fluorinated 2-styrylchromones.   
 
The biological activities of 2-styrylchromones have recently been reviewed by Gomes et al. 
(2010).  The 2-styrylchromones were shown to be A3 adenosine receptor antagonists (Karton 
et al., 1996), have hepatoprotective activity (Fernandes et al., 2003), be potent antioxidants 
(Filipe et al., 2004), have anti allergic properties (Doria, et al., 1979), antiviral activity 
(Desideri, et al., 2000),  anticancer activity (Marinho et al., 2008; Momoi et al., 2005; 
Gerwick, 1987) and shown to display xanthine oxidase inhibition to treat for example gout, 
hypertension and hepatitis linked to xanthine oxidase inhibition (Fernandes et al., 2002).   
 
 The synthesis of these compounds has been reviewed by Silva et al. (2004) and involves the 
aldol condensation between cinnammaldehydes and 2-hydroxyacetophenones followed by an 
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oxidative cyclisation (Silva et al., 1998) or the Baker-Venkataraman rearrangement, 
involving the O-acylation of 2’-hydroxyacetophenones with cinnamic acids, followed by 
rearrangement of the ester and then cyclisation into the styrylchromone (Pinto et al., 2000a).  
They can also be made directly from 2’-hydroxyacetophenones with cinnamoyl chlorides 
(Reddy and David, 1996). 
 
The 2-styrylchromones have a structure analogous to the flavonoids, with an extra two carbon 
olefinic bond between the chromone and the phenyl ring.  Thus, instead of a phenyl group 
attached to C-2 of the chromone ring as in the flavonoids, a styryl group is attached in stead 
(see 5 in Scheme 2-1).  Due to the double bond in the backbone of the structure, the 2-
styrylchromones are reactive molecules, acting as dienes in the pericylic reactions of 
xanthones (Pinto et al., 2005), dienophiles forming flavones with ortho benzoquinodimethane 
(Silva et al., 1999a) and are readily transformed into pyrazolines (Pinto et al., 1998; Toth et 
al., 1993), 1,2,3-triazoles (Silva et al., 1999b), pyrazoles (Takagi et al., 1986; Pinto et al., 
1997; Pinto, et al., 2000b) and pyrimidines (Karale, et al., 2003). 
 
To our knowledge, there have only beenonly two studies on fluorinated styrylchromones, 
where the 6-fluoro-2-styrylchromones have shown anti-rhinovirus activity (Conti et al., 2005) 
and the 4’-fluoro-, the 4’-trifluoromethyl- and 4’-trifluoromethoxy-2-styrylchromones were 
shown to have antitumour activity (Shaw, et al., 2009).  We report here on the synthesis and 
antibacterial activity of a series of fluorinated 2-styrylchromones as well as the novel crystal 





2.2. Results and Discussion 
Chemistry 
Seven new fluorinated 2-styrylchromones were prepared in good overall yields of between 60 
and 90% with only one compound (5e) having a yield of 45%.  The synthesis was carried out 
according to the three-step sequence shown in Scheme 2-1 and based on the Baker-
Venkataraman rearrangement (Pinto, et al., 2000a) with modifications.  This involved the 
formation of the desired 2-cinnamoyloxyacetophenone esters from substituted ortho-
hydroxyacetophenones and cinnamic acid derivatives in pyridine using POCl3 as a 
condensing agent.   A strong base such as potassium hydroxid then abstracts a proton from 
the methyl ketone and the resultant carbanion attacks the ester carbonyl groupresulting in the 
conversion of the cinnamoyloxyacetophenones to the ketoenols.  Cyclisation to the chromone 
was achieved with the strong acid catalyst para-toluene sulphonic acid, which protonates the 
-hydroxy group, increasing the electrophilicity of the -carbon, which is attacked by the 2’-
hydroxy group, ultimately resulting in formation of a chromone ring.   The cinnamic acids, 
2a-c and 2h-i were prepared by an aldol condensation and elimination reaction from the 
corresponding benzaldehydes and malonic acid before being reacted with the corresponding 
acetophenones. 
 
The series of 2-styrylchromones synthesized contained a single fluorine atom on the ortho, 
meta and para positions (5a-c) of the phenyl ring, two fluorine atoms at the 3’ and 5’ 
positions on the phenyl ring (5d), fluorine atoms on both of the aromatic rings (at the 7 and 4’ 
positions) (5e), as well as a single fluorine atom on the 7- (5f) and 6- (5g) positions on the 
chromone ring.   These substitution patterns were chosen to observe the effect of fluorine at 
different positions on the phenyl ring as well as the effect of fluorine on the chromone ring.  
The difluorinated compounds would provide information on multiple sites of the molecule as 
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well as substitution on both the phenyl and chromone rings simultaneously.   Two 
methoxylated 2-styrylchromones, the 4’-methoxy- and the 3’,4’-dimethoxy-2-
styrylchromones as well as the 3’,4’-methylenedioxy-2-styrylchromone (5h-j) were also 






































































a 2’-F b 3’-F c 4’-F d 3’,5’-F e 7,4’-F 
f 7-F g 6-F h 4’-OCH3 i 3’,4’-OCH3 j 3’,4’-OCH2O 
 
Scheme 2-1The preparation of 2-styrylchromones 5a-j from their corresponding 
acetophenones and cinnamic acids  (i) Pyridine, POCl3, rt. 4-5 h. (ii) DMSO, 
KOH, rt. 2h (iii) DMSO, PTSA, 90-95 °C, 2-3h. 
 
The structures of the prepared compounds were elucidated using 1D and 2D NMR 
spectroscopy along with mass spectrometry and IR spectroscopy.  Compounds 5g-j and their 
intermediates have all been prepared previously (Conti et al., 2005; Momoi et al., 2005), but 
only the NMR data for only 4g and 5g (Conti et al., 2005), 3h and 4h (Pinto, 1998) and 3i 
and 4i (Santos et al., 2009) are available in the literature.  Furthermore, only the 1H NMR 
data is given for 5g (Conti et al., 2005) while only the ethylene resonance is reported for 5h-j 
in Momoi et al. (2005).  The NMR data for 3g, 3j, 4j and 5g-j are therefore also reported here 
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along with the new compounds 5a-f and their intermediates, 3a-f and 4a-fto provide a 
complete set of NMR data for all the synthesized 2-styrylchromones and their intermediates. 
 
Synthesis of the cinnamoyloxyacetophenone (3a) was established by the presence of  and  
unsaturated proton resonances in the 1H NMR spectrum at H 6.76 and 8.00 as two doublets 
with large coupling constants of 16.16 Hz, typical of trans olefinic protons, a methyl singlet 
at H 2.55, an aromatic 8H signal between H 7.11 to 7.85.  The structure of 3a was further 
supported by two carbonyl resonances in the 13C NMR spectrum at C 197.74 for the ketone 
and C 165.10 for the ester carbonyl group.The aromatic carbon to which fluorine was 
attached was detected at C 161.80 (J = 252.60 Hz).The fluorine NMR resonance at  -113.57 
was used to confirm the presence of fluorine on the aromatic ring and the structure confirmed 
by the detection of the molecular ion at m/z 284 in the EIMS.All of the other intermediates 
3b-j had similar NMR data and their structures were elucidated in the same manner as 3a.  
The aromatic oxygenated carbon resonance in 3h was recorded at C 161.91 with similar 
resonances occurring in 3i-j. 
 
Conversion to the ketoenol (4a) was indicated by the disappearance of the methyl singlet 
resonance and the appearance of a singlet proton resonance at H 6.32 for the olefinic  
proton.  This was supported by the enol carbon resonance at C 173.63 and the keto resonance 
at C 196.25.  The fluorinated carbon resonance could be seen at C 164.87 with a coupling 
constant of 247.22 Hz and the olefinic C-O resonance at C 162.68.  The 19F NMR resonance 
at  -112.32 and the molecular ion at m/z 284 in the mass spectrum further confirmed the 
structure. The structures of the other intermediates, 4b-j were elucidated in a similar manner.   
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Cyclisation to the 2-styrylchromones was indicated by a marked shift in the H-6' resonance 
from H 7.69 in 4a to H 8.17 as H-5 in 5a.  Further to this, only a single chromene carbonyl 
resonance could be seen at C 178.37 in the 13C NMR spectrum.   The C-2 resonance was 
evident at C 161.47 and the doublet C-F resonance at 161.17 (J = 253.27), which was 
supported by the 19F NMR resonance at  -115.39.  The structures of 5b-j were confirmed 
similarly.The structures of all intermediates and final products were further confirmed by 2D 
NMR spectroscopy and by the presence of the molecular ion using mass spectrometry. 
 
In addition, the crystal structure of 5g, 6-fluoro-2-styrylchromone, the most active compound, 
was carried out to determine the extent to which the molecule was planar.  As can be seen in 
Figure 2-1 and from the data inTable 2-1, the molecule is almost planar with the bond angles 
between 116 and 124.  The compound crystallizes with four planar molecules in the 
symmetric unit and contains four molecules per unit cell. The molecular conformation is 
stabilized by a C-F distance of 1.363 Å and a C=O distance of 1.239Å (Table 2-1).  It is 
postulated that the planarity of the molecule makes it very suitable to fit into enzyme pockets 
of substrates allowing for greater interaction between the molecule and enzyme. 
 
Antibacterial activity 
The fluorinated derivatives were most effective against Gram-positive bacteria, particularly 
B. subtilis and S. aureus, with that against B. subtilis being more predominant.  The two 
methoxy derivatives were effective only against B. subtilis, with the dimethoxy derivative 
also being active against a strain of S. aureus (ATCC 29212), while the methylenedioxy 5j 




Figure 2-1ORTEP diagram of a crystal of 6-fluorostyrylchromone at 50% probability level 
 
Table 2-1Selected bond angles and bond lengths for 6-fluorostyrylchromone 
No. Atom1 Atom2 Atom3 Angle Atoms Length(Ao) 
1 O2 C1 C6 122.2 C1-O2 1.374 
2 O2 C1 C2 116.1 O2-C9 1.372 
3 F1 C4 C5 119.0 C1-C6 1.388 
4 F1 C4 C3 117.8 F1-C4 1.363 
5 C9 O2 C1 118.7 C7-O1 1.239 
6 O1 C7 C8 124.0 C6-C5 1.394 
7 O1 C7 C6 121.5 C10-C11 1.331 
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Thus, in comparing the methoxy and fluoro derivatives, the latter were far superior in their 
activity to the methoxy compounds.  Limited anti-bacterial activity was observed with Gram-
negative bacteria (Table 2-2), with K. pneumoniae and P. aeruginosa being completely 
resistant to all of the tested compounds.  Although the addition of fluorine to the benzene ring 
resulted in anti-bacterial action against E. coli ATCC 25922, it was not effective against the 
E. coli ATCC 25218 strain (Table 2-2) and the activity appeared to be strain-specific.  The 
difluorinated styrylchromones showed a broader spectrum, with only5d and 5ebeing effective 
against both E. coli strains tested (Table 2-2), indicating that multiple fluorinations on the 2-
styrylchromone backbone could lead to enhanced activity against E. coli.  However, 
fluorination on the chromone ring only resulted in no activity against E. coli.  
 
The 3’,5’ derivative (5d) showed the greatest activity of all the compounds substituted on the 
phenyl ring. This compound also showed activity against both E. coli strains tested.  This 
could therefore indicate that the activity of the 2-styrylchromones increases with increased 
fluorine substitution on the phenyl ring. Fluorination at position 7 on the chromone ring 
resulted in the compound being active against B. subtilis alone.  This activity increased 
slightly with additional fluorine substitution at the 4’-position, as activity was now 
experienced with S. scuii and both of the E. coli strains with 5e.  However, both compounds 
with fluorine substitution at the 7-position showed no activity against S. aureus.  In contrast, 
the 5g derivative, with fluorine at position-6 of the chromone ring, was the most effective of 
all the tested compounds, with an observable inhibitory effect against allof the Gram-positive 
bacteria (Table 2-2).  In fact, it was the only compound that showed any activity against E. 
faecium.  This compound however did not show any activity against of the Gram negative 
bacteria.  In another study, the 5g derivative (6-fluorinated) also showed anti-rhinovirus 
65 
activity by interfering with the replication of HRV serotype 14 and serotype 1B (Conti et al., 
2005). 
 
Table 2-2 In vitro anti-bacterial activity of 200 g/ml of 2-styrylchromone derivatives using 
the disk diffusion method 




























































































































5-a 20 - 14  10 - - 14 - - - 
5-b 22 - 15 16 - - 12 - - - 
5-c 24 - 8 8 - - 12 - - - 
5-d 25 - 19 13 - - 14 10 - - 
5-e 27 - - - 12 - 12 14 - - 
5-f 18 - - - - - - - - - 
5-g 20 10 12 11 8 10 - - - - 
5-h 21 - - - - - - - - - 
5-i 23 - 9 - - - - - - - 
5-j - - - - - - - - - - 
*AMP10 38 24 25 20 34 32 20 0 0 0 
**TE30 36 22 28 32 25 36 27 23 12 14 
*AMP (Concentration: 10ug/ml): Ampicilin control, 
** TE (Concentration: 30ug/ml): Tetracycline control. 
 
Although an activity index of greater than or equal to 1, relative to tetracycline susceptibility 
is ideal, in the present study activity indices ranged from 0 (no activity) to 0.75 (Table 2-3).  
Activity indices ranging from 0.27 – 0.56 were obtained following testing of the 6-F 
derivative (5g) against Gram-positive bacteria.Gram-positive organisms appeared to be more 
susceptible to the fluorine and methoxy derivatives compared to Gram-negative bacteria.  
This may be related to their mode of antimicrobial action, which remains to be elucidated.  
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The low activity indices obtained do not preclude the use of these derivatives as anti-bacterial 
agents.Further studies combined with standard antimicrobial agents is needed to investigate 
the synergistic activity of the 2-styrylchromones such as those carried out by Sweeney and 
Zurenko (2003). 
 





























































































































5-a 0.56 0 0.50  0.31 0 0 0.52 0 0 0 
5-b 0.61 0 0.54 0.50 0 0 0.44 0 0 0 
5-c 0.67 0 0.29 0.02 0 0 0.44 0 0 0 
5-d 0.69 0 0.68 0.41 0 0 0.42 0.44 0 0 
5-e 0.75 0 0 0 0.48 0 0.44 0.61 0 0 
5-f 0.50 0 0 0 0 0 0 0 0 0 
5-g 0.56 0.46 0.43 0.34 0.32 0.27 0 0 0 0 
5-h 0.58 0 0 0 0 0 0 0 0 0 
5-i 0.64 0 0.32 0 0 0 0 0 0 0 
5-j 0 0 0 0 0 0 0 0 0 0 
*TE30 1 1 1 1 1 1 1 1 1 1 




General Experimental Procedures 
Reagents and chemicals used in this study were purchased from Sigma Aldrich via Capital 
Lab, South Africa and were reagent grade.  All organic solvents were redistilled and dried 
according to standard procedures.  NMR spectra were recorded using a Bruker AvanceIII 400 
MHz spectrometerat room temperature with chemical shifts (δ) recorded against the internal 
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standard, tetramethylsilane (TMS).  IR spectra were recorded on a Perkin Elmer Spectrum 
100 FT-IR spectrometer with universal ATR sampling accessory. For GC-MS analyses, the 
samples were analysed on an Agilent GC–MSD apparatus equipped with DB-5SIL MS (30 m 
x 0.25 mm i.d., 0.25 µm film thickness) fused-silica capillary column. Helium (at 2 ml/min) 
was used as a carrier gas. The MS was operated in the EI mode at 70 eV.Melting points were 
recorded on an Ernst Leitz Wetziar micro-hot stage melting point apparatus. 
 
Typical procedure for the preparation of cinnamic acids 
For the preparation of the cinnamic acids 2a-c and 2h-i, the procedure in Qian (2010) was 
adopted with slight modifications   The required aromatic aldehydes (3.2 mmol), malonic 
acid (3.87 mmol) and piperidine (0.387 mmol) was dissolved in pyridine and stirred at 80-
90C for 4-5 hours. The pyridine was removed under vacuum and the reaction mixture 
poured into water and washed with HCl.  The precipitate formed was filtered and washed 
thrice with hexane, after which it was dried under vacuum to afford the cinnamic acids2a-c 
and 2h-i (Scheme 2-1). 
 
Typical procedure for the synthesis of substituted 2-(cinnamoyloxy)acetophenones 
Phosphorous oxychloride (15.6 mmol) was added to a solution of the appropriate 2-
hydroxyacetophenone (12.0 mmol) and the appropriate cinnamic acid (15.6 mmol) in dry 
pyridine. The solution was stirred at 60–70 C for 3h, and then poured into ice and water, and 
the reactionmixture acidified with hydrochloric acid (pH3-4). The obtained solid was 
removed by filtration and dissolved inethyl acetate (100 ml) and purified by silica gel column 
chromatography using a 7:3 mixture of ethyl acetate:n-hexane as the eluent. The solvent was 




Typical procedure for the synthesis of substituted 3-hydroxy-1-(2-hydroxyphenyl)-5-(phenyl)-
2,4-pentadien-1-ones 
Potassium hydroxide powder (0.05 mmol, 2.8 g) was added to a solution of 2-
cinnamoyloxy)acetophenones 3a–j (10 mmol) in dimethyl sulfoxide (15 ml). The solution 
was stirred at room temperature until complete disappearance of the startingmaterial, which 
was monitored by TLC.  A typical reaction time was 2h. The solution was then poured into 
ice water and HCl and the pH adjusted to 5. The obtained solid was removed by filtration, 
dissolved in ethyl acetate (150 ml) and purified by silica gel chromatography using ethyl 
acetate:n-hexane (7:3) as the eluent. The solvent was evaporated to dryness and the residue 
recrystallized from ethanol, resulting in 4a-j. 
 
Typical procedure for the synthesis of substituted 2-styrylchromones 
p-Toluenesulfonic acid (3.42 mmol) was added to a solution of the appropriate 3-hydroxy-1-
(2-hydroxyphenyl)-5-(phenyl)-2,4-pentadien-1-ones 4a–j (6.5 mmol) in dimethyl sulfoxide 
(20 ml). The reaction mixture was heated at 90 C for 2h, and then poured into ice andwater 
andstirred for 10 min. The obtained solid was removed by filtration, dissolved in chloroform 
(100 ml) and washed with a 20% aqueous solution of sodium thiosulphate. The solvent was 
evaporated to dryness and the residue was purified by silica gel chromatography, using 
chloroform: n-hexane (7:3) as the eluent, to produce 5a-j. 
 
2-(2’-Fluorocinnamoyloxy) acetophenone (3a) brownsolid residue (90% yield);mp 68-70o C; 
IR (KBr)max:1682 (br C=O),1627 (C=C),1612 (aromatic C-C),1483,1456,1284 (C-
F),1227cm-1; 1H NMR (CDCl3, 400 MHz)  8.00 (d, J=16.16 Hz, 1H),7.85 (dd , J=7.85, 1.58 
Hz, 1H), 7.59 (td, J=7.92, 1.65  Hz, 1H),7.54 (td, J=7.64, 1.58 Hz, 1H), 7.39 (m), 7.33 (td, 
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J=7.64, 0.84 Hz, 1H),7.19 (dd, J= 8.0, 0.84 Hz, 1H), 7.18 (t,J= 7.50 Hz, 1H), 7.11 (dd, 
J=10.25, 8.80 Hz, 1H), 6.76 (d,J=16.16 Hz, 1H), 2.55 (s, 3H, CH3); 13C NMR (CDCl3, 100 
MHz)  197.74 (C=O), 165.10 (C=O), 161.80 (d, JCF = 252.60 Hz), 149.09, 139.95 (d, J= 
2.72 Hz), 133.36, 132.21 (d, J= 14.23 Hz), 131.29, 130.16, 129.43 (d, J= 2.65 Hz), 126.12, 
124.56 (d, J= 3.62 Hz), 123.77, 122.17 (d, J= 11.56 Hz), 119.42 (d, J= 6.93 Hz), 116.32 (d, 
J= 21.72 Hz), 29.77 (CH3);19F NMR (CDCl3, 376.5 MHz) -113.57; EIMS (probe) 70 eV, 
m/z(rel. int.): 284 M+ (3), 149 (100), 121 (63), 101 (65), 75 (15); calculated molecular mass: 
284.28. 
 
2-(3’-Fluorocinnamoyloxy) acetophenone (3b) brown solid residue (68% yield): mp 55-56 
C;IR(KBr)max: 1733 and 1673 (C=O ),1637 (C=C),1444,1136 (C-F),1073cm-1; 1H NMR 
(CDCl3, 400 MHz)  7.83 (dd, J= 7.56, 1.64 Hz, 1H), 7.82 (d, J= 15.96 Hz, 1H,H),  7.55 
(td, J=7.84, 1.64 Hz, 1H), 7.35 (m, 2H),  7.33 (td, J= 7.66, 0.84, 1H), 7.27 (d, J= 9.64 Hz , 
1H),  7.17 (dd, J= 8.0, 0.68 Hz, 1H), 7.10 (tt, J=8.20, 2.0 Hz, 1H), 6.55 (d, J= 15.96 Hz, 1H, 
H), 2.55 (s, 3H, CH3);  13C NMR (CDCl3, 100 MHz) 197.68 (C=O),164.90 (ester C=O ), 
163.02 (d, JCF = 245.63 Hz), 148.99, 145.83 (d, J= 2.73 Hz), 136.27 (d, J=7.85 Hz), 133.39, 
131.21, 130.56 (d, J= 8.04 Hz), 130.19, 126.17, 124.42 (d, J= 2.87 Hz), 123.76, 118.31, 
117.71 (d, J= 21.25 Hz), 114.63 (d, J= 21.88 Hz),29.97(CH3);19F NMR (CDCl3, 376.5 MHz) 
 -112.27; EIMS (probe) 70 eV, m/z(rel. int.): 284 M+ (3), 149 (100), 121 (60), 101(55), 
75(11);calculated molecular mass: 284.28. 
 
2-(4’-Fluorocinnamoyloxy) acetophenone (3c) cream solid residue (72% yield); mp 80-82C; 
IR(KBr)max:1729 (C=O), 1670 (C=O), 1624 (C=C), 1590, 1446, 1221 (C-F), 1202, 1159, 
1050 cm-1;1H NMR (CDCl3, 400 MHz) 7.84 (d, J= 15.96 Hz, 1H, H),7.81 (dd, J=8.00, 
1.60 Hz, 1H), 7.58 (dd, J= 8.60, 5.42 Hz,2H), 7.53 (dd,J=8.00, 1.52 Hz, 
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1H),7.33(td,J=8.06,0.72 Hz, 1H),7.17(dd, J= 8.06, 0.72 Hz, 1H), 7.09 (t, J=8.60 Hz, 2H),6.58 
(d, J= 15.96 Hz, 1H, H), 2.54(s, 3H, CH3); 13C NMR (CDCl3, 100 MHz) 197.78 (C=O), 
165.14 (C=O), 163.02 (d, JCF = 250.70 Hz), 149.07, 145.99, 133.36, 131.30, 130.43 (d, J= 
8.37 Hz), 130.32 (d, J= 3.55 Hz), 130.15, 126.10, 123.78, 116.58 (d, J= 2.37 Hz), 116.20 (d, 
J= 21.85 Hz),29.71 (CH3);19F NMR (CDCl3, 376.5 MHz)  -108.54; EIMS (probe) 70 eV, 
(m/z, rel. int.) 284 M+(21), 149(100), 121(25), 101(20); calculated molecular mass: 284.28. 
 
2-(3’,5’-Difluorocinnamoyloxy) acetophenone (3d)  brown solid residue (70% yield); mp 58-
59C;IR(KBr)max: 1729 (C=O), 1682 (C=O), 1249 (C-F), 1201, 1122 cm-1;  1H NMR 
(CDCl3, 400 MHz) 7.82 (dd, J=7.92,1.04 Hz,1H), 7.75 (d,J=15.96 Hz, 1H, H), 7.55 
(td,J=7.60, 1.06 Hz, 1H), 7.34 (t, J=7.60 Hz, 1H),7.16 (dd, J = 7.92, 0.80 Hz, 1H), 7.08 (m, 
2H), 6.85 (tt, J=8.68, 2.28 Hz, 1H), 6.64 (d, J=15.96 Hz, 1H, H), 2.54 (s, 3H, CH3); 13C 
NMR (CDCl3, 100 MHz) 197.60 (C=O), 164.58 (C=O), 163.03 (d, JCF = 248.29 Hz, 2C), 
148.86, 144.47,137.27 (d, J= 9.54 Hz), 133.47, 131.00,130.28,126.26, 123.74, 119.72, 111.52 
(d, J= 26.08 Hz, 2C),  105.92 (t, J= 24.44 Hz), 29.51 (CH3);  19F NMR (CDCl3, 376.5 MHz) 
 -108.75; EIMS (probe) 70 eV, (m/z, rel. int.):302 M+(3), 167(100), 139(79), 119(60); 
calculated molecular mass: 302.27. 
 
4-fluoro-2-(4’-Fluorocinnamoyloxy) acetophenone (3e)off white solid residue (68% yield); 
mp 60-62C; IR (KBr)max:1724 (C=O),1679 (C=O),1361 (C-O), 1225 (C-F), 1143 cm-1; 1H 
NMR (CDCl3, 400 MHz) 7.87 (dd,J= 8.75, 6.34 Hz, 1H),7.84 (d, J=15.96 Hz, 1H, H),7.58 
(dd, J = 5.40, 1.98 Hz, 2H), 7.10 (dd, J = 8.70, 2.48 Hz, 2H), 7.03 (td,J=8.75, 2.45 Hz, 1H), 
6.92(dd, J= 8.90,2.45 Hz,1H), 6.56(d, J= 15.96 Hz, 1H, H), 2.53 (s,3H, CH3); 13C NMR 
(CDCl3, 100 MHz)  196.11 (C=O), 165.11 (C=O), 164.99 (d, JCF = 254.07 Hz),164.35 (d, 
JCF = 250.95 Hz), 151.16, 146.55, 132.20 (d, J= 10.14 Hz), 130.47 (d, J= 8.47 Hz, 2C), 
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130.17 (d, J= 3.0 Hz), 127.62 (d, J= 3.51 Hz), 116.26 (d, J= 21.94 Hz, 2C), 116.11 (d, J= 
2.24 Hz), 113.24 (d, J= 21.20 Hz), 111.70 (d, J= 23.99 Hz), 29.73 (CH3); 19F NMR (CDCl3, 
376.5 MHz)  -103.81, -103.17; EIMS (probe) 70 eV (m/z, rel. int.)302 M+ (3), 149(100), 
121(92), 101(75); calculated molecular mass: 302.27. 
 
4-fluoro-2-cinnamoyloxy acetophenone (3f)brownsolid residue (86% yield); mp 98-100 C;  
IR(KBr)max:1730 (C=O),1678 (C=O),1634,1598,1247 (C-F),1100,886cm-1; 1H NMR 
(CDCl3, 400 MHz) 7.88(d, J=15.92 Hz, 1H, H), 7.86 (dd, J= 8.60, 5.40 Hz, 1H),7.58 (dd, 
J= 7.50, 1.90 2H),7.44 (m, 2H), 7.41 (m, 1H), 7.03 (ddd,J=8.60, 7.87, 2.48 Hz, 1H),6.94 (dd, 
J = 8.90, 2.48 Hz, 1H),  6.63(d, J=15.92 Hz, 1H, H), 2.53 (s, 3H, CH3); 13C NMR (CDCl3, 
100 MHz)  196.13 (C=O), 166.44 (d, JCF = 255.80 Hz), 164.75 (C=O), 151.00, 145.40, 
133.86, 132.29 (d, J = 10.15 Hz), 131.08, 129.04 (2C), 128.51 (2C), 127.00, 116.29, 113.43 
(d, J = 21.13 Hz), 111.73 (d, J = 24.07 Hz), 29.83 (CH3);19F NMR (CDCl3, 376.5 MHz) -
103.91; EIMS (probe) 70 eV (m/z, rel. int.) 284 M+ (3), 131(100), 103(71), 77 (39), 
51(11);calculated molecular mass: 284.28.  
 
5-fluoro-2-cinnamoyloxy acetophenone (3g)brownsolid residue(90% yield ); mp 81-83C; IR 
(KBr)max: 1731 (C=O), 1681 (C=O), 1632, 1581, 1131 (C-F), 983 cm-1;1H NMR (CDCl3, 
400 MHz)  7.88(d, J=15.92 Hz, 1H, H),7.58 (m, 2H),  7.49 (dd, J=8.70, 3.04 Hz, 1H),7.40 
(m, 1H), 7.39 (m, 2H), 7.23 (dd, J = 7.80, 3.04 Hz, 1H),7.15(dd,J = 8.70, 4.65 Hz, 1H), 6.64 
(d, J=15.92 Hz, 1H, H), 2.53 (s, 3H, CH3); 13C NMR (CDCl3, 100 MHz) 196.35 (C=O), 
165.22 (C=O), 159.90 (d, JCF = 245.12 Hz), 147.79, 145.03, 133.90,132.63 (d, J= 6.10 Hz), 
131.04, 129.04 (2C), 128.48 (2C),125.44 (d, J= 7.96 Hz), 120.08 (d, J= 23.26 Hz), 116.51 (d, 
J= 20.48 Hz), 116.61, 29.78 (CH3); 19F NMR (CDCl3, 376.5 MHz) -115.35; EIMS (probe) 
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70 eV (m/z, rel. int.)  284 M+ (30), 266(8), 145(25), 131(100), 103(44), 77 (21); calculated 
molecular mass: 284.28. 
 
2-(4’-methoxycinnamoyloxy) acetophenone (3h)off white solid residue (91% yield); mp 97-
99 C; IR (KBr) max: 1711 (C=O), 1680 (C=O), 1600 (C=C), 1509, 1581, 1246, 1189 cm-
1;1H NMR (CDCl3, 400 MHz) 7.83 (d, J =15.92 Hz, 1H), 7.80 (dd, J = 8.04, 1.55 Hz, 1H), 
7.53 (d, J = 8.72 Hz, 2H), 7.51 (td, J = 7.55, 1.55 Hz, 1H), 7.31 (td, J = 8.04, 0.76 Hz, 1H), 
7.17 (d, J = 8.0 Hz, 1H), 6.91 (dd, J = 8.72, 2.64 Hz, 2H), 6.52 (d, J = 15.92 Hz, 1H), 3.84 (s, 
3H, OCH3),  2.54 (s, 3H, CH3); 13C NMR (CDCl3, 100 MHz)  197.90 (C=O), 165.53 (C=O), 
161.91, 149.28, 147.15, 133.26, 131.54, 130.23 (2C), 130.04, 126.78, 125.95, 123.81, 114.45 
(2C), 114.10,  55.43, 29.92;  EIMS (probe) 70 eV (m/z, rel. int.) 296  M+(7), 161 (100), 133 
(49), 118 (16), 90 (15), 77 (16);calculated molecular mass: 296.10. 
 
2-(3’,4’-methoxycinnamoyloxy) acetophenone (3i) off white solid residue(56% yield); mp 99-
101 C; IR (KBr)max: 1728 (C=O), 1683 (C=O), 1633 (C=C), 1515, 1254  cm-1;  1H NMR 
(CDCl3, 400 MHz)7.82 (d, J = 15.88 Hz, 1H),  7.81 (dd, J =7.80, 1.72 Hz, 1H), 7.54 (td, J 
= 7.92, 1.56 Hz, 1H), 7.31 (td, J = 7.55, 0.90 Hz, 1H), 7.17 (d, J = 8.0 Hz, 1H), 7.16 (dd, J = 
8.24, 1.88 Hz, 1H), 7.10 (d, J= 1.88 Hz, 1H), 6.87 (d, J = 8.24 Hz, 1H), 6.52 (d, J = 15.88 Hz, 
1H), 3.91 (s, 6H, 2 x OCH3),  2.55 (s, 3H, CH3); 13C NMR (CDCl3, 100 MHz)  197.90 
(C=O), 165.48 (C=O),  151.67, 149.30, 149.23, 147.36, 133.29, 131.49, 130.06, 127.03, 
125.98, 123.81, 123.31, 114.34, 111.05, 109.82, 55.94, 56.00, 29.86; EIMS (probe) 70 eV 




2-(3’,4’-methylenedioxycinnamoyloxy) acetophenone (3j)off white solid residue (59% yield), 
mp 99-100 C, IR (KBr) max: 1715 (C=O), 1679 (C=O), 1600 (C=C), 1449, 1202 (C-F), 925 
cm-1; 1H NMR (CDCl3, 400 MHz) 7.80 (dd, J = 7.92, 1.56 Hz, 1H), 7.78 (d, J = 15.88 Hz, 
1H), 7.53 (td, J = 7.92, 1.56 Hz, 1H), 7.31 (td, J = 7.92, 1.56 Hz, 1H), 7.16 (d, J = 7.92 Hz, 
1H), 7.08 (d, J = 1.56 Hz, 1H), 7.05 (dd, J = 7.94, 1.56 Hz, 1H ),  6.82 (d, J = 7.94 Hz, 1H), 
6.47 (d, J = 15.88 Hz, 1H), 6.00 (s, 2H, OCH2O), 2.54 (s, 3H, CH3);13C NMR (CDCl3, 100 
MHz)  197.84 (C=O), 165.39 (C=O), 150.17, 149.21, 148.47, 147.11, 133.28, 131.47, 
130.06, 128.49, 125.99, 125.18, 123.79, 114.60, 108.64, 106.70, 101.70 (OCH2O), 29.86; 
EIMS (probe) 70 eV (m/z, rel. int.)  310 M+(12), 175(100), 145(64), 117(24), 89(40), 63(16); 
calculated molecular mass: 310.30. 
 
3-Hydroxy-1-(2-hydroxyphenyl)-5-(2-fluorophenyl)-2,4-pentadien-1-one (4a)pale yellowsolid 
residue (93% yield); mp 158-160C, IR (KBr)max:1680 (C=O), 1626, 1581, 1483, 1283 (C-
F), 1227 (C-O) cm-1;1H NMR (CDCl3, 400 MHz) 14.55 (s, 3-OH), 12.17(s, 2'-OH), 7.73(d, 
J= 16.00 Hz, 1H Hβ),7.69 (dd, J=8.01, 1.44  Hz, 1H),7.54 (td, J=7.65, 1.48 Hz, 1H), 7.43 
(ddd,J= 8.48, 7.08, 1.44 Hz, 1H),  7.32 (m, 1H), 7.16(t, J=7.56 Hz, 1H),7.09(t, J= 8.20 Hz, 
1H),6.97(dd, J=8.48, 0.68 Hz, 1H),6.88 (td, J = 8.12, 0.84 Hz, 1H), 6.70 (d, J= 16.00 Hz, 1H, 
Hα), 6.32 (s,1H);13C NMR (CDCl3, 100 MHz) 196.47 (C=O), 174.03 (C3),162.63, 161.41 
(d, JCF = 253.82 Hz),136.18, 132.62 (d, J= 2.23 Hz),131.38 (d, J= 8.82 Hz), 129.23 (d, J = 
3.00 Hz),128.56, 124.84 (d, J = 7.77 Hz), 124.52 (d, J = 3.57 Hz),123.11 (d, J = 11.54 Hz), 
119.06,119.04,118.76, 116.29 (d, J = 21.90 Hz), 97.41 (C2);19F NMR (CDCl3, 376.5 MHz)  
-114.18;EIMS (probe) 70 eV (m/z, rel. int.) 284 M+ (26), 264(7), 149(100), 121 (59), 
101(20); calculated molecular mass: 284.28. 
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3-Hydroxy-1-(2-hydroxyphenyl)-5-(3-fluorophenyl)-2,4-pentadien-1-one (4b)yellow solid 
residue (72% yield), mp 115-117C,IR (KBr)max:1641 (C=O), 1626 (C=C), 1581, 1488, 
1429, 1294 (C-F),1236 cm-1;1H NMR (CDCl3, 400 MHz) 14.55 (s, 3-OH), 12.15(s, 2'-OH), 
7.68(dd, J=8.01, 2.01 Hz, 1H), 7.58(d, J=15.78 Hz, 1H, Hβ), 7.44 (ddd,J=8.53, 7.05, 1.54 
Hz, 1H), 7.34 (dd, J= 7.92, 5.70 Hz, 1H), 7.30 (d, J=7.76 Hz, 1H), 7.24 (m, 1H), 7.06 (m, 
1H), 6.89 (ddd, J=8.01, 7.05, 0.90 Hz, 1H), 6.97 (dd, J= 7.90, 0.90 Hz, 1H),6.56 (d, J=15.78 
Hz, 1H, Hα), 6.32 (s, 1H);  13C NMR (CDCl3,100MHz) 196.25 (C=O), 173.63,164.87 (d, 
JCF = 247.22 Hz),162.68,138.32 (d, J= 2.51 Hz),137.28 (d, J= 7.75 Hz), 136.00, 130.50 (d, J= 
8.23 Hz), 128.53, 124.06 (d, J= 2.75 Hz), 123.51,119.05, 119.01, 118.81, 116.90 (d, J= 21.60 
Hz), 114.05 (d, J= 20.01 Hz), 97.44 (C2);19F NMR (CDCl3, 376.5 MHz) -112.32; EIMS 
(probe) 70 eV (m/z, rel. int.) 284 M+(25), 149 (100), 265 (8), 121 (88), 101 (17); calculated 
molecular mass: 284.28. 
 
3-Hydroxy-1-(2-hydroxyphenyl)-5-(4-fluorophenyl)-2,4-pentadien-1-one (4c) pale yellow 
solid residue (92% yield); mp 130-132 C, IR (KBr) max: 1683 (C=O), 1627 (C=C), 1598, 
1572, 1489, 1156 (C-F) cm-1; 1H NMR (CDCl3, 400 MHz) 14.62 (s, 3-OH ), 12.17(s, 2'-
OH),7.68 (dd,J=8.05,1.44 Hz, 1H), 7.60 (d, J=15.95 Hz, 1H, Hβ),7.52 (dd, J= 8.85, 5.36 Hz, 
2H),7.44 (ddd, J=8.52, 7.10, 1.44 Hz, 1H), 7.08 (t, J=8.85 Hz, 2H),6.97 (dd, J=8.52, 0.85 Hz, 
1H),6.88(ddd, J= 8.05, 7.10, 0.85 Hz, 1H), 6.49(d, J=15.95 Hz, 1H, Hα), 6.29(s,1H); 13C 
NMR (CDCl3, 100 MHz) 196.03 (C=O), 174.25 (C3), 163.78 (d, JCF = 250.26 Hz), 162.64, 
138.53,135.87, 130.23 (d, J = 3.52 Hz), 129.81 (d, J = 8.21 Hz, 2C), 128.47, 121.88, 119.04 
(2C), 118.79, 116.15 (d, J = 21.85 Hz, 2C), 96.98 (C2); 19F NMR (CDCl3, 376.5 MHz)  -
109.55; EIMS (m/z, rel. int.) 284 M+(21), 149 (100), 121 (71), 265 (4),163 (16), 101 (18); 
calculated molecular mass: 284.28. 
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3-Hydroxy-1-(2-hydroxyphenyl)-5-(3,5-difluorophenyl)-2,4-pentadien-1-one (4d) light brown 
solid residue (91% yield), mp 130-132 C, IR (KBr)max: 1698 (C=O),1658 (C=C),1119 (C-
F), 962, 843 cm-1;  1H NMR (CDCl3, 400 MHz)  14.46 (s, 3-OH), 12.10(s, 2'-OH), 7.67 
(dd,J=8.05,1.40 Hz, 1H), 7.51(d, J=15.70 Hz, 1H, Hβ ),7.45 (ddd, J= 8.47, 7.24, 1.62 Hz, 
1H), 7.04 (dd, J=8.22, 2.16 Hz, 2H), 6.98  (dd, J= 8.47, 1.06 Hz, 1H), 6.89 (ddd, J= 8.05, 
7.24, 1.06 Hz, 1H), 6.80(tt, J=8.76, 2.16 Hz, 1H),6.55(d, J= 15.70 Hz, 1H, Hα), 6.32 (s,1H); 
13C NMR (CDCl3, 100 MHz) 196.42 (C=O), 172.84 (C3), 163.29 (dd, JCF= 247.76, 13.10 
Hz, 2C), 162.73, 138.30 (t, J = 9.54 Hz),136.97,136.17,128.56,124.80,119.14,118.94, 118.85, 
110.48 (dd, J= 18.53, 6.83 Hz, 2C),105.07 (d, J = 25.60 Hz),97.89 (C2);19F NMR (CDCl3, 
376.5 MHz) δ -109.10;  EIMS (m/z, rel. int.)302 M+ (28), 167(100), 121(76), 285(10), 
139(29), 121(76); calculated molecular mass: 302.27. 
 
3-Hydroxy-1-(4-fluoro-2-hydroxyphenyl)-5-(4-fluorophenyl)-2,4-pentadien-1-one (4e) yellow 
solid residue (82%yield); mp143-145C; IR (KBr)max:1726 (C=O),1629 (C=C),1234 (C-F), 
1157, 975, 824, 803, 789 cm-1;1H NMR (CDCl3,400MHz) 14.42 (s, 3-OH), 12.47 (s, 2'OH), 
7.60(d,J=15.90 Hz, 1H, Hβ),7.68 (dd,J=8.98, 6.40 Hz,1H),7.52(dd,J=8.72 5.40 Hz, 2H), 7.08 
(t,J=8.58 Hz, 2H),6.65 (dd, J= 10.37, 2.50 Hz, 1H ), 6.60(ddd,J= 8.77, 8.16,2.15 Hz, 1H), 
6.51 (d, J = 15.90 Hz, 1H, Hα),6.20 (s, 1H); 13C NMR (CDCl3, 100 MHz)  194.87 (C=O), 
174.21 (C3),166.40 (d,JCF= 212.10 Hz), 165.16 (d, J = 14.10 Hz), 162.98 (d, JCF=250.55 Hz), 
138.72,130.65 (d, J =11.90 Hz),130.41 (d, J =10.83 Hz),129.85 (d, J=8.55 Hz, 2C), 121.70, 
116.17 (d, J =21.88 Hz, 2C), 115.95, 107.31 (d, J = 22.57 Hz),105.30 (d, J = 23.57 Hz), 
96.76 (C2); 19FNMR (CDCl3, 376.5 MHz)-100.64, -109.57; EIMS (m/z, rel. int.) 302 M+ 
(41), 149 (100), 283 (18), 207 (11), 163 (35), 139 (95), 121 (37), 101 (35); calculated 
molecular mass: 302.27. 
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3-Hydroxy-1-(4-fluoro-2-hydroxyphenyl)-5-(phenyl)-2,4-pentadien-1-one (4f) yellowsolid 
residue (64% yield); mp 143-145C; IR (KBr)max: 1632 (C=O), 1579 (C=C), 1178 (C-F) 
cm-1; 1H NMR (CDCl3, 400 MHz)  14.48 (s, 3-OH ), 12.55 (s, 2'-OH), 7.68 (dd, J= 8.94, 
6.42 Hz, 1H),7.64(d, J= 15.80 Hz, 1H, Hβ), 7.53 (dd, J= 8.06, 2.05 Hz, 2H), 7.38 
(m,3H),6.65 (dd, J=10.30, 2.50 Hz, 1H), 6.60(td, J = 8.0, 2.50 Hz, 1H), 6.57 (d, J= 15.80 Hz, 
1H, Hα),6.21 (s,1H); 13C NMR (CDCl3, 100 MHz) 194.85 (C=O),174.42 (C3), 165.17 
(d,JCF= 209.24 Hz), 165.08 (d, J = 14.07 Hz), 140.14, 134.92, 130.47 (d, J = 11.65 Hz), 
130.18, 128.99 (2C), 128.02 (2C), 122.00, 115.95, 107.29 (d, J = 22.65 Hz), 105.27 (d, J = 
23.41 Hz), 96.78 (C2);19F (CDCl3, 376.5 MHz)  -100.72;EIMS (m/z, rel. int.) 284 M+(33), 
131 (100), 265 (14), 139 (64), 103 (42), 77 (39), 51 (11); calculated molecular mass: 284.28. 
 
3-Hydroxy-1-(5-fluoro-2-hydroxyphenyl)-5-phenyl-2,4-pentadien-1-one (4g) yellow solid 
residue (90% yield); mp 118-120oC; IR (KBr):1632(C=O),1550,1487,1248,1180,960,781,754 
cm-1;1H NMR (CDCl3, 400 MHz) 14.59 (s, 3-OH ), 11.94 (s, 2'-OH), 7.66 (d, J= 15.81 Hz, 
1H Hβ), 7.54(dd , J= 7.88, 2.20 Hz, 2H), 7.40 (m, 3H), 7.34 (dd,J= 9.0, 3.08 Hz, 1H), 7.17 
(ddd, J= 9.16, 7.88, 3.00 Hz, 1H), 6.93 (dd, J= 9.08, 4.68 Hz, 1H),6.58 (d, J= 15.81 Hz, 1H, 
Hα),6.20(s,1H);13C NMR (CDCl3, 100 MHz) 194.82 (d, J = 2.72 Hz, C=O), 175.23 (C3), 
158.72, 155.12 (d,JCF= 236.79 Hz), 140.67, 134.84, 130.42, 129.02 (2C), 128.10 (2C), 123.19 
(d, J = 23.38 Hz), 121.86,  119.95 (d, J = 7.41 Hz), 118.72 (d, J = 6.50 Hz), 113.46 (d, J = 
23.53 Hz), 96.81 (C2);19F (CDCl3, 376.5 MHz)  -124.33;EIMS (probe) 70 eV (m/z, rel. int.) 
284 M+(5), 131 (100), 103 (80), 77 (35); calculated molecular mass: 284.28. 
 
3-Hydroxy-1-(2-hydroxyphenyl)-5-(4-methoxyphenyl)-2,4-pentadien-1-one (4h) yellowsolid 
residue (90% yield); mp 167-169 C; IR (KBr)max:1645 (C=O),1599, 1514, 1462, 1258, 
963, 828, 749 cm-1;1H NMR (CDCl3, 400 MHz) 14.72 (s, 3-OH),12.24 (s, 2'-OH), 7.67 (dd, 
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J=7.95, 1.60 Hz, 1H),7.61 (d, J= 15.76 Hz, 1H),7.49 (d, J = 8.80 Hz, 2H), 7.42 (ddd, J= 8.50, 
7.50, 1.60 Hz, 1H),6.96 (dd,J=8.50, 2.10 Hz, 1H), 6.91 (d, J = 8.80 Hz, 2H), 6.89 (m, 1H), 
6.45 (d, J= 15.76 Hz, 1H),6.26 (s,1H),3.83 (s, 3H, OCH3);13C NMR (CDCl3, 100 MHz) 
195.32 (C=O),174.91 (C3), 162.26, 161.12, 139.49, 135.33, 129.77, 129.44 (2C), 128.83, 
119.41, 118.85, 118.69, 118.44, 114.16 (2C),  96.13, 55.15;EIMS (probe) 70 eV (m/z, rel. 
int.) 296  M+(14), 161(100), 207(18), 133(77), 118(29); calculated molecular mass: 296.10. 
 
3-Hydroxy-1-(2-hydroxyphenyl)-5-(3,4-dimethoxyphenyl)-2,4-pentadien-1-one(4i)yellow 
solid residue (84% yield); mp 130-132oC; IR(KBr): 1685(C=O), 1621, 1564, 1488, 1252, 
1161;1H NMR (CDCl3, 400 MHz) 14.71 (s, 3-OH),12.23 (s, 2'-OH), 7.67 (dd, J= 8.08, 1.45 
Hz,1H),7.59 (d, J = 15.68 Hz, 1H, Hβ),7.42 (ddd, J= 8.52, 8.30, 1.45 Hz, 1H),7.11 (dd, J = 
8.30, 1.90 Hz, 1H), 7.06 (d,J= 1.82 Hz, 1H),6.96 (dd, J= 8.43, 0.68 Hz,1H), 6.87 (d, J = 8.30 
Hz, 1H), 6.85 (td, J = 8.30, 0.68 Hz, 1H), 6.45 (d, J= 15.68 Hz, 1H, Hα),  6.28 (s,1H),3.92 (s, 
3H, OCH3), 3.91 (s, 3H, OCH3); 13C NMR (CDCl3, 100 MHz) 195.62 (C=O),175.00 (C3), 
162.54,151.13, 149.31, 139.98, 135.64, 128.39, 128.02, 122.60, 119.91, 119.12, 118.96, 
118.74, 111.19, 109.67, 96.48 (C2), 56.01, 55.93;EIMS (probe) 70 eV (m/z, rel. int.) 326 
M+(15), 191 (100), 207 (16), 163 (49), 148 (19), 133 (18), 77 (23);calculated molecular mass: 
326.12. 
 
3-Hydroxy-1-(2-hydroxyphenyl)-5-(3,4-methelenedioxyphenyl)-2,4-pentadien-1-one (4j) light 
yellow solid residue (94%yield); mp165-167C; IR (KBr)max:1693 (C=O), 1621, 1602, 
1566, 1484, 1446, 1239 (C-O), 1171, 1035, 925 cm-1; 1H NMR (CDCl3, 400 MHz) 14.68 (s, 
3-OH ), 12.24 (s, 2'-OH), 7.66 (dd, J=8.01, 1.56 Hz, 1H), 7.55 (d, J=15.64 Hz, 1H Hβ), 7.42 
(ddd, J = 8.45, 8.01, 1.56  Hz, 1H), 7.04 (bd, J = 0.35 Hz), 7.02 (dd, J= 8.00, 1.20 Hz,1H), 
6.96 (dd,J=8.45, 0.50  Hz, 1H), 6.87 (td, J = 8.01, 0.50  Hz, 1H), 6.81 (d, J=8.00 Hz, 
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1H),6.39 (d, J= 15.64 Hz, 1H, Hα),6.26 (s,1H),  6.00 (s, 2H, OCH2O); 13C NMR (CDCl3, 100 
MHz) 195.69(C=O), 174.83 (C3), 162.55, 149.57(C4’), 148.47(C3’), 139.73, 135.68, 
129.50, 128.42, 124.56, 120.13, 119.09, 118.99, 118.73, 108.70, 106.31, 101.61 (OCH2O), 
96.61 (C2); EIMS (probe) 70 eV (m/z, rel. int.) 310 M+ (18), 175(100), 207(28), 145(87), 
157(42), 117 (44), 89(52), 43(62); calculated molecular mass: 310.30. 
 
2'-Fluoro-2-styrylchromone (5a)light yellowsolid residue (68% yield); mp 150-152 C; UV 
λmax (CH3OH) nm (log ): 325 (3.37); IR (KBr) max: 1682 (C=O), 1625, 1589 (C-C), 1562, 
1464, 1391 (C-F), 1125, 968 cm-1;1H NMR (CDCl3, 400 MHz) 8.17 (dd,J= 7.94, 1.56 Hz, 
1H),7.72 (d, J=16.24 Hz, 1H, H), 7.66 (ddd,J= 8.56, 7.20, 1.56 Hz,1H),7.59 (td, J= 7.60, 
1.50 Hz, 1H), 7.53 (d,J=8.28 Hz,1H),7.37 (td, J = 7.92, 0.80  Hz, 1H) ,7.32 (m, 1H), 7.17 
(t,J=7.92 Hz,1H), 7.11 (ddd, J = 9.20, 8.20, 2.36 Hz, 1H),  6.87 (d, J=16.24 Hz, 1H, H), 
6.32 (s, 1H);  13C NMR (CDCl3, 100 MHz)  178.46 (C=O), 161.47, 161.17 (d, JCF=253.27 
Hz, C2’), 156.02,133.88,131.25 (d, J= 8.67 Hz), 129.47 (d, J= 3.10 Hz, C), 128.39 (d, J= 
2.72 Hz), 125.69, 125.06, 124.56 (d, J= 3.57 Hz),124.13, 123.09 (d, J = 11.68 Hz), 122.67 (d, 
J = 6.52 Hz, C), 117.93, 116.23 (d, J= 21.81 Hz), 111.21; 19F NMR (CDCl3, 376.5 MHz) 
-115.39; EIMS (m/z, rel. int.) 265 (M+-1)(100), 237(12), 207(20), 146(36), 92(25); HRMS 
(m/z) M+ 266.0733 (calculated for C17H11FO2: 266.0743). 
 
3’-Fluoro-2-styrylchromone (5b) brown solid residue (62% yield), mp 105-108 C; UV λmax 
(CH3OH) nm (log ): 325 (3.34); IR (KBr) max:1694 (C=O), 1622, 1579 (C-C),1465,1389 
(C-F),1247,1122,967,775 cm-1;1H NMR (CDCl3, 400 MHz) 8.18 (dd, J = 7.92, 1.32 Hz, 
1H), 7.68 (dt, J = 8.60, 1.64 Hz, 1H), 7.55 (d, J = 16.00 Hz, 1H), 7.52 (d, J = 8.60 Hz, 1H), 
7.36 (m, 3H), 7.26 (m, 1H), 7.06 (t, J = 8.04 Hz, 1H), 6.77 (d, J = 16.00 Hz, 1H), 6.34 (s, 
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1H);13C NMR (CDCl3, 100 MHz)  178.51 (C=O), 163.15 (d, J = 245.48 Hz, C3'), 161.22, 
156.00, 137.28 (d, J = 7.84 Hz), 135.57 (d, J = 2.77 Hz, C), 133.89, 130.54 (d, J = 8.30 Hz), 
125.76, 125.14, 124.09, 123.61 (d, J = 2.67 Hz), 121.67 (C),  117.87, 116.69 (d, J = 21.60 
Hz), 113.99 (d, J = 21.99 Hz), 111.15; 19F NMR (CDCl3, 376.5 MHz) -112.42; EIMS (m/z, 
rel. int.) 265 (M+-1) (100), 237(6), 209(8), 173(16), 146(40), 121(20), 92(27); HRMS (m/z): 
266.0726 M+ (calculated for C17H11FO2: 266.0743). 
 
4'–Fluoro-2-styrylchromone (5c) off white solid residue (70% yield), mp 158-160C; UV 
λmax (CH3OH) nm (log ): 328 (3.39); IR (KBr):1691 (C=O), 1623, 1594, 1506, 1466, 1391 
(C-F), 1224, 969, 817 cm-1;  1H NMR (DMSO-d6, 400 MHz) 8.01 (dd, J= 7.92, 1.44 Hz, 
1H), 7.82 (m, 1H), 7.79(m, 2H), 7.70 (d, J = 16.16 Hz, 1H, H), 7.69 (d,J= 8.48 Hz,1H),7.47 
(t, J = 7.44 Hz, 1H),  7.28(t,J=8.78 Hz, 2H), 7.16 (d, J=16.16 Hz, 1H, H),  6.46 (s, 1H); 13C 
NMR (DMSO-d6, 100 MHz)  177.42 (C=O), 162.88 (d, JCF =240.60 Hz, C4'),161.64, 
155.43, 135.38 (C), 134.35, 131.60 (d, J = 3.22 Hz), 130.02 (d, J = 8.11 Hz, 2C), 125.31, 
124.76, 123.39, 120.38 (C),118.20, 115.97 (d, J = 24.34 Hz, 2C), 110.06; 19F NMR 
(DMSO-d6, 376.5 MHz) -110.72;EIMS (m/z, rel. int.) 265 (M+-1) (100), 237(8), 207(13), 
173(10), 146(39), 120(18), 92 (20); HRMS (m/z): 266.0721 M+ (calculated for C17H11FO2: 
266.0743). 
 
3’,5'-Difluoro-2-styrylchromone (5d )light brown solid residue (92% yield); mp 114-116 C; 
UV λmax(CH3OH) nm (log )322 (3.49); IR (KBr) max:1701 (C=O), 1615,1586,1465,1390 
(C-F),1309,1272,1117 (C-F),966,847,751 cm-1;1H NMR (CDCl3, 400 MHz) 8.18 (dd, J= 
7.92, 1.56 Hz, 1H),7.72 (ddd,J= 8.55, 7.20, 1.56 Hz,1H),7.55 (d,J=8.30 Hz,1H), 7.53 (d, 
J=15.96 Hz, 1H, H), 7.43 (td, J = 7.92, 0.68 Hz, 1H),7.12 (m, 3H), 6.85 (tt,J=8.70, 2.35 
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Hz,1H),6.80 (d, J=15.96 Hz, 1H, H), 6.34 (s, 1H);  13C NMR (CDCl3, 100 MHz) 178.37 
(C=O), 163.47 (d, JCF=248.84 Hz, C3’), 160.59, 155.97,138.28 (d, J = 9.50 Hz),134.22 (d, J 
= 3.02 Hz, C),133.99,125.79, 125.25, 124.11,122.98(C), 117.87, 111.70, 110.41, 110.20 
(d, J = 11.25 Hz), 110.15 (d, J = 25.90 Hz), 104.96 (d, J = 25.31 Hz);19F NMR (CDCl3, 376.5 
MHz)  -108.99; EIMS (m/z, rel. int.) 284 M+ (100), 267(82), 191(40), 164(63), 121(58), 
92(65),64(21); HRMS (m/z): 284.0633 M+ (calculated for C17H10F2O2: 284.0649). 
 
7,4'-Difluro-2-styrylchromone (5e) pale yellow solid residue(45% yield); mp 182-184C; UV 
λmax (CH3OH) nm (log ) 322 (3.54); IR(KBr): 1659 (C=O),1621 (C=C), 
1598,1511,1438,1377 (C-F),1233,1140,1112, 967 cm-1; 1H NMR (CDCl3, 400 MHz)  8.18 
(dd, J=8.80, 6.35 Hz, 1H), 7.56 (dd,J= 8.60, 5.56, Hz, 2H), 7.53 (d, J= 16.00 Hz, 1H, Hβ), 
7.20 (dd, J= 9.04, 2.40 Hz, 1H), 7.12 (m, 1H ), 7.10 (t, J= 8.60 Hz, 2H), 6.67 (d, J = 16.00 
Hz, 1H, H), 6.28 (s, 1H);13C NMR (CDCl3, 100 MHz) 177.41 (C=O),167.07(d, JCF= 
210.10 Hz),164.97 (d, JCF= 251.55 Hz), 161.82, 156.88, 135.83, 131.15 (d, J= 3.56 Hz), 
129.52 (d, J= 8.19 Hz, 2C), 128.22 (d, J= 10.51 Hz), 120.96, 119.67, 116.21 (d, J= 21.88 Hz, 
2C), 113.73 (d, J= 22.45 Hz), 110.63, 104.60 (d, J= 25.49 Hz); 19F NMR (CDCl3, 376.5 
MHz)  -102.96, -109.89; EIMS (m/z, rel. int.) 283 (M+-1) (100), 267(56), 255(8), 227(13), 
173(13), 146(50), 120(10);HRMS (m/z): 284.0642 (calculated for C17H10F2O2: 284.0649). 
 
7-Fluoro-2-strychromone (5f) off white solid residue (94% yield); mp 116-118 C; UV λmax 
(CH3OH) nm (log ) 312 (3.35); IR (KBr)max:1667 (C=O),1599,1538, 1438, 1382 (C-F 
stretch), 1143, 1012, 960 cm-1; 1H NMR (CDCl3, 400 MHz) 8.19 (dd, J=8.85, 6.35 Hz, 1H), 
7.59 (d, J = 15.96 Hz, 1H, H),7.58 (dd, J = 8.10, 1.48 Hz, 2H),7.41 (m, 3H), 7.21 (dd, 
J=9.13, 2.40 Hz, 1H),  6.76 (d, J= 15.96 Hz, 1H, H), 7.10 (td, J = 8.60, 2.40 Hz, 1H),  6.29 
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(s, 1H); 13C NMR (CDCl3, 100 MHz)  177.48 (C=O),164.48 (d, JCF = 240.00 Hz), 
162.01,157.05 (d, J = 13.20 Hz), 137.19 (C), 134.88, 130.00, 129.05 (2C),128.20 (d, J = 
10.64 Hz),127.72 (2C), 121.00, 119.89 (C),113.69 (d, J = 22.56 Hz),110.62, 104.63 (d, J = 
25.39 Hz);19F NMR (CDCl3, 376.5 MHz) -103.04; EIMS (m/z, rel. int.) 265 (M+-1) (100), 
250(36), 237(5), 209(7), 128(29), 102(8); HRMS (m/z): 266.0730 (calculated for C17H11FO2: 
266.0743). 
 
6-Fluoro-2-styrylchromone (5g) light green solid residue (89% yield); mp 108-110o C; IR 
(KBr): 1710 (C=O), 1628,1567,1478,1445,1378,1284,1172,967,818,751 cm-1;  1H NMR 
(CDCl3, 400 MHz) δ 7.81 (dd, J=8.20, 3.15 Hz, 1H), 7.58 (d, J=16.08 Hz, 1H, Hβ),7.56 (d, 
J= 8.0 Hz, 2H),7.52 (dd, J = 9.10, 4.15 Hz, 1H), 7.40 (m, 3H), 6.77 (d, J=16.08 Hz,1H, Hα), 
6.31 (s, 1H); 13C NMR (CDCl3, 100 MHz)  177.62 (d, J = 2.28 Hz, C=O), 161.99, 159.50 
(d, JCF=245.09 Hz), 152.20, 137.35 (C), 134.88, 130.02, 129.05 (2C), 127.73 (2C), 125.47 
(d, J = 7.10 Hz), 121.76 (d, J = 25.13 Hz), 120.03 (C), 119.89 (d, J = 7.89 Hz), 110.69 (d, J 
= 23.42 Hz), 109.89; 19F NMR (CDCl3, 376.5 MHz)  -115.51; EIMS (m/z, rel. int.) 265 (M+ 
-1) (100), 249(43), 237(9), 209(12), 128(56); calculated molecular mass: 266.67. 
 
4'-Methoxy-2-styrylchromone (5h) yellow solid residue (90% yield); mp 167-169 C; UV 
λmax (CH3OH) nm (log ) 354 (3.33); IR (KBr)max:1645 (C=O), 1599, 1514, 1462, 1258, 
963, 828, 749 cm-1; 1H NMR (CDCl3, 400 MHz) dd, J = 7.95, 1.60 Hz, 1H), 7.65 
(ddd, J = 8.56, 7.12, 1.60 Hz, 1H),  7.55 (d, J = 15.96 Hz, 1H, H), 7.52 (d, J = 8.56 Hz), 
7.48 (d, J = 8.70 Hz, 2H), 7.36 (t, J = 7.95 Hz, 1H),  6.92 (d, J = 8.70 Hz, 2H), 6.64 (d, J = 
15.96 Hz, 1H, H), 6.28 (s, 1H), 3.84 (s, 3H, OCH3); 13C NMR (CDCl3, 100 MHz) 
C=O), 162.25, 161.11, 156.03, 136.65 (C), 133.60, 129.29 (2C), 125.69, 124.91, 
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124.15, 117.85(C), 117.90, 117.85, 114.48 (2C), 109.94, 55.42 (OCH3); EIMS (m/z, rel. 
int.) 277 (M+-1) (100), 247(21), 207(19), 158(38), 115(55); calculated molecular mass: 
278.30.  
 
3’,4’-Dimethoxy-2-styrylchromone (5i) yellow solid residue (55% yield); mp 162-163 C; 
UV λmax (CH3OH) nm (log )367 (3.18); IR (KBr)max: 1682 (C=O), 1617, 1558, 1509, 1464, 
1381, 1261, 1138, 1025, 965, 780, 759 cm-1; 1H NMR (DMSO-d6, 400 MHz) 8.01 (dd,  J = 
7.88, 1.72 Hz, 1H), 7.81(ddd, J = 8.20, 7.16, 1.72 Hz, 1H), 7.70(d, J=8.20 Hz, 1H), 7.65 (d, 
J=16.04 Hz, 1H, H), 7.47 (ddd, J=7.88, 7.16, 0.68 Hz, 1H), 7.36(d,J = 1.72 Hz, 1H),7.27(d, 
J=8.28, 1.72 Hz, 1H), 7.11(d, J=16.04 Hz, 1H, H),  7.02(d,J=8.28 Hz, 1H), 6.40 (s, 1H), 
3.80 (s, 3H, OCH3),3.83 (s, 3H, OCH3); 13C NMR (DMSO-d6, 100 MHz) C=O), 
162.26, 155.44, 150.53, 149.00, 136.87, 134.21, 127.79, 125.22, 124.74, 123.42, 122.31, 
118.11, 118.01, 111.67, 109.92, 109.17, 55.54 (2 x OCH3); EIMS (m/z, rel. int.) 308 (M+) 
(100), 277(22), 250(10), 221(14), 188(70), 121(19);calculated molecular mass: 308.33. 
 
3’,4’-Methylenedioxy-2-styrylchromone (5j) yellow solid residue (92% yield); mp 209-210 
C; UV λmax (CH3OH) nm (log )329 (3.36); IR (KBr)max: 1694 (C=O), 1625, 1461, 1499, 
1447, 1383, 1251, 845 cm-1; 1H NMR (CDCl3, 400 MHz) d, J = 7.62 Hz, 1H), 7.65 
(ddd, J = 8.11, 7.14, 0.98 Hz, 1H), 7.51 (d, J = 7.82 Hz, 1H), 7.50 (d, J = 16.06 Hz, 1H, H), 
7.37 (t, J = 7.53, 1H),  7.08 (s, 1H), 7.05 (d, J = 8.06 Hz, 1H), 6.81 (d, J= 8.06 Hz, 1H), 6.59 
(d, J = 16.06, 1H, H), 6.28 (s, 1H), 6.01 (s, 2H, OCH2O); 13C NMR (CDCl3, 100 MHz) 
C=O), 161.98, 156.01, 149.32 (C4'),148.52 (C3'), 136.67, 133.65, 129.53, 125.70, 
124.95, 123.91, 123.25, 118.35, 117.80, 110.17, 108.69, 106.15, 101.60 (OCH2O);  EIMS 
(m/z, rel. int.) 291 (M+-1) (100), 275(55), 233(18), 205(24), 172(67), 114(29);calculated 
molecular mass: 292.29. 
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X-ray Crystallographic Study 
Single-crystal X-ray diffraction data were collected on a Bruker KAPPA APEX II DUO 
diffractometer using graphite-monochromated Mo-K radiation ( = 0.71073 Å). Data 
collection was carried out at 173(2) K. Temperature was controlled by an Oxford Cryostream 
cooling system (Oxford Cryostat). Cell refinement and data reduction were performed using 
the program SAINT (SAINT, Version 7.60a, 2006). The data were scaled and absorption 
correction performed using SADABS (Sheldrick, 1997). The structure was solved by direct 
methods using SHELXS-97 (Sheldrick, 1997) and refined by full-matrix least-squares 
methods based on F2 using SHELXL-97 (Sheldrick, 1997) and using the graphics interface 
program X-Seed (Barbour, 2001; Atwood and Barbour, 2003). The programs X-Seed and 
POV-Raywere both used to prepare molecular graphic images. All non-hydrogen atoms were 
refined anisotropically andall hydrogen atoms could be found in the difference electron 
density maps but were placed in idealised positions and refined in riding models with Uiso set 
at 1.2 times those of their parent atoms and at a distance(C-H) of 0.95 Å. The structure was 
refined to an R factor of 0.0503.  
 
Antibacterial Assay 
In vitro evaluation of antibacterial activity was carried out on all synthesized fluorinated and 
oxygenated 2-styrylchromones by the disc diffusion method as described by Bauer et al. 
(1966) against the Gram positive bacteria, Bacillus subtilis, Enterococcus faecium and three 
Staphylococcus species, aureus,scuii and xylosus, and the Gram negative bacteria, 
Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.  The standard 
antibiotics, tetracycline (Te) and ampicillin (Amp) were used for controls and for 
comparison.  Briefly, Mueller Hilton agar was prepared (38 g in 1 L of water) and poured 
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into prelabeled sterile Petri dishes, which was then allowed to set and dry at room 
temperature.  The bacterial organisms were standardized using a turbidity standard and then 
swabbed onto the agar plates. Paper discs with dissolved sample and a control disc was 
placed onto the agar plates and the inoculum spots allowed to  dry at room temperature before 
being inverted and incubated at 35-37 ºC for 18 hours.   The diameter of inhibition zone was 
then measured in mm.  The tests were done in triplicate and the results reported as means of 
at least three determinations.  The results are summarized in Table 2-2 and Table 2-3. 
 
The activity index of the product 2-styrylchromoneswas calculated as follows: Activity index 




Several new fluorinated 2-styrylchromones (5a-5f) were synthesized along with a known 
fluorinated compound, two methoxylated compounds and a methylenedioxy derivative.  The 
compounds were characterized and screened for their antibacterial activity.  In general, the 
fluorinated compounds displayed antibacterial activity against Gram-positive bacteria more 
than Gram-negative bacteria, with the fluorinated styrylchromones being most active against 
B. subtilis followed by S. aureus and then a single strain of E. coli (ATCC 25922), but not the 
E.coli (ATCC 25218) strain, indicating that their activity toward E. coli is strain specific.  
However, the styrylchromones with two fluorine substitutions showed activity against both E. 
coli strains, indicating that a broader spectrum could be obtained with multiple fluorinations 
on the styrylchromone backbone.  Furthermore, the 3’,5’-difluorostyrylchromone (5d) 
showed the best activity from all the compounds fluorinated on the phenyl ring, also 
indicating that more fluorine substitutions on the styrylchromone could lead to enhanced 
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activity.  Activity of the styrylchromones substituted on the chromone ring was specific to 
fluorination at the 6-position, which showed the best activity amongst all the compounds 
tested.  Fluorination at the 7-position was only active against one bacterial strain, B. subtilis.  
Thus, the position and number of fluorine substituents on either the phenyl or the chromone 
ring has an effect on the antibacterial activity of the 2-styrylchromones.  It is worthwhile 
exploring the effect of hydroxy, methoxy and fluorine substitution on the phenyl ring together 
with fluorine substitution at the 6-position, as these compounds may show enhanced activity. 
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Fluoro- and methoxy-2-styrylchromonederivatives have been synthesised by the Baker–
Venkataraman method in a three step synthesis starting with acetophenones and (E) cinnamic 
acids and proceeding through substituted (E) cinnamoyloxyacetophenone and substituted 3-
hydroxy-2,4-pentadien-1-one intermediates. Full structural elucidation of the substituted (E) 
cinnamoyloxyacetophenones and 3-hydroxy-2,4-pentadienone intermediates and the 2-
styrylchromone derivatives are presented.  The structure elucidation were carried out using 
extensive 1D (1H, 13C) and 2D(COSY, HSQC and HMBC) NMR spectroscopic studies. 
 




2-Styrylchromones (2-SC) are a chemical family of oxygen heterocyclic compounds, similar 
to the flavonoids (2-phenylchromones), but with a vinyl group bridging the chromone ring to 
the phenyl moiety.  Many derivatives of 2-styrylchromones have been synthesised (Silva et 
al., 2004) and their occurrence in nature has also been reported (Gerwick et al., 1989).   There 
have also been numerous reports on the biological activity of the synthesised derivatives of 2-
styrylchromones, which has recently been reviewed by Gomes et al. (2010) and these 
compounds have been seen to have antioxidant (Filipe et al., 2004), antiviral (Desideri, et al., 
2000), anticancer (Gerwick et al., 1987; Momoi et al., 2005; Marinho et al., 2008), anti-
allergic (Doria, et al., 1979)and hepatoprotective activities (Fernandes, 2003) as well as A3 
adenosine receptor antagonists (Karton, 1996)and xanthine oxidase inhibitors (Fernandes, 
2002). 
 
Although the NMR data for 2-styrylchromones are always reported in the synthetic 
publications that also report the biological activity, they are never assigned to particular 
protons or carbon atoms. We have noticed only one publication on the structural elucidation 
of these compounds in which the nitro derivatives were described (Barros and Silva, 2009).  
To the best of our knowledge there are no publications in which the structural elucidation of 
these compounds has been discussed with substituents on the aromatic rings which donate 
electrons by resonance into the aromatic rings. Furthermore, the structural elucidation of 
fluorinated molecules is more challenging due to the 19F nucleus being NMR active and 
coupling with both the protons and the carbon atoms.  We herein report the structural 
elucidation of seven fluorinated, two methoxylated and a methylenedioxy derivative of 2-
styrylchromone along with their (E) cinnamoyloxyacetophenone and 3-hydroxy-2,4-
pentadien-1-one intermediates.  The structural elucidation and NMR data reported here can 
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The synthesis of the 2-styrylchromones (5a-j) along with the (E) cinnamoyloxyacetophenone 
(3a-j) and 3-hydroxy-2,4-pentadienone (4a-j) intermediates were carried out using the Baker-
Venkataraman rearrangment in a three step reaction according to Scheme 2-1and is reported 
in Chapter 2.  Essentially, the substituted 2-hydroxyacetophenones (1) were reacted with 
substituted (E) cinnamic acids (2) in pyridine and phosphorus oxychloride (POCl3) at room 
temperature for 4-5 h producing the (E) cinnamoyloxyacetophenone intermediates (3a-j), 
which were then converted to the 3-hydroxy-2,4-pentadienone intermediates (4a-j) with 
potassium hydroxide in dimethyl sulphoxide (DMSO) by being stirred at room temperature 
for 2 h.  Final conversion to the 2-styrylchromone derivatives (5a-j) was carried out using 
para-toluene sulphonic (PTSA) acid in DMSO by reflux at 90-95 °C for 2-3 h.  The 
compounds were named similarly for each of the intermediates and the 2-styrylchromone 
according to their substitution pattern, for example, 2-(2'-fluoro(E)cinnamoyloxy) 
acetophenone (3a), 3-hydroxy-1-(2-hydroxyphenyl)-5-(2-fluorophenyl)-2,4-pentadien-1-one 
(4a) and 2'-fluoro-2-(E)styrylchromone (5a).  
 
NMR spectra 
The 1H and 13C NMR spectra were recorded at 298 K with 5-10 mg samples dissolved in 0.5 
ml of CDCl3 in 5-mm NMR tubes using a Bruker AvanceIII400 MHz NMR spectrometer(9.4 
T; Bruker, Germany) (400.22 MHz for 1H, 100.63 MHz for 13C and 376.58 Hz for 19F. 
Chemical shifts () are reported in ppm and coupling constants (J) in Hz. The 1H and 13C 
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chemical shifts of the deuterated solvent were  7.24 and 77.0 referenced to the internal 
standard, TMS, respectively.  For the 19F NMR spectra, the chemical shift of trifluorotoluene 
(TFT, 0.05% in CDCl3) was referenced at  -62.73.  For the 1H NMR analyses, 16 transients 
were acquired with a 1s relaxation delay using 32K data points.  The 90° pulse duration was 
10.0 s, and the spectral width was 8223.68 Hz.  The 13C NMR spectra were obtained with a 
spectral width of 24038.46 Hz using 64K data points.  The 90° pulse duration was of 8.40 s.  
For the 19F NMR spectra, the spectral width was 89285.71 Hz using 131K data points and the 
90° pulse duration was 12.50s.  For the two dimensional experiments including COSY, 
NOESY, HSQC and HMBC, all data were acquired with 4K × 128 data points (t2 × t1).  The 
mixing time for the NOESY experiment was 0.3s, and the long range coupling time for 
HMBC was 65 ms.  All data were analysed using Bruker Topspin 2.1 (2008) software.   
 
 
3.3. Results and Discussion 
Compounds 3-5 are fully characterised in Table 3-1 to Table 3-7 with their 1H and 13C NMR 
assignments unambiguously assigned using splitting patterns, chemical shifts and 2D NMR 
data from HSQC, HMBC and NOESY spectra.  An extensive discussion on the splitting 
patterns and chemical shifts of the compounds are presented below for the intermediates and 
the 2-styrylchromone molecules.  The discussion is divided into several parts, discussing the 
carbon chain linking the two aromatic units together and discussing the two aromatic rings in 
detail.  This is done in detail for the intermediate 3 and then a comparison to 4 and 5 is done, 
pointing out salient features and resonances that have changed as well as the proton and 




The acetyl group and the ,  unsaturated ester of the intermediate 3 
In 3a, the  and  proton resonances are characteristic and occur at H 6.76 and 8.00 
respectively as two doublets with large coupling constants of 16.16 Hz characteristic of trans 
olefinic protons.  Their corresponding carbon resonances were present at C 119.42 (J = 6.93 
Hz, C-) and 139.95 (J = 2.72 Hz, C-).  The C- resonance is more deshielded than the C- 
resonance because of conjugation between the double bond and the carbonyl group; the 
enolate anion resonance structure showing electron density being removed from C-.  The 
coupling constants experienced in 3a for these two resonances are attributed to that of the 
fluorine atom three and four bonds away from C- and C- respectively.  This small 
coupling in the carbon resonances was also seen in 3b (3''-F) with the C- resonance and 3c 
(4''-F) and 3e (4',4''-diF) with the C- resonance, but not in 3d (3'',5''-diF), 3f (4'-F) and 3g 
(5'-F), the remaining fluorinated acetophenone derivatives. The 1H and 13C chemical shifts of 
these resonances (C- and C-) were similar in all of the other cinnamoyloxy acetophenone 
derivatives (3b-3j).  The acetophenone methyl resonance occurred at H 2.55 as an intense 
singlet, also consistent with all the other derivatives 3b-3jand the acetophenone carbonyl 
resonance (C-1) was present at C 197.74, distinguished from the other ester carbonyl 
resonance (C=O) at C 165.10 because the latter showed HMBC correlations to both the  
and  proton resonances. 
 
The acetophenone aromatic ring 
The proton resonances of 3a-3d (the unsubstituted acetophenone ring) are all similar with H-
3' and H-6' appearing as doublet doublets at H 7.19 (J = 8.00, 0.84 Hz) and H 7.85 (J = 7.85, 
1.58 Hz) respectively.  The H-3' resonance ortho to the oxygenated position is more shielded 
because of electron donation from the oxygen atom by resonance and the H-6' resonance 
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more deshielded since this same electron donation by resonance results in the meta position 
becoming electron deficient.  The H-4' and H-5' proton resonances both appear as triplets of 
doublets at H 7.54 (J = 7.64, 1.58 Hz) and H 7.33 (J = 7.64, 0.84 Hz) since they experience 
the same coupling constant with each of their adjacent protons resulting in the triplet, which 
is split into doublets due to meta coupling, hence the second small coupling constant.  Only in 
3b does H-5' appear as a multiplet because of overlap with other resonances.  The C-3' to C-6' 
carbon resonances for 3a-d are all similar and occur between C 123.77 and 130.16.  The C-1' 
carbon resonance occurs at C 131.29 and was assigned because of HMBC correlations to H-
3' and H-5'.  The oxygenated aromatic resonance C-2' was assigned to C 149.09 because of 
HMBC correlations to H-6' and H-4'. 
 
In 3e and 3f, where a fluorine atom is substituted at the 4'-position, the H-3' resonance also 
occurs as a double doublet as in 3a-d, but now the meta coupling is much larger at 2.45 Hz, 
the first coupling constant of 8.90 Hz occurring because of H-F ortho coupling.  The H-5' 
resonance occurs as a triplet of doublets as for 3a-d since the H-F ortho coupling constant is 
similar to the H-H ortho coupling constant at J = 8.75 Hz, but as for H-3', the meta coupling 
constant is larger than that for 3a-d at J = 2.45 Hz.  The H-6' resonance occurs as a double 
doublet, but distinctly different from the double doublet in 3a-d because of the larger meta H-
F coupling constant of 6.34 Hz in addition to the ortho H-H coupling constant of 8.75 Hz.  
The H-6' resonance also overlaps with the H- resonance as well in these two compounds. 
 
In the 13C NMR spectrum, C-4' occurs as a doublet with J = 254.07 Hz at H 164.99 in 3e.  
The coupling constant is so large that the two resonances which make up the doublet could 
easily be mistaken for two separate resonances.  The carbon resonances however can be 
identified from the HMBC spectrum where both the resonances making up the doublet show 
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HMBC correlations to a nearby proton resonance; in the case of 3e, C-4' to H-6'.  To verify 
this, coupling constants of approximately 220-250 Hz are normally observed.  Two bonds 
away from fluorine, F-C coupling of 23.99 and 21.20 Hz are observed respectively at C 
111.70 and 113.34 for the two doublets assigned to C-3' and C-5'.  Their chemical shifts are 
more shielded than their corresponding carbon resonances in 3a-d due to electron donation 
by resonance from the fluorine, shielding the carbon atoms more than that of hydrogen.  
Three bonds away from fluorine, F-C coupling of 11.22 Hz is observed at C 150.90 for C-2' 
and 10.14 Hz at C 132.20 for C-6'.  F-C coupling four bonds away at C 127.62 for C-1' is 
also observed with a coupling constant of 3.51 Hz in 3e, however this is not seen in 3f.   
 
When the fluoro group moves to the 5' position in 3g, the H-3' resonance is now meta to the 
fluorine atom, which by resonance deshields the meta hydrogen resulting in it appearing at H 
7.49 in 3g as opposed to H 6.92-6.94 in 3e and 3f. The multiplicity is retained as a double 
doublet with J = 8.70 and 3.04 Hz for the H-H and H-F coupling respectively.  The H-4' 
proton resonance coincides with the solvent peak appearing as a triplet of doublets at H 7.23 
with J = 7.80 and 3.04 Hz, the triplet being due to similar coupling between H-4'-F and H-4'-
H-3', similar to the H-5' resonance in 3e.  Due to the fluoro group being placed adjacent to H-
6', shielding this proton through electron donation by resonance, the H-6' proton resonance 
moves from being the most deshielded resonance in 3e at H 7.87, where it was meta to both 
the oxygenated moiety and the fluorine atom, to the most shielded of the aromatic resonances 
at H 7.15 in 3g.  The resonance retains its multiplicity as a double doublet since it couples to 
fluorine with a similar coupling constant to that of hydrogen with J = 8.70 and 4.65 Hz.  In 
the 13C NMR spectrum, all the carbon resonances on the aromatic ring appear as doublets 
except for C-2', which is para to the fluorinated carbon and appears at C 147.79.  The 
fluorinated carbon is present at C 159.90 with J = 245.12 Hz.  The carbon meta to the 
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fluorine C-1' occurs at C 132.63 (J = 6.10 Hz), followed by the other meta carbon C-3', at C 
125.44 (J = 7.96 Hz), both being more deshielded than the two ortho carbon atoms at C 
120.08 (J = 23.26, C-6') and C 116.51 (J = 20.48, C-4'). 
 
In the 1H and 13C NMR spectra of the methoxy and methylenedioxy derivatives 3h-3j, H-3' to 
H-6', H and H and C-1, C-2, C-1' to C-6', C-, C- and the ester C=O were all similar to 
3a-3d. 
 
The cinnamoyl aromatic ring 
In the absence of any substituents on this ring as in 3f and 3g, the H-3''/4''/5'' resonances 
overlap at H 7.44 and appear as a multiplet in 3f and the H-2''/6'' resonance appears as a 
double doublet with J = 7.56 and 3.88 in 3f.  Their carbon resonances apppear between C 
128.48 and C 133.90 with the C-2''/6'' and C-3''/5'' resonances being equivalent.  For the 4''-
methoxy derivative 3h, a characteristic pair of doublets is seen as for other para-substituted 
aromatic compounds at H 7.53 for H-2''/6'' and H 6.91 for H-3''/5'' with a coupling constant 
of 8.72 Hz.  The H-3''/5'' resonance is more shielded than that of H-2''/6'' because of the 
electron donating effects of the methoxy group by resonance to the ortho positions.  The 
carbon resonances of C-2''/6'' and C-3''/5'' occur at C 130.23 and 114.45, the C-3''/5'' 
resonance being more shielded due to the resonance effects explained above.  The 
oxygenated C-4'' resonance appears at C 161.91 and C-1'' appears at C 126.78.   
 
When the phenyl ring is substituted at both C-3'' and C-4'' with oxygenated substituents, as in 
3i and 3j, meta coupling is observed for H-2'' at H 7.10 (J = 1.88 Hz) in 3i and ortho 
coupling is observed for H-5'' at H 6.87 (J = 8.24 Hz) with H-6'' experiencing both ortho and 
99 
meta coupling at H 7.16 (J = 8.24, 1.88 Hz).  The carbon resonances of the two carbon atoms 
ortho to the methoxy groups, C-2'' and C-5'' occur more upfield at C 109.82 and C 111.05 
while C-6'' meta positioned to the 4''-methoxy substituent appears slighlty more downfield at 
C 123.31.  The two aromatic C-O resonances C-3'' and C-4'' occur at C 149.23 and 149.30 
respectively.  The two methoxy resonances in 3i overlap at H 3.91 with corresponding 
carbon resonances at C 55.94 and 56.00.  The methylenedioxy group proton resonance 
occurs at H 6.01 with a corresponding carbon resonance of C 101.70. 
 
In 3a-e, fluorination occurred at either 2'', 3'', 4'' or was difluorinated at the 3'' and 5'' 
positions.  For the 2''-fluoro derivative 3a, the H-5'' proton only experiences coupling from 
the adjacent protons and appears as a triplet at H 7.18 with J = 7.50 Hz.  This resonance 
overlaps with H-3', which may account for the meta coupling with H-3'' not being 
experienced.  The H-3'' proton resonance at H 7.11 couples with both the fluorine and the 
proton of H-4'' and appears as a double doublet with J = 10.25 Hz (H-F coupling) and 8.80 
Hz (H-H coupling).  The H-4'' proton resonance appears as a multiplet at H 7.39 due to 
coupling with all of H-3'', H-5'', H-6'' and the F.  However, the only coupling constant that 
can be observed in this multiplet is that between H-4'' and H-6'' of 1.65 Hz.  The H-6'' proton 
resonance is the most deshielded of these resonances at H 7.59 appearing as a triplet of 
doublets with J = 7.92 and 1.65 Hz.  The triplet is probably caused by the meta F atom at C-
2'' and the ortho proton of H-5'' having the same coupling constant. 
 
The carbon resonances of the aromatic ring of 3a with fluorine substituted at the 2'' position, 
results in all the carbon resonances of the ring being doublets with the largest coupling 
occurring on the carbon directly bonded to fluorine (C-2'') at C 161.80 (J = 252.60 Hz), 
followed by ortho coupling of 21.72 Hz for C-3'' at C 116.32.  For some unknown reason, C-
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1'', the other ortho carbon has a much smaller coupling constant of 11.56 Hz at C 122.17.  It 
is further noticed that while meta coupling of 14.23 Hz is observed for C-4'' at C 132.21, the 
same is not observed for C-6'' at C 129.43 which only has a coupling constant of 2.65 Hz, 
probably because of interference from the moiety attached to C-1''.  The C-5'' carbon 
resonance, para to the fluourine atom has a small coupling constant of 3.62 Hz as expected at 
C 124.56.   
 
The same trends were observed for the 3''-fluorinated derivative 3b, but now in the 13C NMR 
spectrum all the usual coupling constants were observed for the ortho carbon resonances, C-
2'' and C-4'' at C 114.63 (J = 21.88 Hz) and 117.71 (J = 21.25 Hz), the meta carbon 
resonances, C-1'' and C-5'' at C 136.27 (J = 7.85 Hz) and 130.56 (J = 8.04 Hz) and the para 
carbon resonance of C-6'' at C 124.42 (J = 2.87 Hz). 
 
In the para-fluoro substituted compounds, 3c and 3e, instead of the usual pair of doublets 
with a coupling constant of approximately 8 Hz being observed as for the para methoxy 
compound 3h, the splitting pattern is a bit more complex because of coupling to fluorine.  
The H-3'' and H-5'' protons are equivalent and their resonance appears as a triplet at H 7.09 
(J = 8.60 Hz).  This is due to similar coupling constants between H-2''/6'' and H-3''/5'', and H-
3''/5'' and the fluorine atom.  The H-2'' and H-6'' protons are also equivalent with their 
resonance appearing as a doublet of doublets, due to a smaller meta coupling constant 
between H-2''/6'' and the fluorine atom and occurs at H 7.58 (J = 8.60, 5.42 Hz).  The 13C 
NMR spectrum of 3c shows the fluorinated carbon resonance as a doublet at C 164.25 (J = 
250.70 Hz) and a doublet resonance for C-3''/5'' at C 116.20 (J = 21.85 Hz) and C-2''/6'' at C 
130.43 (J = 8.37 Hz).  The C-1'' resonance, also a doublet, overlaps with the C-2''/6'' 
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resonance at C130.32 with a coupling constant of J = 3.55 Hz.  This resonance can be seen 
more clearly in 3e at C 130.17 (J = 3.44 Hz). 
 
For the 3'',5''-difluorinated compound 3d, the H-4'' resonance was split into a triplet of triplets 
with J = 8.68 and 2.28 Hz.  This was due to H-4'' coupling to F (J = 8.68 Hz) and H-4'' 
coupling to the meta protons H-2''/6'' (J = 2.28 Hz).  The H-2'' and H-6'' protons are 
equivalent and appear as a double doublet at H 7.08 with J = 7.92 Hz for the H-F coupling 
and 1.92 Hz for the meta coupling with H-4''.  The slight variation in J4'',2''/6'' is due to the 
coalescing and broadening of peaks for H-2''/6'', however coupling between these two 
resonances were verified in the COSY spectrum.  In the 13C NMR spectrum, the C-3'' and C-
5'' resonances are equivalent and splits into a double doublet at C 163.24 due to coupling 
between the fluorine attached to (J = 248.29 Hz) and the fluorine meta to it (J = 12.83 Hz).  
The C-2'' and C-6'' resonances are also equivalent and appear as a double doublet at C 
111.02 (J = 18.80, 7.18 Hz) arising from coupling to the fluorine ortho to it and the fluorine 
para to it respectively.  The C-4'', C-1'' and C- resonances appear as triplets at C 105.92 (J 
= 25.36 Hz), C 137.27 (J = 9.44 Hz) and C 144.47 (J = 2.81 Hz) respectively since these 
carbon atoms are in the middle of the two fluorine atoms.   
 
The substituted 3-hydroxy-2,4-pentadien-1-one intermediates (4a-j) 
In these intermediates, there is a noticeable shift from the acetophenone methyl group at H 
2.59 in 3a to an olefinic resonance (H-2) at H 6.32 in 4a.  This is indicative that the 
cinnamoyloxyacetophenones (3) had converted to the 3-hydroxy-2,4-pentadien-1-ones (4).  
With regard to the ,-unsaturated double bond, both the resonances shift more upfield by 
0.27 Hz for the  resonance in 3a to H-5 in 4a and 0.06 Hz for the  resonance in 3a to H-4 
in 4a.  This is because the double bond is now conjugated with the newly formed keto-enol 
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moiety, shielding H-4 and H-5 more than the H- and H- protons in 3.  The trans 
configuration of the double bond is retained as evidenced by the large coupling constant of 
16.00 Hz.  The H-3' to H-6' resonances also move more upfield by 0.22, 0.11, 0.45 and 0.16 
Hz for H-3', H-4', H-5' and H-6', respectively from 3a to 4a.  This is probably due to greater 
electron donation by the hydroxy group as opposed to the ester group in 3a.  A further 
characteristic trait of the 1H NMR spectra of the intermediates 4 are the two hydroxyl 
resonances occurring at H 14.55 (3-OH) and 12.18 (2'-OH).   
 
In the 13C NMR spectrum of 4a, the appearance of the alkene carbon resonance C-2 at C 
97.42 and an enol carbon resonance C-3 at C 174.03 instead of the methyl carbon resonance 
at C 29.78 and the ester carbonyl resonance at C 165.10 in 3ais further evidence that 3a had 
converted to 4a.  Due to the ester group being converted to a hydroxy group from 3a to 4a, 
the ortho and para positions are now some what more shielded by electron donation by 
resonance.  As such, C-1' shifts from  131.29 in 3a to  119.04 in 4a, C-3' from  123.77 to 
 118.76 and C-5' from  126.12 to  119.06.  The C-2' resonance which is bonded to the 
hydroxy group however shifts more upfield to the Ar-OH range at C 162.67 in 4a from the 
Ar-ester resonance at C 149.09 in 3a.  The resonances on the aromatic ring adjacent to the 4 
double bond remain relatively unchanged and the 1H NMR spectra of 4b-4j contain the same 
differences as that pointed out between 3a and 4a. 
 
The substituted 2-styrylchromones 
In the substituted 2-styrylchromones 5, the splitting patterns and chemical shifts of the phenyl 
rings in the 1H and 13C NMR spectra did not change much from those of the intermediates 
3and 4 and therefore a discussion of these will not be repeated.  There was also not much 
change in the C- and C- carbon resonances as well as the H- resonance.   However, in the 
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formation of the chromone ring, the H- proton experiences a slight shift more downfield to 
H6.87 in 5a, approximately 0.17 Hz from the corresponding resonance in 4a.   
 
All the proton resonances in the chromone ring are also deshielded in forming the chromone 
ring from the 3-hydroxy-2,4-pentadien-1-one intermediates4.  The most characteristic and 
noticeable of these resonances is that of H-5 occurring at H 8.17 in 5a from 7.69 in 4a, with 
the H-6, H-7 and H-8 proton resonances having significant downfield shifts between 0.23 and 
0.56, at H 7.37, 7.66 and 7.53 respectively in 5a from H 6.88, 7.43 and 6.97 in 4a.  These 
downfield shifts must occur because of delocalisation of the π electrons within the chromone 
skeleton, thus reducing the electron density at these specific protons.  The difference in 
chemical shift of the H-5 proton is also due to hydrogen bonding with the C-4 carbonyl 
group.  This is now possible since the carbonyl group is locked into position by formation of 
the chromone ring. 
 
With regard to the 13C NMR spectra, there is not much change in both the C- and C- 
resonances or the aromatic resonances on the chromone ring with the exception of C-6, which 
is para to the oxygen substituent forming the chromone ring.  This shift is slightly downfield 
by approximately 7 ppm at C 125.05 in 5a from 119.06 in 4a. The most notable shifts in the 
13C NMR spectrum are that of C-2, C-3 and C-4, the carbon atoms involved in forming the 
chromone ring from the 3-hydroxy-2,4-pentadien-1-one.  In 5a, these carbon resonances 
occur at C 161.47, 111.21 and 178.48 for C-2, C-3 and C-4 as opposed to their 
corresponding resonances in 4a at C 174.03, 97.41 and 196.47 respectively.  These three 
resonances can also be used as evidence that the 2-styrylchromone derivatives had been 
formed from the 3-hydroxy-2,4-pentadienone intermediates. 
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All structures were confirmed and assignments of the resonances of each of the proton and 
carbon atoms were made with aid of HSQC, HMBC and NOESY data.  Selected HMBC 
correlations for 5a are shown in Figure 3-1 below and the 1H NMR spectrum of 5a is shown 
in Figure 3-2 depicting the splitting patterns and chemical shifts of the proton resonances.  
Table 3-1 to Table 3-7 contain the 1H, 13C and 19F NMR data for all the prepared compounds.  










































Figure 3-21H NMR spectrum of 2'-fluoro-2-styrylchromone (5a) depicting chemical shifts 
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Table 3-11H NMR chemical shifts (δ in ppm) for compounds 3a–j (J is given in Hz) 
 H-3' H-4' H-5' H-6' H-α H-β H-2'' H-3'' H-4'' H-5'' H-6'' CH3 OCH3/ 
OCH2O 
3a 7.19 dd 
J = 8.00, 
0.84 
7.54 td 
J = 7.64, 
1.58 
7.33 td 
J = 7.64, 
0.84 
7.85 dd 
J = 7.85, 
1.58 
6.76 d 
J = 16.16 
8.00 d 
J = 16.16 
--- 7.11 dd 
J = 10.25, 
8.80 
7.39 m 7.18 t 
J = 7.50 
7.59 td 





3b 7.17 dd 
J = 8.00, 
0.68 
7.55 td 





J = 7.56, 
1.64 
6.55 d 
J = 15.96 
7.82 d 
J = 15.96 
7.27 d  
J = 9.64 
 
--- 7.10 tt 
J = 8.20, 
2.00 
7.33 td 




2.55 s --- 
3c 7.17 dd 
J = 8.00, 
0.72 
7.53 td 
J = 8.0, 
1.52 
7.33 td 
J = 8.00, 
0.72 
7.81 dd 
J = 8.00, 
1.60 
6.58 d 
J = 15.96 
7.84 d 





J = 8.60 
--- 7.09 t 
J = 8.60 
7.58 dd 






3d 7.16 dd 
J = 7.92, 
0.80 
7.55 td 
J = 7.60, 
1.00 
7.34 td 
J = 7.60, 
0.76 
7.82 dd 
J = 7.92, 
1.00 
6.64 d 
J = 15.96 
7.75 d 
J = 15.96 
7.08 m 
 
--- 6.85 tt 
J = 8.68, 
2.28 
--- 7.08 m 2.54 s 
 
--- 
3e 6.92 dd 





J = 8.75, 
2.45 
7.87 dd 
J = 8.75, 
6.34 
6.56 d 
J = 15.96 
7.84 d 
J = 15.96 
7.58 dd 
J = 8.72, 
5.40 
7.10 dd 





J = 8.60 
 
7.58 dd 
J = 8.72, 
5.40 
2.53 s --- 
3f 6.94 dd 





J = 8.60, 
2.48 
7.86 dd 
J = 8.60, 
5.40 
6.63 d 
J = 15.92 
7.88 d 
J = 15.92 
7.58 dd 




7.44 m 7.44 m 7.58 dd 
J = 7.56 
3.88 
2.53 s --- 
3g 7.49 dd 
J = 8.70, 
3.04 
7.23 dd 
J = 7.80, 
3.04 
--- 7.15 dd 
J = 8.70, 
4.65 
6.64 d 
J = 15.92 
7.88 d 
J = 15.92 
7.58 dd 
J = 7.44, 
3.60 
7.39 m 7.39 m 7.39 m 7.58 dd 
J = 7.44, 
3.60 
2.53 s --- 
3h 7.17 d 
J = 8.00 
 
7.51 td 
J = 7.55, 
1.55 
7.31 td 
J = 8.04, 
0.76 
7.80 dd 
J = 8.04, 
1.55 
6.52 d 
J = 15.92 
7.83 d 
J = 15.92 
7.53d 
J = 8.72 
6.91 dd 
J = 8.72 
--- 6.91 dd 
J = 8.72 
7.53 d 





3i 7.17 d 




J = 7.80, 
1.72 
7.31 td 
J = 7.55, 
0.90 
7.81 dd 
J = 7.80, 
1.72 
6.52 d 
J = 15.88 
7.82 d 
J = 15.88 
7.10  d 
J = 1.88 
--- --- 6.87 d 
J = 8.24 
7.16 dd 








3j 7.16 d 
J = 7.92 
7.53 td 
J = 7.92, 
1.56 
7.31 td 
J = 7.92, 
0.76 
7.80 dd 
J = 7.92, 
1.56 
6.47 d 
J = 15.88 
7.78 d 
J = 15.88 
7.05 d 
J = 1.56 
--- --- 6.82 d 
J = 7.94 
7.08 dd 


















































3a 197.74 29.77 165.10 119.42 d 
J = 6.93 
 
139.95 d 
J = 2.72 















J = 3.62 
129.43 d 
J = 2.65 
- 
3b 197.68 29.97 164.90 
 
118.31 145.83 d 
J = 2.73 
131.21 
 












J = 8.04 
124.42 d 
J = 2.87 
- 
3c 197.78 29.71 165.14 116.58 d 
J = 2.37 
145.99 131.30 149.07 123.78 133.36 126.10 130.15 130.32 d 
J = 3.55 
130.43 d 











J = 8.37 
- 
3d 197.60 29.51 164.58 119.72 144.47 t 
J = 2.81 





















3e 196.11 29.73 165.11 116.11 d 
J = 2.24 
146.55 127.62 d 


















J = 3.44  
130.47 d 











J = 8.47 
- 















133.86 129.04 128.51 131.08 128.51 129.04 - 
3g 196.35 29.78 165.22 116.61 145.03 132.63 d 
J = 6.1 
147.79 125.44 d 











133.90 128.48 129.04 131.04 129.04 128.48 - 
3h 197.90 29.92 165.53 114.10 147.15 131.54 149.28 123.81 133.26 125.95 130.04 126.78 130.23 114.45 161.91 114.45 130.23 55.43 
3i 197.90 29.86 165.48 114.34 147.36 131.49 151.67 123.81 133.29 125.98 130.06 127.03 109.82 149.23 149.30 111.05 123.31 55.94 s, 
56.0 s 
3j 197.84 29.86 165.39 114.60 147.11 131.47 150.17 125.18 133.28 125.99 130.06 128.49 106.70 148.47 149.21 108.64 123.79 101.70 
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Table 3-31H NMR chemical shifts (δ in ppm) for compounds 4a–j(J is given in Hz) 
 2'-OH H-3' H-4' H-5' H-6' H-2 3-OH H-4 H-5 H-2'' H-3'' H-4'' H-5'' H-6'' OCH3/O
CH2O 










J = 8.01, 
1.44 
6.32 s 14.55 s 6.70 d  
J = 16.00 
7.73 d  





J = 8.20 
 
7.32 m  
 
7.16 t 





















6.32 s 14.55 s 6.56 d  
J = 15.78 
7.58 d  
J = 15.78 









J = 7.76 
 
--- 
4c 12.17 s 
 
6.97 dd 
J =  8.52, 
0.85 
7.44ddd 
J = 8.52, 
7.10, 1.44 
6.88 ddd 





6.29 s 14.62 s  6.49 d  
J = 15.95 
7.60 d  
J = 15.95 
7.52 dd 








J = 8.85 
 
7.52 dd 




4d 12.10 s 
 
6.98 dd 
J =  
8.47,1.06 
7.45 ddd  
J = 8.47, 
7.24,1.62 





J = 8.05, 
1.40 
6.32 s 14.46 s  6.55 d  
J = 15.70 
7.51 d  
J = 15.70 
7.04 dd  










J = 8.22, 
2.16 
--- 








J = 8.77, 
8.16,2.15 
7.68dd 




14.42 s  6.51 d  
J = 15.96 
7.60 d  
J = 15.90 
7.52 dd 
J = 8.72, 
5.40 
7.08 t 
J = 8.58 
 
--- 
7.08 t  
J = 8.58 
7.52 dd 
J = 8.72, 
5.40 
--- 











J = 8.94, 
6.42 
6.21 s 14.48 s  6.57 d  
J = 15.80 
7.64 d  
J = 15.80 
7.53 dd  
J = 8.06, 
2.05 
7.38  m 7.38 m 
 
7.38 m 7.53 dd 
J = 8.06, 
2.05 
--- 








-  7.34 dd 
J =9.00, 
3.00 
6.20 s 14.59 s  6.58 d  
J = 15.81 
7.66 d  















J = 8.50, 
7.50,1.60 
6.89 m 7.67 dd 
J = 7.95, 
1.60 
6.26 s 14.72 s  6.45 d  
J = 15.76 
7.61 d  





J = 8.80 










7.42 ddd  






J = 8.08, 
1.45 
6.28 s 14.71 s  6.45 d  
J = 15.68 
7.59 d  
J = 15.68 
7.06 d 
J=1.82 








4j 12.21 s 
 
6.96 dd 
J =  8.45, 
0.50 
7.42 ddd  
J = 8.45, 
8.01,1.56 
6.87 td 
J = 8.01, 
0.50 
7.66 dd 




14.68 s  6.39 d  
J = 15.64 
7.55 d  





--- --- 6.81 d  
J = 8.00 
7.02 dd 





Table 3-413C NMR chemical shifts (δ in ppm) for compounds 4a–j (J is given in Hz) 
 C-1 C-2 C-3 C-4 C-5 C-1' C-2' C-3' 
 
C-4' C-5' C-6' C-1'' C-2'' C-3'' C-4'' C-5'' C-6'' CH3/ 
OCH2O 







162.63 118.76 136.18 
 

















4b 196.25 97.44 173.63 123.51 138.32 d 
J=2.51 












J = 2.75 
 
- 

































































































134.84 128.10 129.02 130.42 129.02 128.10 - 
4h 195.32 96.13 174.91 119.41 139.49 118.85 162.26 118.44 135.33 118.69 128.83 129.77 129.44 114.16 161.12 114.16 129.44 55.15 
4i 195.62 96.48 175.00 119.91 139.98 119.12 162.54 118.74 135.64 118.96 128.39 128.02 109.67 151.13 149.31 111.19 122.60 56.01, 
55.93 
4j 195.69 96.61 174.83 120.13 139.73 119.09 162.55 118.73 135.68 118.99 128.42 129.50 106.31 149.57 148.47 108.70 124.56 101.61 
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Table 3-51H NMR chemical shifts (δ in ppm) for compounds 5a–j(J is givenin Hz) 
 
H-3 H-5 H-6 H-7 H-8 H-2' H-3' H-4' H-5' H-6' H-α H-β OCH3/OCH2O 
5a 6.32 s  
8.17 dd 






J = 8.56, 
7.20, 1.56 
7.53 d 
J = 8.28 --- 
7.11ddd 
J = 9.20, 
8.20, 2.36 
7.32 m 7.17 t J = 7.92 
7.59 td 




J = 16.24 
7.72 d 
J = 16.24 --- 
5b 6.34 s  
8.18 dd 





J = 8.60, 
1.64 
7.52 d 
J = 8.60 7.26 m --- 
7.06 t 
J = 8.04 7.36 m 7.36 m 
6.77 d 
J =  16.00 
7.55 d 
J =  16.00 --- 
5c* 6.46 s  
8.01 dd 
J = 7.92, 
1.44 
7.47 t 
J = 7.44 7.82 m 
7.69 d 
J = 8.48 7.79 m 
7.28 t 
J = 8.78 --- 
7.28 t 
J = 8.78 7.79 m 
7.16 d 
J = 16.16 
7.70 d 
J = 16.16 --- 
5d 6.34 s  
8.18 dd 
J = 7.92, 
1.56 
7.39 td 
J = 7.92, 
0.68 
7.72ddd 
J = 8.55, 
7.20,1.56 
7.51 d 
J = 8.30 
7.08 dd  








J = 8.08, 
1.88 
6.76 d 
J = 15.96 
7.49 d 
J = 15.96 --- 
5e 6.28 s  
8.18 dd 
J = 8.80, 
6.35 
7.12 m --- 
7.20 dd 





7.10  t 










J = 16.00 
7.53 d 
J = 16.00 --- 
5f 6.29s  
8.19 dd 


















J = 15.96 
7.59 d 
J = 15.96 --- 









J = 8.00 
 
7.40 d 




J = 8.00 
 
7.56 d 
J = 8.00 
 
6.77 d 
J = 16.08 
7.60d 
J = 16.08 --- 
5h 6.28 s  
8.18 dd 








J = 8.56 
7.48 d 
J = 8.70 
 
6.92 d 
J = 8.70 --- 
6.92 d 
J = 8.70 
 
7.48 d 
J = 8.70 
 
6.64 d 
J = 15.96 
7.55 d 

















J = 8.20 
7.36 d 
J=1.72 --- --- 
7.02 d 
J = 8.28 
7.27 dd 
J = 8.28, 
1.72 
7.11 d 
J = 16.04 
7.65 d 
J = 16.04 
3.80 s 
3.83s 
5j 6.28 s  
8.17 d 




J = 8.11 
7.14,0.98 
7.51 d 
J = 7.82 7.08 s --- --- 
6.81 d 
J = 8.06 
7.05 d 
J = 8.06 
 
6.59  d 
J = 16.06 
7.50 d 
J = 16.06 6.01  
*in DMSO-d6   
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Table 3-613C NMR chemical shifts (δ in ppm) for compounds 5a–j (J is given in Hz) 




C-4' C-5' C-6' OCH3/OCH2O 
5a 161.47 111.21 178.48 125.69 125.05 133.88 117.93 156.02 124.13 
122.67 






d J = 
11.68 
161.17 













d J = 
2.72 
 
5b 161.22 111.15 178.51 125.76 125.14 133.89 117.87 156.00 124.09 121.67 
135.57 
d J = 
2.77 
137.28 
d J = 
7.84 
113.99 
d J = 
21.99 
163.15 
d J = 
245.48 
116.69 
d J = 
21.60 
130.54 
d J = 
8.30 
123.61 
d J = 
2.67 
 



























t J = 
11.24 
110.28 















































































121.00 119.89 137.19 134.88 127.72 129.05 130.00 129.05 127.72  
5g 161.99 109.89 
177.62



















120.03 137.35 134.88 127.73 129.05 130.02 129.05 127.73  
5h 162.25 109.94 178.48 125.69 124.91 133.60 117.85 156.03 124.15 117.90 136.65 130.95 129.29 114.48 161.11 114.48 129.29 55.42 
5i* 162.26 109.17 177.02 124.74 125.22 134.21 118.11 155.44 123.42 118.01 136.87 127.79 109.92 149.00 150.53 111.67 122.31 55.54 




Table 3-719F NMR  chemical shifts (δ in ppm)of compounds 3a-g , 4a-g and 5a-g 
No. 3  4 5 
a -113.57 -114.18 -115.39 
b -112.27 -112.32 -112.42 
c -108.54 -109.55 -110.72 
d -108.75 109.10 -109.31 
e -103.81, -103.17 -100.64, -109.57 -102.96, -109.89 
f -103.91 -100.72 -103.04 
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The fluoro aryl and methoxy aryl analogues of (2Z,4E)-3-hydroxy-1-(2-hydroxyphenyl)-5-
(phenyl)penta-2,4-dien-1-one were synthesised from different combinations of substituted 2-
hydroxacetophenones and (E)-cinnamic acids.  They were then screened for their antioxidant 
activity by the 2, 2-diphenyl-1-picryl-hydrazyl (DPPH) radical scavenging assay and Ferric 
Reducing Power assay (FRAP).All the methoxylated analogues showedbetter activity thanthe 
fluorinated analogues and comparable to that of ascorbic acid. 
 
KEYWORDS: Antioxidant activity, 3-hydroxy-pentadien-1-ones, fluorinated aromatics, 




Oxidative stress is caused by an imbalance in the ratio of antioxidants to oxidants present in 
the body (Bhuyan et al., 2011).  Antioxidants are gaining popularity to help fight off a large 
number of life-style diseases such as cancer, diabetes, cardiovascular and other degenerative 
diseases.  Some of these, for example cancer, may be caused by the deleterious effects of 
pollution and overexposure to harmful chemicals (Roopan et al., 2009), while others such as 
diabetes and cardiovascular diseases may be caused by modern lifestyles where diets rich in 
fatty acids and carbohydrates coupled with a lack of exercise and work or family related 
stress is prevalent.  These conditions can cause biochemical changes in the body, causing an 
accumulation of harmful free radicals (Kumar, 2011). 
 
A free radical is a highly reactive chemical species, which contains an unpaired electron 
(Jaslin et al., 2011).  The family of free radicals generated from oxygen is called reactive 
oxygen species (ROS).  These species cause damage to other molecules by extracting 
electrons from them in order to attain stability (Chanda et al., 2010).  While most fruits and 
vegetables are rich in antioxidants such as polyphenolic compounds ( e.q the flavonoids, also 
a major constituent in red wine), most people experiencing the effects of oxidative stress do 
not contain these natural antioxidant supplements in their diet and the human body does not 
synthesize the required antioxidants to compensate with the damaging effects of ROS 
(Halliwell, 1996; Uttara et al., 2009). 
 
Although synthetic antioxidants such as tert butylated hydroxy toluene, tert butylate hydroxy 
anisole, gallic acid esters and tertiary butylated hydroquinones have shown the potential to 
neutralize free radicals, they have been criticized, mainly for having possible toxic effects, 
low solubility and only moderate antioxidant activity.  For decades, vitamin C (ascorbic acid) 
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has been used as an antioxidant supplement, but nowadays even this dietary supplement is 
not enough to ward off the deleterious effects of the free radicals generated in our bodies.  
There is thus a constant need to discover newpotential sources of antioxidants (Kothari et al., 
2010). 
 
The carbonyl group and the phenolic hydroxyl and methoxyl groups in molecules can 
contribute to enhanced antioxidant activity (Wright, 2002., Atmani et al., 2009).  Since the 3-
hydroxy-pentadien-1-ones contain most or all of these functional groups, they were subjected 
to the 1,1-diphenyl-2-picryl hydrazyl (DPPH) radical scavenging assay and the 
FerricReducing Power assay (FRAP)to determination their potential to act as free radical 
scavengers and hence potential antioxidants. 
 
4.2. Materials and Methods 
 
Chemistry 
In general, different combinations of 2-hydroxyacetophenones (1) and cinnamic acid 
derivatives (2) were reacted with phosphorus oxychloride in pyridine at room temperature for 
4-5 hours to produce substituted (E) cinnamoyloxyacetophenones (3), which were subjected 
to basic conditions in DMSO at room temperature for 2 hours to produce the substituted 
(2Z,4E)-3-hydroxy-1-(2-hydroxyaryl)-5-(aryl)penta-2,4-dien-1-ones (4a-4j) (Scheme 4-1).  
The molecules were named according to their substitution pattern on the aromatic rings: for 
example, 4a was named as (2Z,4E)-3-hydroxy-1-(2-hydroxyphenyl)-5-(2-fluorophenyl)-2,4-
pentadien-1-one. The structures of the molecules were confirmed by 1D and 2D NMR 
spectroscopy and mass spectrometry.  The detailed synthesis is given in Chapter 2 and a full 






The determination of the free radical scavenging activity of 4a-4j was carried using the 1,1-
diphenyl-2-picrylhydrazyl (DPPH) assay as described by Mensor et al. (2001) with a slight 
modification. Various concentrations (10, 25, 50, 125, and 250 µgmL-1) of sample extracts in 
methanol were prepared. A 1.0 mLaliquot of a 0.3 mM DPPH solution in methanol was 
added to a 2.5 mL solution of the product or standard and allowed to stand at room 
temperature in a dark chamber for 30 minutes. The change in colour from deep violet tolight 
yellow was then measured at 518 nm on a UVspectrophotometer (Jenway 6025). The 
decrease in absorbance was then converted to percentage antioxidant activity (% AA) using 
the formula:  
AA%=100 -{[(Abssample-Absblank) x100] / Abscontrol} 
Blank = Methanol (1.0 mL) plus sample solution (2.0 mL), Negativecontrol=DPPH solution 
(1.0 mL, 0.25 mM) plus methanol (2.0 mL), Ascorbic acid and gallic acid were used as 
standards.The scavenging reaction between (DPPH·) and an antioxidant (HA)can be written 
as: 
(DPPH·) + (H-A) DPPH-H + (A·) 
 
Ferric Reducing Power assay 
The FRAP was determined according the method of Oyaizu et al. (1986). The product or 
standard (100µgmL-1) was mixed with phosphate buffer (pH 6.6) and potassium ferricyanide. 
The mixture was incubated at50°C for 20 min. Trichloroacetic acid (10%, 2.5 mL) was added 
to themixture. A portion of the resulting mixture was mixed with FeCl3(0.1%, 0.5mL) and the 
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absorbance was measured at 700 nm in aspectrophotometer (Jenway 6025). A higher 
absorbance of the reaction mixture indicated a greater reductive potential of the sample. 
 
4.3. Results and Discussion 
Seven fluorinated and three methoxylatedanalogues of 3-hydroxy-1-(2-hydroxyphenyl)-5-
(phenyl)-2,4-pentadien-1-oneswere synthesized in a two-step reaction from different 
combinations of (E) cinnamic acids and 2-hydroxyacetophenones according toScheme 4-1.  
The resultant compounds were evaluated for their antioxidant activity using the FRAP and 
DPPH assays since they contained carbonyl, hydroxy, methoxy and fluoro functional groups 
in the molecule.  In particular, we wanted to see whether the fluorinated derivatives had 































a 2''-F b 3''-F c 4''-F d 3'',5''-F e 4',4''-F 
f 4'-F g 5'-F h 4''-OCH3 i 3'',4''-OCH3 j 3'',4''-OCH2O 
 
Scheme 4-1 The preparation of (2Z,4E)-3-hydroxy-1-(2-hydroxyaryl)-5-(aryl)penta-2,4-dien-
1-ones 4a-j from their corresponding acetophenones and (E) cinnamic acids  (i) Pyridine, 
POCl3, rt. 4-5 h. (ii) DMSO, KOH, rt. 2h. 
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The results obtained from the FRAP assay (Table 4-1) showed that the reducing power of all 
compounds increased with increasing concentration, indicating that they all contained 
antioxidant activity and were capable of donating electrons to radicals, quenching them and 
rendering them inactive. The reducing power of the ten compounds tested decreased in the 
following order: 4i>4h>4j>4e>4d>4g>4f>4b>4c>4a.The reducing power of the standard 
ascorbic acid was however better than the tested compounds.Five of the tested compounds, 
three fluorinated, (the 3'',5''-difluoro4d, 4',4''-difluoro 4e and the 4'-fluoro 4f derivatives) and 
two methoxylated (the 4''-methoxy 4h and 3'',4''-methoxy 4i derivatives) were relatively 
comparable to ascorbic acid having antioxidant activity of between 54 and 65% to that of 
ascorbic acid at low concentrations (31.1 g mL-1), with the 4',4'' fluoro derivative 4i having 
the highest activity.  However, with increased concentration, better antioxidant activity was 
seen in the methoxy derivatives 4h and 4i, with 4i showing the best activity from all the 
tested compounds, increasing from 62% to 86% to that of ascorbic acid with a two-fold 
increase in concentration.  At higher concentrations (125 and 250 g mL-1), both methoxy 
derivatives 4h and 4i and the methylenedioxy derivative 4j showed good activity in 
comparison to ascorbic acid, having activity of between 57 and 82% (125 g mL-1) and 
between 70 and 80% (250 g mL-1) of that of ascorbic acid. 
 
With regard to the fluorinated compounds, 4e substituted with fluorine on both the chromone 
ring at C-4' and the phenyl ring at C-4'' showed the best activity, slightly higher than that with 
a fluorine substituted at C-4' alone as in 4f.  The activity of the 3'',5''-difluoro derivative 4d 
also has antioxidant activity comparable to 4e and 4f but 4g with the 5'-fluoro substitution 
and all the derivatives with mono-fluoro substitution on the phenyl ring 4a-4c showed much 
lower antioxidant activity. 
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Table 4-1Antioxidant activity of 4a-j measured by the FRAP method 
 Absorbance at the given concentration 
31.1g mL-1 62.5g mL-1 125g mL-1 250g mL-1 
4a 0.15±0.03 0.41±0.02 0.48±0.02 0.82±0.01 
4b 0.21±0.01 0.30±0.01 0.45±0.01 0.88±0.02 
4c 0.26±0.02 0.28±0.01 0.74±0.01 0.83±0.01 
4d 0.38±0.01 0.46±0.02 0.69±0.01 0.99±0.01 
4e 0.42±0.02 0.53±0.02 0.93±0.02 1.12±0.03 
4f 0.36±0.01 0.38±0.01 0.67±0.01 0.94±0.00 
4g 0.25±0.02 0.28±0.01 0.41±0.01 0.97±0.01 
4h 0.35±0.02 0.58±0.02 1.10±0.02 1.55±0.03 
4i 0.40±0.01 0.85±0.04 1.51±0.02 1.83±0.02 
4j 0.27±0.02 0.44±0.01 1.58±0.02 1.50±0.02 
Ascorbic acid 0.65±0.03 0.99±0.01 1.93±0.02 2.15±0.03 
Data are presented as means ±SD of triplicate. 
 
The reduction of DPPH can be correlated with thenumber of available hydroxyl groups in the 
test samples and their ability to donate these to the DPPH radicals, quenching them and 
showing the probability of rendering other radicals of this type inactive.  The results from this 
assay (Table 4-2) shows that all the fluorinated compounds did not have as good antioxidant 
activity as the methoxylated or the methylenedioxy derivatives.  The activity of the ten 
compounds decreased in the following order 4i>4j>4h>4f>4a>4g>4e>4c>4d >4b.  The 
highest activity was shown by 4i, the 3'',4''-dimethoxy derivative, which also had the highest 
activity in the FRAP assay and had an activity of 76% to that of ascorbic acid at the highest 
concentration (250 g mL-1) and 71% at the lowest concentration (31.1 g mL-1).   The other 
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two oxygenated derivatives, 4h and 4j also had good activity in this assay of between 52 and 
65% at 62.5 g mL-1 and 66 and 73% at 250 g mL-1 to that of ascorbic acid at the same 
concentrations.  It appears that activating electron donating substituents such as the methoxy 
group is much better at allowing the hydroxy group on the alkene to donate its proton to the 
DPPH radical than the deactivating fluoro groups are.  Thus, fluorine substitution at either the 
phenyl or the chromone ring did not make much difference to the antioxidant activity as 
compared to oxygenated substituents such as the methoxy group. 
 
Table 4-2  Antioxidant activity of 4a-j measured by the DPPH method 
 Absorbance of the given concentration. 
31.1g mL-1 62.5g mL-1 125g mL-1 250g mL-1 
4a 12.56±0.65 26.78±0.46 38.12±0.27 48.46±0.56 
4b 9.98±0.29 16.70±0.44 34.96±0.77 42.35±1.41 
4c 16.44±0.47 20.04±1.05 34.31±0.63 45.98±0.60 
4d 10.99±0.28 15.74±0.32 26.54±0.47 44.79±1.06 
4e 19.75±0.58 21.45±0.64 30.17±0.25 47.50±0.28 
4f 11.57±0.70 21.38±0.35 39.00±0.40 52.31±0.53 
4g 16.72±0.15 31.83±1.16 34.96±0.81 46.30±1.10 
4h 18.40±0.23 35.95±0.42 44.44±0.21 61.21±0.47 
4i 34.57±0.81 43.62±0.75 59.20±0.53 70.05±0.77 
4j 23.99±0.99 45.39±0.65 50.99±0.73 67.52±0.40 
Ascorbic acid 48.54±0.70 69.42±0.60 86.42±0.60 92.42±0.72 





The FRAP assay deals with the electron donating capacity of the molecules and reflects the 
reducing power of active molecules.The presence of reductants with antioxidant property 
causes the reduction of the Fe3+/ferricynide complex to the ferrous (Fe2+) ion.In the DPPH 
assay, DPPH is a stable free radical and accepts an electron or hydrogen radical (like O-H) to 
become a stable diamagnetic molecule. 
 
In comparison to the methoxylated and methylenedioxy derivatives, the fluorinated 
derivatives were not as active as antioxidant agents, however in the FRAP assay, three 
fluorinated derivatives, the 3'',5''-difluoro 4d, the 4',4''-difluoro 4e and the 4'-fluoro 4f 
derivatives showed comparable activity to the oxygenated derivatives 4h-4j.  Amongst the 
three most active fluorinated compounds, 4e showed the best activity.  At higher 
concentrations, the antioxidant activity of the methoxy and methylenedioxy derivatives were 
comparable to that of ascorbic acid in both the FRAP and DPPH assays.  The results show 
that the methoxylated and methylenedioxy derivatives of (2Z,4E)-3-hydroxy-1-(2-
hydroxyphenyl)-5-(phenyl)penta-2,4-dien-1-one could be considered as good alternative 
sources of antioxidants.   
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To synthesise a small library of fluorinated derivatives of imidazole-2-thiones and to screen 
the synthesised compounds in vitro for antiplatelet aggregation activity to identify lead 
compounds which could either be used or developed further into antithrombotic drugs and to 
compare the activity of the fluorinated derivatives with the nitro and chloro derivatives. 
Methods 
Seven fluorinated derivatives of diethyl-2-(benzylthio)-2,3-dihydro-1H-imidazole-4,5-
dicarboxylate (6a-6g) as well as a nitro and chloro derivative (6h-6i) were prepared in five 
steps from glycine, ethyl formate, diethyl oxalate, potassium thiocyanate and substituted 
benzyl bromides.  The structures of the synthesised compounds were elucidated and verified 
using 1H and 13C NMR spectroscopy and, where appropriate, 2D NMR spectroscopy. 
Key Findings 
The synthesized compounds exhibited concentration dependent anti-platelet aggregation 
activity on both the thrombin and ADP induced platelet aggregation. The 4-nitro (6h) and 4-
fluoro (6b) compounds exhibited the highest activity from the compounds tested, with 
estimated IC50 values of 0.40 and 0.35mg/mL for the thrombin-induced and ADP-induced 
platelet aggregation respectively 
Conclusions 
Three of the compounds, the 3,4-difluoro(6c), 4-nitro(6h) and 3-chloro(6i) derivatives have 
reasonable activity in both of the assays and could have potential as broad spectrum 
antiplatelet inhibitors.  With the exception of 6c, however the fluoro derivatives were not as 
active as the nitro and chloro compounds. 
Keywords: flourine, imidazole, antiplatelet activity, thrombin, ADP.  
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5.1. Introduction 
The imidazole moiety is an important constituent of many biological molecules and hence 
has been the focus of many synthetic approaches in the quest for pharmaceutically active 
compounds in a wide range of medical conditions and diseases.  Imidazole drugs themselves 
are well known to have many pharmaceutical applications (Bhatnagar et al., 2011).  The 
imidazole-2-thiones are a subgroup of these molecules that contain a thioamide group and as 
such have an ambidentate anion, either on nitrogen or sulphur after proton abstraction, which 
makes them reactive toward electrophilic agents.  This normally involves the highly polarised 
and nucleophilic sulphur atom, which reacts first with most electrophilic centres (Dawood et 
al., 2010). 
 
Recent reviews by Dawood et al. (2010) and Savjani et al. (2011) include a number of 
synthetic methods that have been employed to synthesise and react these compounds, to 
produce a wide range of imidazole-2-thiones, substituted at almost all positions on the 
imidazole-2-thione skeleton.  They can be formed from -bromoketones with substituted 
hydrazines and potassium thiocyanate (Lagoja et al., 2003), from-hydroxyketones, thiourea 
and ammonium thiocyanate (Maduskuie et al., 1995), from benzil and thiourea (Muccioli et 
al., 2006), from phenylglycine methyl ester with phenyl or alkyl isothiocynate (Muccioli et 
al., 2006) and from diamines and CS2 over a zinc oxide/aluminium oxide catalyst (Ballabeni 
et al., 1999) to name a few.  The imidazole-2-thiones are extremely reactive and can be 
alkylated and arylated at both sulphur and nitrogen using a variety of reagents 
(Trzhtsinskayaand Abramova, 1991) added to activated double bonds such as 2-cyanoethene 
(Bagrii and Vasilenko, 1978; Trzhtsinskaya et al., 1992), acetylene (Skvortsova et al., 1974), 
aliphatic and alicyclic ketones and acetophenones (Hozien et al., 2000). 
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The imidazole-2-thiones have also shown a wide range of biological activities, having 
antitumor (Iradyan et al., 1987), antiulcer (Tsuji et al., 1989), in vitroanti-inflammatory (Selig 
et al., 2011; Tsuji et al., 1989), antiarthritic, analgesic (Sharpe et al., 1985), antihyperthyroid 
(Doerge et al., 1993), tuberculostatic (Trzhtsinskaya et al., 1992), in vitro antibacterial, 
antifungal and insecticidal activity (Saeed et al., 2007).  They were also shown to possess in 
vitro anti-HIV activity, by showing non-nucleoside reverse transcriptase inhibition (Yasser et 
al., 2003) andhuman cytosolic phospholipase A2 activity having a role in preventing 
inflammation (Makita et al., 2000).  They are known to be in vitro Acyl-CoA: Cholesterol 
acyltransferase(ACAT ) inhibitors, limiting the absorption of dietary cholesterol (Maduskuie 
et al., 1995), protein kinase inhibitors responsible for preventing the gene expression of 
proinflammatory cytokines (Buhler et al., 2011), in vitro platelet aggregation inhibitors 
(Hayashi et al., 1989), and known to be in vitro anti-hypercholesteremics (Billheimer et al., 
1990). 
 
Platelets play an important role in hemostasis during tissue injury. Platelet adhesion and its 
activation is a normal physiological response to the accidental rupture of blood vessels. 
Platelets interact with activated plasma clottingfactors at the site of injury in the blood vessel, 
forming a mechanical plug which blocks the defect and terminates blood loss (Aruna et al., 
2010; Jantan et al., 2009).  However, when such activity is uncontrolled, this may cause 
thromboembolic artery occlusion, acute coronary syndrome, and ischemic stroke (Aruna et 
al., 2010). Anti-platelet aggregation (e.g. aspirin, clopidogrel and dipyridamole) are used in 
the treatment of cardiovascular diseases, myocardial infarction and stroke (Hankey, 2003).  
However, some patients are allergic to these drugs, necessitating the need for alternative 
antithrombotic drugs.   
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As part of an ongoing study on the search for fluorinated pharmaceuticals and our interest in 
platelet aggregation inhibitors, we have synthesised a range of fluorinated imidazole-2-
thiones and tested them for their ability to inhibit platelet aggregation in vitro.  We have also 





General Experimental Procedures 
Reagents and chemicals used in this study were purchased from Sigma Aldrich via Capital 
Lab, South Africa and were reagent grade.  All organic solvents were redistilled and dried 
according to standard procedures.  NMR spectra were recorded using a Bruker AvanceIII 600 
MHz spectrometer at room temperature with chemical shifts (δ) recorded against the internal 
standard, tetramethylsilane (TMS).  IR spectra were recorded on a Perkin Elmer Spectrum 
100 FT-IR spectrometer with universal ATR sampling accessory. For GC-MS analyses, the 
samples were analysed on an Agilent GC–MSD apparatus equipped with DB-5SIL MS (30 m 
x 0.25 mm i.d., 0.25 µm film thickness) fused-silica capillary column. Helium (at 2 ml/min) 
was used as a carrier gas. The MS was operated in the EI mode at 70 eV.  Optical rotation 
was recorded using a PerkinElmerTM, Model 341 Polarimeter. Melting points were recorded 
on an Ernst Leitz Wetziar micro-hot stage melting point apparatus. 
 
Preparation of glycine ethyl ester hydrochloride (2). 
A solution of glycine (1)(0.266 mol; 20.0g)in ethanol was added to a 1L three-necked round 
bottomed flask fitted with a reflux condenser carrying a calcium chloride guard tube.  
Thionyl chloride (0.293 mol, 21.3ml) was added slowly using a dropping funnel over a 
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period of 1 h at -5oC. A vigorous reaction takes place. After complete addition, the reaction 
mixture was refluxed for 5 h and then cooled at room temperature.  A white solid separated 
out, which was filtered, dried and recrystallized from ethanol to afford the glycine ethyl ester 
hydrochloride (2), in 94% yield, mp145-146.  The structure was confirmed by1H NMR. 
1H NMR (DMSO-d6, 400 MHz): δ 8.50 (s, 2H, N-H), 4.18 (q, J= 7.38 Hz, 2H), 3.74 (s, 2H), 
1.22 (t, J = 7.38 Hz, 3H); 13C NMR (DMSO-d6, 100 MHz): δ 167.51 (C=O), 61.47 (2C), 
13.92. 
 
Preparation of N-formylglycine ethyl ester (3) 
A mixture of glycine ethyl ester hydrochloride (2) (0.122 mol, 17.0g) and ethyl formate 
(0.792 mol, 120.0 ml) was added to a three-necked round bottomed flask fitted with a reflux 
condenser. The contents of the flask were heated to 50-55oC, after which triethylamine (0.134 
mol, 18.66 ml) was added and the contents refluxed for 24 h. The solution was then cooled 
and filtered with celite. The pure compound was obtained by completely distilling the filtrate 
to obtain N-formylglycine ethyl ester (3) in 93%yield with a bp of206-207oC.  The 
structurewas confirmed by 1H NMR.  1H NMR (CDCl3, 400 MHz): δ 8.19 (s, 1H, CHO), 4.17 
(q, J = 6.72 Hz, 2H), 4.01 (d, J = 5.28 Hz, 2H), 1.23 (t, J = 7.50 Hz, 3H). 
 
Preparation of sodium 1,2-bis-ethoxycarbonyl-2-formylamino-ethenolate (4) and diethyl 2-
mercapto-4,5-imidazoledicarboxylate (5) 
The procedures in Jones (1952) and Anderson et al. (1989) were adapted and modified.  
Inadry 2L three-necked flask provided with a stirrer, dropping funnel and reflux condenser, 
80 mL of anhydrous ether and 3.2 g (1.25 g per piece) of clean sodium was placed.  
Thereafter, absolute ethanol (15 mL) was added followed by the slow addition of diethyl 
oxalate (1.43 moles; 19.4ml) so that the reaction did not become too vigorous.N-
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formylglycineethyl ester (3) (0.114 mol; 15.0 g) was added to the resultant solution from a 
droppingfunnel whilst stirring the contents of the flask. Aprecipitate formed (4) which turned 
to adark red-brown gummy mass upon standing.  The mixture was then left to stand for 24h, 
after which 100 ml of iced water was added, and the mixture agitated until the solid 
dissolved.  The aqueous layer was separated from the organic layer and 19.5g (0.20moles) of 
potassium thiocyanate followed by 25 mL of concentrated hydrochloric acid was added to the 
aqueous layer.The resultant solution was warmed on a water bathfor a few minutes to remove 
any remaining dissolvedetherand then refluxed at 40-60°C for six h during which time a 
heavy yellow crystallineprecipitate of diethyl 2-mercapto-4,5-imidazoledicarboxylate(5) 
separated. The mixture was cooled, filtered and washed with 10 mL of iced water. By 
evaporating the filtrate under reducedpressure to a volume of about 700 mL, an additional 
quantityof the product was obtained. The total yield of the crude productwas 12.75 g(46% 
yield), mp 202-204oC.  The 1H and 13C NMR data of 5 compare well with that in Anderson et 
al., (1989). 
1H NMR (DMSO-d6, 400 MHz): δ 13.20 (s, 2H, N-H), 4.26(q, J=6.92Hz, 4H), 1.27(t, 
J=7.0Hz, 6H); 13C NMR (DMSO-d6, 100 MHz): δ 164.21 (C=S), 157.71 (C=O), 123.37, 
62.04, 14.28. 
 
Preparation of diethyl-2-(benzylsulfanyl)-1H-imidazole-4,5-dicarboxylate derivatives (6a-i) 
Diethyl 2-mercapto-4,5-imidazoledicarboxylate(5) (0.00409 mol, 1.0g) in DMF (10 mL), 
sodium bicarbonate (0.00595 mol, 0.50 g) and substituted benzyl halides (approximately 
0.00500 mol of each) were added together in a 100 mL round bottom flask and stirred for 1.5 
h.  The contents were then diluted with 20 mL ofethyl acetate, followed by water to separate 
out the organic layer, which was further washed with water.  The organic layer was 
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evaporated to yield the products (6a-i), which was recrystallized from ethanol.  The yields 
and melting points are recorded below. 
 
6a) Diethyl 2-(3-fluorobenzylthio)-1H-imidazole-4,5-dicarboxylate: Pale yellow sticky solid 
residue (85% yield); mp 97-98oC, UV λmax (EtOAc) nm (log ) 274 (3.59);IR (KBr)max: 
3387 (N-H), 2983(C-H alkane), 1715 (C=O), 1255 (C-F), 1588 (C=C), 1187 (C-N), 1072, 
1012, 741 cm-1;1H NMR (CDCl3, 600MHz) δ 7.96 (s, N-H), 7.22 (td, J = 7.92, 5.94 Hz, 1H, 
H-5''),7.07(d, J=7.68 Hz, 1H, H-6''), 7.02 (dt, J=9.50, 1.77 Hz, 1H, H-2''), 6.92 (td, J= 8.94, 
2.34 Hz, 1H, H-4''), 4.42(s, 2H, H-7''), 4.31(q, J = 7.14 Hz, 4H, 2H-7/7'), 1.30(t, J=7.14 Hz, 
6H, 3H-8/8'); 13C NMR (CDCl3, 150 MHz) δ 162.69(d,JCF= 246.42 Hz, C-3''),159.44(2C, C-
6/6'), 144.11 (C-2), 138.52 (d, J=7.40 Hz, C-1''), 130.27 (d, J=7.75 Hz, C-5''), 124.69 (d, 
J=3.19 Hz, C-6''), 115.93 (d, J= 22.01 Hz, C-2''), 114.89 (d, J=21.04 Hz, C-4''), 62.09 (2C, C-
7/7'),37.58 (C-7''), 14.09 (2C, C-8/8'); 19FNMR (CDCl3, 376.5 MHz) . -112.22;  EIMS (m/z, 
% rel. int.)   352 [M+] (25), 307 (8), 278 (4), 234 (12), 206 (35), 109 (100);HRMS (m/z): 
353.0961 M+ + H (calculated for C16H17FN2O4S: 352.0893). 
The C-4/5 13C NMR resonances could not be detected in the spectrum. 
 
6b)Diethyl 2-(4-fluorobenzylthio)-1H-imidazole-4,5-dicarboxylate: Pale yellow sticky solid 
residue (85%yield); mp 99-101oC, UV λmax (EtOAc) nm (log ) 280 (3.59); IR (KBr)max: 
3202 (N-H), 2984 (C-H alkane ), 1709 (C=O), 1600 (C=C),  1256 (C-F), 1184 (C-N), 1070, 
1012, 766 cm-1;1H NMR (CDCl3, 600MHz)  7.24 (dd, J = 8.04, 5.58 Hz, 2H, H-2''/6''),6.93 
(t, J= 8.40 Hz, 2H, H-3''/5''),  4.34 (q,J= 7.14 Hz , 4H, 2H-7/7'), 4.32 (s, 2H, 2H-7''), 1.28 (t, 
J= 7.08 Hz, 6H, 3H-8/8');13C NMR (CDCl3, 150 MHz) 163.01(2C, C-6/6') , 162.20 (d,JCF= 
248.20 Hz, C-4''), 144.39 (C-2), 132.36(d, J=3.28 Hz, C-1''), 131.61 (d, J=8.82 Hz, 2C, C-
2''/6''),115.54 (d, J= 20.80 Hz, 2C, C-3''/5''),61.42(2C, C-7/7'), 36.82 (C-7''), 14.10(2C, C-
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8/8') ; 19FNMR (CDCl3, 376.5 MHz)  -115.40;  EIMS (m/z, % rel. int.)   352 (20), 307 (5), 
273 (3), 234 (7), 206 (13), 109 (100); HRMS (m/z): 353.0970 M+ + H (calculated for 
C16H17FN2O4S: 352.0893). 
 
6c)Diethyl2-(3,4-difluorobenzylthio)-1H-imidazole-4,5-dicarboxylate: Pale yellow solid 
residue (89% yield);mp 93-95C;UV λmax (EtOAc) nm (log ) 273 (3.59); IR (KBr)max: 
3534 (N-H), 2985 (C-H alkane ), 1719 (C=O), 1609 (C=C),  1288 (C-F), 1113 (C-N), 1078, 
1008, 953, 778 cm-1;1H NMR (CDCl3, 600MHz) 7.22 (td, J = 7.43, 1.80 Hz, H-6''), 7.09 (m, 
H-2''), 7.02 (dd, J= 18.12, 8.28 Hz, H-5''), 5.86 (s, N-H),4.58 (s, 2H, 2H-7''), 4.35(q,J= 7.14 
Hz, 4H, 2H-7/7'), 1.35 (t, J= 7.08 Hz, 6H, 3H-8/8');13C NMR (CDCl3, 150 MHz) δ 158.13 
(2C, C-6/6'), 150.22(#dd,JCF= 248.31, 12.93 Hz, *C3''),150.05 (#dd,JCF= 248.30, 12.08 Hz, 
*C4''),143.99 (C-2), 132.36 (d, J= 5.39 Hz, C-1''), 129.05 (2C, C-4/5), 125.46 (dd, J=6.51, 
3.31 Hz, C-6''), 118.24 (d, J=17.74 Hz, **C-5''), 117.63 (d, J=17.47 Hz, **C-2''), 62.65 (2C, 
C-7/7'), 37.59 (C-7''), 14.08(2C, C-8/8') ; 19FNMR (CDCl3, 376.5 MHz)   -137.93, -136.53; 
EIMS (m/z, % rel. int.) 370 [M+] (21), 325 (6), 291 (3), 252(7), 224(24), 127 (100), HRMS 
(m/z): 371.0875 M+ + H (calculated for C16H16F2N2O4S: 370.0799). 
*, ** Denote carbon resonances that may be interchangeable. 
# Denotes resonances that appear as a doublet of triplets since the resonances coincide with 
each other. 
 
6d)Diethyl 2-(perfluorobenzylthio)-1H-imidazole-4,5-dicarboxylate: Light green solid 
residue (91% yield); mp 110-112C; UV λmax (EtOAc) nm (log ) 270 (3.70); IR (KBr)max: 
3422 (N-H), 2988 (C-H alkane), 1706 (C=O), 1504 (C=C), 1196 (C-F), 1123 (C-N), 988, 
963, 769 cm-1; 1H NMR (CDCl3, 600MHz) δ 4.50 (s, N-H),  4.41 (s, 2H, 2H-7''), 4.25 (q, J= 
7.10 Hz, 4H, 2H-7/7'), 1.26 (t, J=7.11 Hz, 6H, 3H-8/8');13C NMR (CDCl3, 150 MHz) δ 
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161.88 (2C, C-6/6'), 145.14 (d, J=247.99 Hz, 2C, C-3''/5''),142.14 (C-2), 137.46 (d, J=259.02 
Hz,2C, C-2''/6''), 132.69 (*C-4''), 61.38 (2C, C-7/7'), 24.92 (C-7''), 14.40 (2C, C-8/8'); 
19FNMR (CDCl3, 376.5 MHz)  -161.13 (2F), -153.41, 141.45 (2F); EIMS (m/z, % rel. int.) 
424 (35), 378 (14), 350 (15), 306 (10), 278 (40), 181 (100); HRMS (m/z): 425.0591 M+ + H 
(calculated for C16H13F5N2O4S: 424.0516). 
* The doublet could not be clearly seen in the 13C NMR spectrum. 
 
6e)Diethyl2-(4-(trifluoromethyl)benzylthio)-1H-imidazole-4,5-dicarboxylate: Pale yellow 
solid residue (92% yield); mp 68-70C;UV λmax (EtOAc) nm (log ) 278 (3.67); IR 
(KBr)max: 3420 (N-H), 2985 (C-H alkane), 1722 (C=O), 1617 (C=C), 1321 (C-F), 1118 (C-
N), 1065, 1018, 850, 765 cm-1;1H NMR (CDCl3, 400MHz) 10.78 (s, N-H), 7.49 (d, J= 7.76 
Hz, 2H, H-3''/5''), 7.41 (d, J= 8.0 Hz, 2H, H-2''/6''), 4.46 (s, 2H, 2H-7''), 4.33 (q, J= 7.11, 4H, 
2H-7/7'), 1.33 (t, J=7.11 Hz, 6H, 3H-8/8');13C NMR (CDCl3, 100 MHz) δ 157.92 (2C, C-
6/6'), 144.04 (C-2), 139.37 (C-1''), 129.57 (2C, C-2''/6''), 129.16 (d, J = 53.78 Hz, C-4''), 
125.78 (2C, C-3''/5''), 125.18 (CF3*), 62.74 (2C, 7/7'), 38.07 (C-7''), 14.07 (2C, C-8/8'); 
19FNMR (CDCl3, 376.5 MHz)   -62.64; EIMS (m/z, % rel. int.) 402 [M+] (33), 357 (12), 
328 (8), 284(13), 256 (48), 159 (100), 109 (16);HRMS (m/z): 403.0950 M+ + H (calculated 
for C17H17F3N2O4S: 402.0861). 
* Quartet could not be observed. 
 
6f)Diethyl 2-(2,4-bis(trifluoromethyl)benzylthio)-1H-imidazole-4,5-dicarboxylate: Off white 
solid residue (78% yield);mp 93-95C;UV λmax (EtOAc) nm (log ) 277 (3.68); IR 
(KBr)max: 3229 (N-H), 2990 (C-H alkane), 1734 (C=O), 1280 (C-F), 1561 (C=C),  1110 (C-
N), 1085, 1004, 772 cm-1;1H NMR (CDCl3, 600MHz) δ 10.26 (s, N-H), 7.86 (s, H-3''), 7.72 
(d, J=8.10 Hz, H-5''), 7.68 (d, J= 8.20 Hz, H-6''), 4.62 (s, 2H, 2H-7''), 4.33* (q, J= 7.02 Hz, 
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2H, 2H-7), 4.40* (q, J= 7.02 Hz, 2H, 2H-7'), 1.34** (t, J=7.14 Hz, 3H, 3H-8), 1.39** (t, 
J=7.14 Hz, 3H, 3H-8');13C NMR (CDCl3, 150 MHz) 160.63 (2C, C-6/6'), 143.52 (C-2), 
139.98 (C-1''), 132.61 (C-6''), 130.44 (d, J = 33.42 Hz, C-2'') , 129.25 (d, J = 31.62 Hz, C-4''), 
129.05 (C-5''), 123.54 (C-3''), 123.43 (q, J = 272.55 Hz, 2''-CF3), 123.17 (q, J = 270.67 Hz, 
4''-CF3),  61.88 (2C, C-7/7'), 33.41 (C-7''), 14.17 (2C, C-8/8'); 19FNMR (CDCl3, 376.5 MHz)  
 -63.00, -59.77; EIMS (m/z, % rel. int.) 470 [M+] (45), 425(16), 396 (12), 352(12), 
324(100), 227 (80), 177 (22); HRMS (m/z): 471.0825 M+ + H (calculated for C18H16F6N2O4S: 
470.0735). 
*, ** Denote resonances that may be interchanged. 
 
6g)Diethyl2-(4-(trifluoromethoxy)benzylthio)-1H-imidazole-4,5-dicarboxylate: Off white 
solid residue (91%yield); mp77-80C; UV λmax (EtOAc) nm (log ) 279 (3.62); IR 
(KBr)max: 3464 (N-H), 2981 (C-H alkane), 1737 (C=O), 1596 (C=C),  1255 (C-F), 1150 (C-
N), 1078, 1019, 858 cm-1;1H NMR (CDCl3, 600MHz) δ 7.85 (s, N-H), 7.35 (d, J= 8.46 Hz, 
2H, H-2''/6''), 7.05(d, J=8.40 Hz, 2H, H-3''/5''), 4.55 (s, 2H, 2H-7''), 4.32(q, J= 7.14 Hz, 4H, 
2H-7/7'), 1.31 (t, J=7.44 Hz, 6H, 3H-8/8');13C NMR (CDCl3, 150 MHz) δ 158.56 (2C, C-
6/6'), 148.85 (C-4''), 144.18 (C-2), 134.25 (C-1''), 130.65 (2C, C-2''/6''), 129.38 (2C, C-4/5), 
121.18 (2C, C-3''/5''), 120.23 (q*, J = 255.34 Hz, OCF3),  62.45 (2C, C-7/7'), 37.88 (C-7''), 
14.03 (2C, C-8/8'); 19FNMR (CDCl3, 376.5 MHz)   -57.89;  EIMS (m/z, % rel. int.) 418 
[M+] (22), 373 (8), 339 (3), 300 (7), 272 (17), 175(100), 109(7); HRMS (m/z): 419.0893 M+ 
+ H (calculated for C17H17F3N2O5S: 418.0810). 
*The outer peaks of the quartet cannot be seen due to the reduced intensity of these peaks and 
the resonance overlaps with C-3''/5''. 
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6h)Diethyl 2-(4-nitrobenzylthio)-1H-imidazole-4,5-dicarboxylate: Yellow solid residue (88% 
yield);mp 111-112C;UV λmax (EtOAc) nm (log ) 274 (3.69); IR (KBr)max: 3245 (N-H), 
2984 (C-H alkane ), 1734 (C=O),  1561 (C=C), 1519 (NO2), 1478 (CH2 bend), 1339, 1182, 
1079 (C-N), 1013, 704  cm-1;1H NMR (CDCl3, 600MHz) δ 10.94 (s, N-H), 8.07 (d, J= 8.16 
Hz, 2H, H-3''/5''), 7.44 (d, J= 8.16 Hz, 2H, H-2''/6''), 4.41 (s, 2H, H-7''), 4.33 (q, J = 6.72 Hz, 
4H, 2H-7/7'), 1.32 (t, J=6.72 Hz, 6H, 3H-8/8'); 13C NMR (CDCl3, 150 MHz) 162.61 (2C, C-
6/6'), 147.29 (C-4''), 144.54 (C-2), 143.45 (C-1''),129.88 (2C, C-2''/6''), 127.65 (C-4/5), 
123.82 (2C, C-3''/5''),  61.86(2C, C-7/7'),  36.43 (C-7''), 14.15 (2C, C-8/8'); LCMS* (m/z) 380 
[M+ + 1]; HRMS (m/z): 380.0906 M+ + H (calculated for C16H17N3O6S: 379.0838). 
* An EIMS of the compound could not be obtained.   
 
6i)Diethyl 2-(3-chlorobenzylthio)-1H-imidazole-4,5-dicarboxylate: Off white sticky solid 
residue (70% yield); mp 107-109oC; UV λmax (EtOAc) nm (log ) 279 (3.37); IR (KBr)max: 
3334 (N-H), 2982 (C-H alkane), 1721 (C=O), 1597 (C=C), 1472 (CH2 bend),  1077 (C-N), 
1008, 687 (C-Clstretch) cm-1; 1H NMR (CDCl3, 600MHz) δ 10.13 (s, N-H), 7.31 (s, H-2''), 
7.20 (d, J= 7.26 Hz, 2H, H-4''/6''), 7.17 (t, J= 7.68 Hz, H-5''), 4.33 (s, 2H, H-7''), 4.35 (q, 
J=7.08 Hz, 4H, 2H-7/7'), 1.36 (t, J= 7.08  Hz, 6H, 3H-8/8');13C NMR (CDCl3, 150 MHz) 
161.97 (2C, C-6/6'), 143.71 (C-2), 138.71 (C-1''), 134.48 (C-3''), 129.97 (C-5''), 129.13 (C-
2''), 128.01 (C-4''), 127.13 (C-6''), 61.87(2C, C-7/7'), 37.17 (C-7''), 14.17 (2C, C-8/8'); EIMS 
(m/z, % rel. int.) 368 [M+] (27), 322 (8), 294 (6), 250(14), 222 (39), 125 (100), 89 (17); 
HRMS (m/z): 369.0681 M+ + H (calculated for C16H17ClN2O4S: 368.0598). 
 
2.1.6 X-Ray Crystallography 
Single-crystal X-ray diffraction data were collected on a Bruker KAPPA APEX II DUO 
diffractometer using graphite-monochromated Mo-K radiation ( = 0.71073 Å). Data 
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collection was carried out at 173(2) K. The temperature was controlled by an Oxford 
Cryostream cooling system (Oxford Cryostat). Cell refinement and data reduction were 
performed using the program SAINT.  The data were scaled and an absorption correction 
performed using SADABS.  The structure was solved by direct methods using SHELXS-97 
and refined by full-matrix least-squares methods based on F2 using SHELXL-97 and using 
the graphics interface program X-Seed. All non-hydrogen atoms were refined anisotropically 
and all hydrogen atoms could be found in the difference electron density maps but were 
placed in idealised positions and refined in riding models with Uiso set at 1.2 times those of 
their parent atoms and at a distance (C-H) of 0.95 Å. The structure was refined to a R factor 
of 0.0503. 
 
2.2. In vitro antiplatelet aggregation  assay 
The use of experimental animals in this study was in accordance with the guidelines and care 
stipulated by the University of Zululandresearch animal ethics committee. Adult rats (~200g) 
(Sprague-Dawley) of either sex were collected from the Department of Biochemistry and 
Microbiology, University of Zululand. 
 
The blood platelets were prepared following the method described by Tomita et al., (1983) 
and detailed by Mosa et al.(2011).  A rat (~200g) was killed by a blow to the head. Blood was 
immediately collected from the abdominal aorta of the rat and was put in a centrifuge tube 
containing ADA (acid-dextrose-anticoagulant—0.085M trisodium citrate, 0.065 citric acid, 
2% dextrose; 1 ml ADA: 5 ml blood). The blood was centrifuged (Eppendorf centrifuge 5804 
R) at 1200 rpm for 15 min and at 2200 rpm for 3 min consecutively. Supernatant was 
collected and centrifuged at 3200 rpm for 15 min. The supernatant was discarded and the 
sediment (platelets) obtained was resuspended in 5 ml of washing buffer (pH 6.5—phosphate 
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buffer containing 0.113M NaCl, 5.5M glucose, 1mM EDTA). This was centrifuged at 3000 
rpm for 15 min. The supernatant was discarded and the platelets were suspended in a 
smallvolume of a resuspending buffer (pH 7.4; containing 0.14 M NaCl, 15 mM Tris-HCl, 5 
mM glucose). A 1:10 dilution of the platelets in the resuspending buffer was taken.The 
method previously described by Mekhfi et al., (2004) was adapted with some modifications 
to evaluate the antiplatelet aggregation activity of the compounds. The compounds were 
separately solubilized in dimethyl sulfoxide (DMSO) before being made up to the desired 
volume with 50 mM Tris–HCl buffer (pH 7.4; containing 7.5 mM ethylenediaminetetra-
acetic acid (EDTA) and 175mM NaCl) to a final 1% DMSO concentration. The compounds 
were used at the final concentrations of 1, 3 and 10 mg/ml. The antiplatelet aggregation 
activity of the compounds wasseparately investigated on thrombin (5 U/ml) and ADP (5 mM) 
induced aggregation. The platelets (100 µl) were pre-incubated for 5 min with different 
concentrations of the compounds. The aggregation inducer (20 µl) was introduced to the 
mixture.  
The 96-well microplate was used in the experiment and aggregation of the platelets was 
measured with the Biotek plate reader (ELx 808 UI, Biotek Instrument Supplies) using Gen5 
software by following the change in absorbance at 415 nm.  DMSO (1%) and aspirin were 
used as negative and positive controls, respectively. The experiment was done in triplicate 
and the mean slope (A) ± standard error of mean (SEM) reported.The inhibitory effect of the 
compounds on each parameter was calculated using the formula: 
Inhibition (%) = [(Ao – A1)/Ao x100], where Ao is the mean slope of the control and A1is the 
mean slope of the test compound.Estimated IC50 values were determined using a statistical 
package origin 6.1. 
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5.3. Results and discussion 
In our synthetic design, we have chosen the imidazole-2-thione as the basic backbone of the 
molecules with diesters substituted across the double bond and a benzyl moiety covalently 
bonded to the sulfur atom with fluorine being present on this moiety.  Thus, the molecules 
have fluorine, nitrogen and sulphur atoms incorporated in it, increasing its chances of 
reactivity.  We have chosen benzyl moieties with mono-, di- and penta- fluoro groups as well 
as mono- and di- trifluoromethyl and the monotrifluoromethoxy groups as well as a nitro and 
chlorobenzyl moiety.  The choice of the derivatives were governed by their availability as 
starting materials and our desire to investigate the effect that F, CF3, OCF3, NO2 and Cl 
groups at the 3- and 4- positions have on reactivity.    In the case of the 2,4-CF3 derivative, 
this was chosen since the 3,4-CF3 was not available.  We aimed to explore the effect of the 
position of the different groups as well as the effect of di- and penta- fluoro substitution and 
di-trifluoromethyl substitution.  The chloro group was chosen to compare whether the size 
and electronegativity of the halogen had an influence on reactivity and the nitro group chosen 
to compare the reactivity when a strongly electron withdrawing group was present. 
 
The synthesis started with the esterification of glycine (1) with ethanol and thionyl chloride 
resulting in glycine ethyl ester hydrochloride (2), which was then formylated using ethyl 
formate in the presence of a triethylamine catalyst.  The resultant N-formylglycine ethyl ester 
(3) was further reacted with sodium ethoxide and diethyl oxalate to produce the sodium 1,2-
bis-ethoxycarbonyl-2-formylamino-ethenolate (4), which was directly converted to the 
carbamate with potassium thiocyanate and hydrochloric acid to produce the diethyl 2-
mercapto-4,5-imidazoledicarboxylate (5), which was the intermediate that was reacted with 
the various substituted benzyl bromides with the basic sodium bicarbonate catalyst to form 
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the benzyl sulfanyl derivatives 6a-i, which was studied for their antiplatelet activity.  The 
scheme of the reaction is shown in Scheme 5-1. 
 
The 1H NMR spectra of the synthesised benzylthioimidazoles (6a-i) all showed aromatic 
resonances between H 6.8 and 7.8 for the benzyl protons with the exception of 6d 
(fluorinated at all positions on the aryl ring), a singlet for the benzylic protons at H 4.3 to 4.6 
and a quartet and triplet of the ester ethyl group at approximately H 4.3 and 1.3 respectively 
with J = 7.0 Hz.  The benzylic singlet of H-7'' and the quartet of the methylene group (H-7 











































Scheme 5-1The preparation of diethyl-2-(benzylthio)-2,3-dihydro-1H-imidazole-4,5-
dicarboxylate derivatives in five steps(i) SOCl2, -5oC, EtOH, reflux for 5-6 hrs (ii) ethyl 
formate and triethyl amine in EtOH, refluxed at 50-55oC for 24 hrs (iii)  NaOEt , diethyl 
oxalate, left to stand for 24 hrs (iv) KSCN, HCl (v) NaHCO3 , DMF, substituted benzyl 
bromides, stirred at rt for 1.5 hrs. 
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Where fluorine was present on the aromatic ring, triplets of doublets and doublets of triplets 
were seen in the aromatic region due to coupling with both the fluorine and the hydrogen 
atoms.  For example, 6a shows triplets of doublets at H 7.22 and H 6.92 for H-5'' and H-4'' 
with J = 7.92 and 5.94, and 8.94 and 2.34 Hz respectively.  A doublet of triplets can be seen 
for H-2'' with J = 9.50 and 1.77 Hz.  The H-6'' proton, remotely situated from the fluorine 
atom, showed a doublet resonance with an observed J5''/6''of 7.68 Hz, however the peaks for 
this resonance was not as well resolved as that for H-5'', resulting in the slight deviation in 
coupling constants.  For benzyl rings which were para substituted, for example, 6e, g and h, a 
pair of doublets were observed for these compounds with J being approximately 8.0 Hz.  In 
the case of 6b, the para fluorinated compound, H-2''/6'' appears as a double doublet with J = 
8.04 and 5.58 Hz and H-3''/5'' appears as a triplet due to coupling with both the proton and 
fluorine atom, where the double doublet of H-3''/5'' coalesces to produce a triplet with J = 
8.40 Hz. 
 
In the 13C NMR spectrum, the ester carbonyl resonance (C-6/6') occurs at approximately  
160 and the two equivalent ethyl methylene (C-7/7') and methyl (C-8/8') carbon resonances 
occur at approximately  61 and d 14 respectively.  The benzylic carbon resonance (C-7'') 
occurs at approximately  37.  The imidazole carbon resonance (C-2) occurs at  144, with 
the other two resonances C-4 and C-5 only appearing in some spectra as a single resonance, 
probably because of the symmetry in the molecule at  129.  These resonances were too weak 
to be detected in most of the spectra.  The aromatic carbon resonances occur between  110-
140.  Where fluorine is substituted directly on the ring, the ipso carbon is split into a doublet 
with JC-F = 246 Hz and the ortho and meta carbon resonances are also split into doublets with 
J being approximately 22 and 8 Hz respectively.  In some cases para F-C coupling of J = 3 
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Hz can also be seen.  For 6c, the difluorinated compound, a double doublet for each of the 
ipso protons is seen at  150.22 and  150.05 respectively due to the two fluorine atoms being 
ortho to each other.  This appears as a doublet of triplets due to coalescing of each of the 
double doublets.  The CF3 carbon resonances appear at  125 as a quartet with J being 
approximately 270 Hz.  In some cases the quartet could not be clearly observed as in 6e and 
in others, for example 6g, the outer peaks of the quartet could not be seen due to the reduced 
intensity of these peaks, however, these are clearly seen in 6f.  In the pentafluoro compound 
(6d), the C-7'' benzylic carbon is more shielded than the others at  24.92, probably due to 
electron donation by the fluorine atoms. 
 
In addition, the crystal structure of the parent compound, diethyl 2-mercapto-4,5-
imidazoledicarboxylate(5) was determined and was shown to contain two molecules in the 
unit cell with a triclinic P1 space group.  The molecule was essentially planar with bond 
angles in the imidazole ring being between 122-125°, with only one of the bond angles 
between the ester group and the olefinic carbon and the nitrogen of the imidazole ring being 
116°.  The two ester groups point away from each other and extend out of the imidazole 




Figure 5-1ORTEP diagram of diethyl 2-mercapto-4,5-imidazoledicarboxylate(5) 
 
The synthesised compounds exhibited concentration and substituent dependent inhibitory 
activity of platelet aggregation induced by the two platelet agonists.  Six of the ten 
synthesised compounds, including the carbazole intermediate (5), showed activity better than 
or comparable to aspirin (used as a standard) in the thrombin induced platelet aggregation 
assay (Table 5-1), while eight of the compounds showed either better or comparable activity 
to aspirin in the ADP-induced platelet aggregation (Table 5-2).  
 
Table 5-1Percentage inhibition of platelet aggregation at different concentrations of the 
compound on thrombin-induced platelet aggregation 
No. R 0.5 mg/ml 3.0 mg/ml 10.0 mg/ml Estimated 
IC50 (mM) 
5 Carb  0.00  ± 1.91 58.1  ± 1.06 75.4  ± 0.95 11.18 
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6a 3-F 0.00  ± 0.87 0.00  ± 0.28 0.00  ± 0.25 ND 
6b 4-F 0.00  ± 0.41 0.00  ± 0.98 0.00  ± 0.63 ND 
6c 3,4-F 0.00  ± 0.62 51.8  ± 0.83 66.1  ± 0.64 7.99 
6d Penta-F 13.6 ± 0.85 65.9  ± 0.83 80.0  ± 0.84 5.28 
6e 4-CF3 0.00  ± 1.13 0.00  ± 0.21 0.00  ± 0.96 ND 
6f 2,4-CF3 0.00  ± 0.00 82.9  ± 0.94 84.2  ± 2.29 4.38 
6g 4-OCF3 0.00  ± 0.26 0.00  ± 1.14 27.1  ± 1.15 ND 
6h 4-NO2 57.2  ± 0.27 71.4  ± 0.83 76.8  ± 0.39 1.05 
6i 3-Cl 55.8  ± 0.48 80.2  ± 0.99 84.3  ± 0.87 0.44 
C* Aspirin 30.5  ± 0.48 51.2  ± 0.47 66.3 ± 0.24 7.66 
C* = aspirin; ND = not detected 
 
Thrombin induced platelet aggregation assay 
All the inactive compounds in the thrombin induced platelet aggregation assay were 
monosubsituted (3F (6a), 4F (6b), 4CF3 (6e) and 4-OCF3(6g)).  The carbazole (5), together 
with the di and penta deriviatives (6c-d and 6f) showed no or very little activity in the 0.5 
mg/ml range, but their extrapolated estimatedIC50 values were comparable to that of aspirin 
(Table 5-1).  The best activity was displayed by the compounds with the 4-nitro (6h) and 3-
chloro (6i) groups, which had estimatedIC50 values of 0.40 and 0.44 mg/ml respectively.  
Furthermore, they were the only two compounds that showed appreciable activity at a low 
concentration of 0.5 mg/ml.  Thus, electron withdrawing groups seemed to favour inhibition 
in the thrombin induced platelet aggregation assay.  The fact that the monosubstituted fluoro 
atoms have no inhibitory effect could be due to their small size or the inability of the fluorine 
atom to co-ordinate to biological ligands as compared to chlorine.  This however is overcome 
by phenyl groups with multiple fluorine atoms, as this shows an increase in activity. 
 
Table 5-2Percentage inhibition of platelet aggregation at different concentrations of the 
compound on ADP-induced platelet aggregation 
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No. R 0.5 mg/ml 3.0 mg/ml 10.0 mg/ml Estimated 
IC50 (mM) 
5 Carb  0.00  ± 0.90 0.00  ± 1.23 0.00  ± 0.53 ND 
6a 3-F 0.00  ± 0.39 72.2  ± 0.46 74.8  ± 0.57 6.36 
6b 4-F 68.7  ± 0.94 76.4  ± 0.19 86.6  ± 0.43 0.99 
6c 3,4-F 0.00  ± 0.45 66.0  ± 1.08 82.3  ± 0.50 6.64 
6d Penta-F 0.00  ± 0.62 20.8  ± 0.31 35.8  ± 0.42 ND 
6e 4-CF3 0.00  ± 0.80 38.2  ± 0.51 53.8  ± 0.73 21.09 
6f 2,4-CF3 0.00  ± 0.85 0.00  ± 0.91 0.00  ± 0.69 ND 
6g 4-OCF3 14.1  ± 0.90 47.1  ± 1.19 50.9  ± 0.18 21.67 
6h 4-NO2 0.00  ± 0.33 0.00  ± 0.13 88.3  ± 1.73 18.57 
6i 3-Cl 24.7  ± 1.03 46.6  ± 0.79 61.5  ± 0.53 12.90 
C*  23.7  ± 0.90 45.3  ± 0.18 57.1  ± 1.15 32.86 
C* = aspirin; ND = not detected 
 
ADP-induced platelet aggregation assay 
Compared to the thrombin induced platelet aggregation, the situation in this assay is quite 
different.  Multiple fluorine atoms on the phenyl ring (6d) lead to loss of activity, whereas 
fluorine substitution at both the 3- and 3,4- positions (6a and 6c respectively) lead to better 
activity than aspirin with Estimated IC50 values of 2.24 and 2.46 mg/ml respectively (Table 
5-1).  The best activity is seen by the 4-fluorophenyl derivative (6b) which shows an 
Estimated IC50 value of 0.35.    The 3-chloro derivative (6i) also shows slightly better activity 
than aspirin Estimated IC50 of 4.75 compared to 5.92 mg/ml) with the 4-CF3 (6e), 4-OCF3 
(6g) and 4-NO2 (6h) showing slightly weaker activity than aspirin with Estimated IC50 values 
of 8.48, 9.06 and 7.04 mg/ml.  Substitution of an additional CF3 group at the 2-position as in 
6f results in loss of activity as was the case with the carbazole skeleton without any phenyl 
group attached to it. Thus, in this assay, small electron withdrawing groups such as fluorine 
substituted at the para position on the phenyl moiety results in the best activity.  This activity 
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is reduced with larger electron withdrawing groups and electron donating groups and activity 
is reduced by further fluorinations on the phenyl ring. 
 
Since the two platelet aggregation assays have different compounds showing the best activity 
and also have different compounds being inactive in the assays, there seems to be a different 
mechanism of platelet inhibition in both of these assays.  However, three of the compounds, 




Diethyl-2-(benzylsulfanyl)-1H-imidazole-4,5-dicarboxylate derivatives are easily prepared 
from glycine in a five step reaction involving activating glycine with N-formylation and 
transesterification, and then reacting this intermediate with diethyl oxalate followed by 
potassium cyanate and then the benzyl bromides.  Different derivatives are active in each of 
the assays (thrombin induced and ADP-induced platelet aggregation assays), suggesting that 
different mechanisms are involved in each of the assays.  The most active of the compounds 
in the thrombin induced assay are the 4-nitro (6h) and the 3-chloro (6i) derivatives whereas 
the most active compound in the ADP-induced assay is the 4-fluoro (6b) derivative.   Three 
of the compounds, 6c, 6h and 6i, the 3,4-difluoro, the 4-nitro and the 3-chloro derivatives 
have reasonable activity in both of the assays and could have potential as broad spectrum 
antiplatelet inhibitors.  With the exception of 6c, the fluoro derivatives were not as active as 
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Abstract 
In the title compound, C17H13FO3, the dihedral angle between the aromatic rings is 70.34 (5). 
In the crystal, molecules are linked via pairs of bifurcated C—H…(O,O) hydrogen 
bonds,forming inversion dimers. These dimers are linked via C—H…O and C—H…F 
interactions, forming a three-dimensional structure. 
 
Related literature 
For the preparation, see: Pinto et al. (2000). For relatedstructures, see: Santos et al. (2009); 
Ren et al. (2006); Ren et al. (2006b). For bond-length data, see: Allen et al.(1987). The title 
compound is a core structure in variousnatural and pharmaceutically active compounds, 




















Figure 6-1Chemical structure of 2-Acetylphenyl-(2E)-3-(4-fluorophenyl)-acrylate 
 
Table 6-1 Hydrogen-bond geometry (A˚, o). 
Cg1 is the centroid of the C3–C8 ring. 
 
D—H…A D—H H…A D…A D—H…A 
 
C7—H7…F1i 0.95 2.52 3.2402(16) 132 
C11—H11…O3ii 0.95 2.46 3.3369(16) 154 
C13—H13…O3ii 0.95 2.45 3.3191(16) 153 
C16—H16…O1iii 0.95 2.51 3.3590(17) 149 
C6—H6…Cg1iv 0.95 2.99 3.818(1) 146 
Symmetry codes: (i)x, -y+2, z-  (ii)-x, -y+1, -z (iii)-x+ , y + , -z +  (iv)x,-y + 1, z- . 
 
Comment 
The title compound (E)-2-acetylphenyl-3-(4-fluorophenyl)-acrylate was obtained as an 
intermediate en route to thesynthesis of 4′-fluoro-2-styrylchromone and easily converts to the 
2-hydroxyphenyl pentadienone with DMSO in thepresence of a strong base (Santos et al., 
2009). It was synthesized according to the procedure by Pinto et al. (2000) withmodification. 
The title compound is a core structure in various natural and pharmaceutically active 
compounds,displaying a broad spectrum of activity (Gomes et al., 2010). 
 
In the molecule of the title compound (Figure 6-1and Figure 6-2), the two aromatic rings 
(ring 1: C3—C4—C5—C6—C7—C8; ring 2:C12—C13—C14—C15—C16—C17 are 
almost perpendicular to each other with a dihedral angle of 70.34 (5)°.The torsion angle C9—
153 
C10—C11—C12 is -178.8 (1)°, indicating a trans configuration of the double bond. All 
bondlengths and angles are within normal ranges (Allen et al.,1987). In the crytsal packing, 
ring 1 adopts a parallel offsetarrangement with itself of the neighbouring molecule with a 
centroidal distance of 4.125 (1) A. The crystal is furtherstablized by a number of weak 
hydrogen bonds with the type C—H…X (X = O or F) and C—H…π (Table 6-1). 
 
Experimental 
Phosphorous oxychloride (15.6 mmol) was added to a solution of 2-hydroxyacetophenone 
(12.0 mmol) and 4-fluorocinnamic acid (15.6 mmol) in dry pyridine. The solution was stirred 
at 60–70 °C for 3 h, and then poured into ice and waterand the reaction mixture acidified with 
hydrochloric acid (pH 3–4). The obtained solid was removed by filtration anddissolved in 
ethyl acetate (100 ml) and purified by silica gel column chromatography using a 7:3 mixture 
of ethylacetate:n-hexane as the eluent. The solvent was evaporated to dryness and the residue 
recrystallized from ethanol,resulting in the title compound with a 72% yield and am.p of 80–
82°C.IR (KBr) max (cm-1): 1729 (C=O), 1670 (C=O), 1624 (C=C), 1590, 1446, 1221 (C—F), 
1202, 1159, 1050. 1H NMR(CDCl3, 400 MHz): 7.84 (d, J = 15.96 Hz, 1H, H), 7.81 (dd, J 
= 8.00,1.60 Hz, 1H), 7.58 (dd, J = 8.60, 5.42, 2H), 7.53 (td, J = 8.00, 1.52 Hz, 1H), 7.33 (td, J 
= 8.00, 0.72 Hz, 1H), 7.17 (dd, J = 8.00, 0.72 Hz, 1H), 7.09 (t, J = 8.60 Hz,2H), 6.58 (d, J = 
15.96 Hz, 1H, H), 2.54 (s, 3H, CH3). 13C NMR (CDCl3, 100 MHz): 197.78 (C=O), 165.14 
(C=O), 164.25 (d, JCF = 250.70 Hz), 149.07, 145.99, 133.36, 131.30, 130.43 (d, J = 8.37 Hz, 
2C), 130.32 (d, JCF = 3.55 Hz), 130.15, 126.10, 123.78,116.58 (d, J = 2.37 Hz), 116.20 (d, JCF 
= 21.85 Hz, 2C), 29.71 (CH3). 19F NMR (CDCl3, 376.5 MHz): -108.54. EIMS (probe) 70 





All non-hydrogen atoms were refined anisotropically. All hydrogen atoms could be found in 
the difference electrondensity maps but were finally placed in idealized positions refining in 
riding models with Uiso set at 1.2 or 1.5 times Ueqof their parent atoms. 
 
Computing details 
Data collection: COLLECT program (Nonius, 2000); cell refinement: DENZO-SMN 
(Otwinowski& Minor, 1997); datareduction: DENZO-SMN (Otwinowski& Minor, 1997); 
program(s) used to solve structure: SHELXS97 (Sheldrick, 2008); program(s) used to refine 
structure: SHELXL97 (Sheldrick, 2008); molecular graphics: ORTEP-3 (Farrugia, 
2012);software used to prepare material for publication: WinGX(Farrugia, 2012). 
 
 
Figure 6-2ORTEP diagram showing the molecular structure of the titled compound with 
atomic labelling scheme. Non-H atoms are drawn with 50% probability displacement 






Geometry. All e.s.d.'s (except the e.s.d. in the dihedral angle between two l.s. planes) are 
estimated using the fullcovariance matrix. The cell e.s.d.'s are taken into account individually 
in the estimation of e.s.d.'s in distances, angles andtorsion angles; correlations between 
e.s.d.'s in cell parameters are only used when they are defined by crystal symmetry.An 
approximate (isotropic) treatment of cell e.s.d.'s is used for estimating e.s.d.'s involving l.s. 
planes. 
Refinement. Refinement of F2 against ALL reflections. The weighted R-factor wRand 
goodness of fit S are based on F2,conventionalR-factors R are based on F, with F set to zero 
for negative F2. The threshold expression of F2 >σ(F2) is usedonly for calculating R-
factors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based 
on F2 are statistically about twice as large as those based on F, and R-factors based on ALL 
data will be even larger. 
 
Acknowledgement 
We thank the University of KwaZulu-Natal, the NationalResearch Foundation (NRF) and the 




Allen, F. H., Kennard, O., Watson, D. G., Brammer, L., Orpen, A. G. & Taylor,R. (1987). J. 
Chem. Soc. Perkin Trans. 2, S1–19. 
Farrugia, L. J. (2012). J. Appl. Cryst. 45, 849–854. 
Gomes, A., Freitas, M., Fernandes, E., Lima, J. L. F. C. (2010).Mini Rev.Med. Chem. 10, 1–
7. 
Nonius (2000). COLLECT. Nonius BV, Delft, The Netherlands. 
Otwinowski, Z. & Minor, W. (1997). Methods in Enzymology, Vol. 276, 307-326. 
156 
Macromolecular Crystallography, Part A, edited by C. W. Carter  Jr & R. M.Sweet, 307–326. 
New York: Academic Press. 
Pinto, D. C. G. A., Silva, A. M. S., Cavaleiro, J. A. S. (2000). New J. Chem. 24,85–92. 
Ren, R., Li, X.-M., Li, Q. & Zhang, S.-S.(2006a). Acta Cryst. E62, o293–o294. 
Ren, R., Zhang, S.-S., Li, Q., Li, X.-M.& Song, X.-Y. (2006b). Acta Cryst.  E62, o160–o161. 
Santos, C.M.M., Silva, A. M. S. &Cavaleiro, J. A. S. (2009). Eur. J. Org. Chem. 2642–2660. 
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Abstract 
The title compound, C17H12F2O3, crystallizes with two planar molecules in the asymmetric 
unit.The title molecule has the packing 4 molecules in a unicell.The molecule confirmation is 
stabilized by O—H intra-molecular hydrogen-bond inter-action with a distance of 2.677Å. 
 
Related literature 
For the preparation, see: Pinto et al. (2000). For related structures, see: Santos et al. (2009); 
Ren, et al. (2006a); Renet al. (2006b). For bond-length data, see: Allen et al.(1987). The title 
compound is a core structure in various natural and pharmaceutically active compounds, 
























Figure 6-3Chemical structure of (E)-2-Acetyl-4-fluorophenyl 3-(4-fluorophenyl)-acrylate 
 
Table 6-2Hydrogen-bond geometry (Å, °) 
D----H…..A D - H H…A D…A D - H…A 
C1A—H1A2B···O1B 0.98 2.51 3.314(3) 139 
C4B—H4B···O1B i i 0.95 2.40 2.734(3) 101 
C10A—H10A···O3B i 0.95 2.46 3.407(2) 172 
C10B—H10B···O3A i 0.95 2.54 3.484(2) 174 
C11A—H11A···O2A 0.95 2.39 2.750(2) 102 
C11B—H11B···O1A i i i 0.95 2.58 3.484(2) 159 
C11B—H11B···O2B 0.95 2.40 2.759(2) 102 
C13A—H13A···O3B i 0.95 2.52 3.455(3) 170 
C13B—H13B···O3A i 0.95 2.55 3.499(3) 177 
 Symmetry codes (i)-x, 1-y, 2-z (ii)-x, 2-y, 1-z (iii)1+x, y, z 
 
Comment 
The title compound (E)-2-acetyl-4-fluorophenyl-3-(4-fluorophenyl)-acrylate was obtained as 
an intermediate en route to the synthesis of the corresponding 2-styrylchromone.It was 
synthesized according to the procedure by Pinto et al. (2000)with modification. The title 
compound is a core structure in various natural and pharmaceutically active compounds, 
displaying a broad spectrum of activity (Gomes et al., 2010). 
 
159 
In the molecule of the title compound (Figure 6-3 and Figure 6-4), the two aromatic rings 
(ring 1: C3—C4—C5—C6—C7—C8; ring 2: C12—C13—C14—C15—C16—C17 are 
almost perpendicular to each other with a dihedral angle of 110.24 (16)°. The torsion angle 
C9—C10—C11—C12 is -176.94 (1)°, indicating a trans configuration of the double bond. 
All bond lengths and angles are within normal ranges (Allen et al.,1987). In the crystal 
packing, ring 1 adopts a parallel offset arrangement with itself of the neighbouring molecule 
with centroidal distance of 4.600 (1) Å. The crystal is further stabilized by a number of weak 
hydrogen bonds (Table 6-2) with the type C—H···X (X = O or F). 
 
Experimental 
Phosphorous oxychloride (15.6 mmol) was added to a solution of 4-fluoro-2-
hydroxyacetophenone (12.0 mmol) and 4'-fluoro cinnamic acid (15.6 mmol) in dry pyridine. 
The solution was stirred at 60–70°C for 3 h, and then poured into ice and water and the 
reaction mixture acidified with hydrochloric acid (pH 3–4). The obtained solid was removed 
by filtration and dissolved in ethyl acetate (100 ml) and purified by silica gel column 
chromatography using a 7:3 mixture of ethyl acetate:n-hexane as the eluent. The solvent was 
evaporated to dryness and the residue recrystallized from ethanol, resulting in the title 
compound with a 68% yield and m.p of 60–62°C.IR (KBr) umax: 1724 (C=O), 1679 (C=O), 
1361 (C—O), 1225 (C—F), 1143 cm-1; 1H NMR (CDCl3, 400 MHz)  7.87 (dd, J = 8.75, 
6.34 Hz, 1H), 7.84 (d, J = 15.96 Hz, 1H, H), 7.58 (dd, J = 8.72, 5.40 Hz, 2H), 7.10 (d, J = 
8.60 Hz, 2H), 7.03 (td, J = 8.75, 2.45 Hz, 1H), 6.92 (dd, J = 8.90, 2.45 Hz, 1H), 6.56 (d, J = 
15.96 Hz, 1H, H), 2.53 (s, 3H, CH3); 13C NMR (CDCl3, 100 MHz)  196.11 (C=O), 165.11 
(C=O), 164.99 (d, JCF = 254.07 Hz), 164.35 (d, JCF = 250.95 Hz), 150.99, 146.55, 132.20 (d, 
J = 10.14 Hz), 130.47 (d, J = 8.47 Hz, 2C), 130.17 (d, J = 3.0 Hz), 127.62 (d, J = 3.51 Hz), 
116.26 (d, J = 21.94 Hz, 2C), 116.11 (d, J = 2.24 Hz), 113.34 (d, J = 21.20 Hz), 111.70 (d, J= 
160 
23.99 Hz), 29.73 (CH3); 19F NMR (CDCl3, 376.5 MHz)  -103.81, -103.17; EIMS (probe) 70 




All non-hydrogen atoms were refined anisotropically. All hydrogen atoms could be found in 
the difference electron density maps but were finally placed in idealized positions refining in 
riding models with Uiso set at 1.2 or 1.5 times Ueq of their parent atoms. 
 
Computing details 
Data collection: SAINT (7.60a, Bruker AXS Inc., Madison, WI, USA, 2006); cell refinement: 
SAINT (7.60a, Bruker AXS Inc., Madison, WI, USA, 2006); data reduction: SAINT (7.60a, 
Bruker AXS Inc., Madison, WI, USA, 2006); program(s) used to solve structure: SHELXS97 
(Sheldrick, 1997); program(s) used to refine structure: SHELXL97 (Sheldrick, 1997); 
molecular graphics: X-SEED (Barbour, 2001); software used to prepare material for 
publication: SHELXL97 (Sheldrick, 2001). 
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Figure 6-4 Mercury diagram showing the molecular structure of the titled compound with 
atomic labelling scheme. 
 
Special details 
Geometry. All esds (except the esd in the dihedral angle between two l.s. planes) are 
estimated using the full covariance matrix. The cell esds are taken into account individually 
in the estimation of esds in distances, angles and torsion angles; correlations between esds in 
cell parameters are only used when they are defined by crystal symmetry. An approximate 
(isotropic) treatment of cell esds is used for estimating esds involving l.s. planes. 
 
Refinement. Refinement of F2 against ALL reflections.  The weighted R-factor wR and   
goodness of fit S are based on F2, conventional R-factors R are based on F, with F set to zero 
for negative F2. The threshold expression of F2>2 sigma (F2) is used only for calculating R-
factors (gt) etc. and is not relevant to the choice of reflections for refinement.  R-factors based   
on F2 are statistically about twice as large as those based on F, and R- factors based on ALL 
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Abstract 
The structure of (E)-2-acetyl-phenyl- 3-(4-methoxyphenyl)acrylate, C18H16O4, at 173 K has 
orthorhombic (Pbca) symmetry.  In the crystal packing, the title compound has eight 
molecules in one unit cell. 
 
Related literature 
For the preparation, see: Pinto et al. (2000). For related structures, see: Santos et al. (2009); 
Ren et al. (2006a); Ren et al. (2006b). For bond-length data, see: Allen et al.(1987). The title 
compound is a core structure in various natural and pharmaceutically active compounds, 



























The title compound (E)-2-acetylphenyl-3-(4-methoxyphenyl)acrylate was obtained as an 
intermediate en route to the synthesis of the corresponding 2-styrylchromone.It was 
synthesized according to the procedure by Pinto et al. (2000) with modification. The title 
compound is a core structure in various natural and pharmaceutically active compounds, 
displaying a broad spectrum of activity (Gomes et al., 2010). 
 
In the molecule of the title compound (Figure 6-5 and Figure 6-6), the two aromatic rings 
(ring 1: C3—C4—C5—C6—C7—C8; ring 2: C12—C13—C14—C15—C16—C17 are 
almost perpendicular to each other. The torsion angle C9—C10—C11—C12 is -176.84 (1)°, 
indicating a trans configuration of the double bond. All bond lengths and angles are within 
normal ranges (Allen et al., 1987). In the crytsal packing, ring 1 adopts a perpendicular offset 




Phosphorous oxychloride (15.6 mmol) was added to a solution of 2-hydroxyacetophenone 
(12.0 mmol) and 4'-methoxy cinnamic acid (15.6 mmol) in dry pyridine. The solution was 
stirred at 60–70°C for 3 h, and then poured into ice and water and the reaction mixture 
165 
acidified with hydrochloric acid (pH 3–4). The obtained solid was removed by filtration and 
dissolved in ethyl acetate (100 ml) and purified by silica gel column chromatography using a 
7:3 mixture of ethyl acetate: n-hexane as the eluent. The solvent was evaporated to dryness 
and the residue recrystallized from ethanol, resulting in the title compound with a 91% yield 
and a m.p of 97–99°C.IR (KBr) max: 1711 (C=O), 1680 (C=O), 1600 (C=C), 1509, 1581, 
1246, 1189 cm-1; 1H NMR (CDCl3, 400 MHz)  7.83 (d, J =15.92 Hz, 1H), 7.80 (dd, J = 
8.04, 1.55 Hz, 1H), 7.53 (d, J = 8.72 Hz, 2H), 7.51 (td, J = 7.55, 1.55 Hz, 1H), 7.31 (td, J = 
8.04, 0.76 Hz, 1H), 7.17 (d, J = 8.00 Hz, 1H), 6.91 (d, J = 8.72, 2H), 6.52 (d, J = 15.92 Hz, 
1H), 3.84 (s, 3H, OCH3), 2.54 (s, 3H, CH3); 13C NMR (CDCl3, 100 MHz)  197.90 (C=O), 
165.53 (C=O), 161.91, 149.28, 147.15, 133.26, 131.54, 130.23 (2C), 130.04, 126.78, 125.95, 
123.81, 114.45 (2C), 114.10, 55.43, 29.92; EIMS (probe) 70 eV (m/z, rel. int.) 296 M+ (7), 
161 (100), 133 (49), 118 (16), 90 (15), 77 (16); calculated molecular mass: 296.10. 
 
Refinement 
All non-hydrogen atoms were refined anisotropically. All hydrogen atoms could be found in 
the difference electron density maps but were finally placed in idealized positions refining in 
riding models with Uiso set at 1.2 or 1.5 times Ueq of their parent atoms. 
 
Computing details 
Data collection: COLLECT program (Nonius et al., 2000); cell refinement: DENZO-
SMN(Otwinowski & Minor et al., 1997); datareduction: DENZO-SMN (Otwinowski & Minor 
et al.,1997); program(s) used to solve structure: SHELXS97 (Sheldrick et al., 
2008);program(s) used to refine structure: SHELXL97 (Sheldrick et al., 2008); molecular 
graphics: ORTEP-3 (Farrugia et al., 2012);software used to prepare material for publication: 
WinGX (Farrugia et al., 2012). 
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Figure 6-6 ORTEP diagram showing the molecular structure of the titled compound with 
atomic labelling scheme. Non-H atoms are drawn with 50% probability 
displacement ellipsoids and H atoms are shown as open circles. 
 
Special details 
Geometry. All esds (except the esd in the dihedral angle between two l.s. planes) are 
estimated using the full covariance matrix.  The cell esds are takeninto account individually 
in the estimation of esds in distances, angles and torsion angles; correlations between esds in 
cell parameters are only used when they are defined by crystal symmetry.  An approximate 
(isotropic) treatment of cell esds is used for estimating esds involving l.s. planes. 
 
Refinement. Refinement of F2 against ALL reflections. The weighted R-factor wR and 
goodness of fit S are based on F2, conventional R-factors R are based on F, with F set to zero 
for negative F2. The threshold expression of F2>2 sigma (F2) is used only for calculating R-
167 
factors (gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based 
on F2 are statistically about twice as large as those based on F, and R- factors based on ALL 
data will be even larger. 
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Abstract 
The title compound, C17H11FO2, has a packing of 4 molecules in a unit cell.  The dihedral 
angle between the benzene rings is 98.04 (5)°.The torsion angle C1—C7—C8—C9 is -
179.67°, indicating a trans configuration of the double bond. All bond lengths and angles are 
within normal ranges (Allen et al.,1987). 
 
Related literature 
For the preparation, see: Pinto et al. (2000). For related structures, see: Santos et al. (2009); 
Conti et al., (2005); Ren et al. (2006a); Renet al. (2006b). For bond-length data, see: Allen et 
al.(1987). The title compound is a core structure in various natural and pharmaceutically 
























Figure 6-7Chemical structure of 2'-fluoro-2-styrylchromone 
 
Comment 
In the title compound (Figure 6-7 and Figure 6-8), the molecule is almost planar with the 
bond angles between 113 and 124.  The compound crystallizes with four planar molecules in 
the symmetric unit and contains four molecules per unit cell. The molecular conformation is 
stabilized by a C-F distance of 1.366 Å and a C=O distance of 1.237Å.  This planarity of the 
molecule makes it very suitable to fit into enzyme pockets of substrates allowing for greater 
interaction between the molecule and enzyme. 
 
The title compound 2'-fluro-2-styrylchromone was synthesized according to the procedure by 
Pinto et al. (2000) with modification.  It is a core structure in various natural and 
pharmaceutically active compounds and was screened for its anti-bacterial activity using 
Gram-positive bacteria (Staphylococcus aureus, scuii and xylosusandBacillus subtilis) and 
Gram-negative bacteria (Escherichia coli, Pseudomonas aeruginosa and Klebsiella 
pneumonia). The compounds were most effective against B. subtilis (ATCC 6633) followed 
by E. coli (ATCC 25922) andS. aureus (ATCC 29212). The compound showed best activity 
from a small library of mono and difluoro 2-styrylchromones, against the B.subtilis strains 
among all tested bacteria.  This could therefore indicate that the activity of the 2-




The title compound was synthesized in a three step reaction in accordance with Silva et al. 
(2000) with modification. 
Step-1: Phosphorous oxychloride (15.6 mmol) was added to a solution of the appropriate 2-
hydroxyacetophenone (12.0 mmol) and the 2-fluoro cinnamic acid (15.6 mmol) in dry 
pyridine. The solution was stirred at 60–70°C for 3h, and then poured into ice and water, and 
the reaction mixture acidified with hydrochloric acid (pH 3-4). The obtained solid was 
removed by filtration and dissolved in ethyl acetate (100 ml) and purified by silica gel 
column chromatography using a 7:3 mixture of ethyl acetate:n-hexane as the eluent.  The 
solvent was evaporated to dryness and the residue recrystallised from ethanol, resulting in 2-
(2’-fluorocinnamoyloxy)acetophenone. 
Step-2: Potassium hydroxide powder (0.05 mmol, 2.8 g) was added to a solution of 2-
cinnamoyloxy)acetophenone (10 mmol) in dimethyl sulfoxide (15 ml). The solution was 
stirred at room temperature until complete disappearance of the starting material, which was 
monitored by TLC.  A typical reaction time was 2h. The solution was then poured into ice 
water and HCl and the pH adjusted to 5. The obtained solid was removed by filtration, 
dissolved in ethyl acetate (150 ml) and purified by silica gel chromatography using ethyl 
acetate :n-hexane (7:3) as the eluent. The solvent was evaporated to dryness and the residue 
recrystallised from ethanol, resulting in 3-hydroxy-1-(2-hydroxyphenyl)-5-(2-fluorophenyl)-
2,4-pentadien-1-one . 
Step-3: p-Toluene-sulfonic acid (3.42 mmol) was added to a solution of the appropriate 3-
hydroxy-1-(2-hydroxyphenyl)-5-(2-fluorophenyl)-2,4-pentadien-1-one (6.5 mmol) in dimethyl 
sulfoxide (20 ml). The reaction mixture was heated at 90°C for 2h, and then poured into ice 
and water and stirred for 10 min. The obtained solid was removed by filtration, dissolved in 
chloroform (100 ml) and washed with a 20% aqueous solution of sodium thiosulphate. The 
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solvent was evaporated to dryness and the residue was purified by silica gel chromatography, 
using chloroform:n-hexane (7:3) as the eluent, to produce2'-fluro-2-styrylchromone, a light 
yellow solid residue (68% yield); mp 150-152°C. UV λmax (CH3OH) nm (log ): 325 (3.37); 
IR (KBr) max: 1682 (C=O), 1625, 1589 (C—C), 1562, 1464, 1391 (C—F), 1125, 968 cm-1; 
1H NMR (CDCl3, 400 MHz)  8.17 (dd, J = 7.94, 1.56 Hz, 1H), 7.72 (d, J = 16.24 Hz, 1H, 
), 7.66 (ddd, J = 8.56, 7.20, 1.56 Hz, 1H), 7.59 (td, J = 7.60, 1.50 Hz, 1H), 7.53 (d, J = 
8.28 Hz, 1H), 7.37 (td, J = 7.92, 0.80 Hz, 1H) , 7.32 (m, 1H), 7.17 (t, J = 7.92 Hz, 1H), 7.11 
(ddd, J = 9.20, 8.20, 2.36 Hz, 1H), 6.87 (d, J = 16.24 Hz, 1H, H), 6.32 (s, 1H); 13C NMR 
(CDCl3, 100 MHz)  178.48 (C=O), 161.47, 161.17 (d, JCF = 253.27 Hz, C2’), 156.02, 
133.88, 131.25 (d, J = 8.67 Hz), 129.47 (d, J = 3.10 Hz, Cβ), 128.39 (d, J = 2.72 Hz), 125.69, 
125.05, 124.56 (d, J = 3.57 Hz), 124.13, 123.09 (d, J = 11.68 Hz), 122.67 (d, J  = 6.51 Hz, 
Cα), 117.93, 116.23 (d, J = 21.81 Hz), 111.21; 19F NMR (CDCl3, 376.5 MHz) δ -115.39; 
EIMS (m/z, rel. int.) 265 (M+-1) (100), 237 (12), 207 (20), 146 (36), 92 (25); HRMS (m/z) M+ 
266.0733 (calculated for C17H11FO2: 266.0743). 
 
Refinement 
All non-hydrogen atoms were refined anisotropically. All hydrogen atoms could be found in 
the difference electron density maps but were finally placed in idealized positions refining in 
riding models with Uiso set at 1.2 or 1.5 times Ueq of their parent atoms. 
 
Computing details 
Data collection: COLLECT program (Nonius et al., 2000); cell refinement: DENZO-SMN 
(Otwinowski & Minor et al., 1997); data reduction: DENZO-SMN (Otwinowski & Minor et 
al., 1997); program(s) used to solve structure: SHELXS97 (Sheldrick et al., 2008); program(s) 
used to refine structure: SHELXL97 (Sheldrick et al., 2008); molecular graphics: ORTEP-3 
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Figure 6-8 Mercury diagram showing the molecular structure of the titled compound with 
atomic labelling scheme. 
 
Special details 
Refinement.Refinement of F2 against ALL reflections.  The weighted R-factor wR and 
goodness of fit S are based on F2, conventional R-factors R are based on F, with F set to zero 
for negative F2. The threshold expression of F2>2 sigma (F2) is used only for calculating R-
factors (gt) etc. and is not relevant to the choice of reflections for refinement.  R-factors based 
on F2 are statistically about twice as large as those based on F, and R-factors based on ALL 
data will be even larger. 
 
Geometry. All esds (except the esd in the dihedral angle between two l.s. planes) are 
estimated using the full covariance matrix.  The cell esds are taken into account individually 
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in the estimation of esds in distances, angles and torsion angles; correlations between esds in 
cell parameters are only used when they are defined by crystal symmetry.  An approximate 
(isotropic) treatment of cell esds is used for estimating esds involving l.s. planes. 
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Chapter 7. Conclusion 
7.1. The 2-styrylchromones 
A series of ten fluorinated and methoxylated 2-styrylchromoneswere prepared in three steps 
based on the Baker-Venkataraman rearrangement and screened for anti-bacterial activity.  Six 
of the ten compounds were novel.  None of thesecompounds were reported to exhibit 
antibacterial activity prior to this study.  Their antibacterial activity was carried out using 
Gram-positive bacteria (three species of Staphylococcus,S. aureus,S.scuii and 
S.xylosusandone Bacillusspecies, B. subtilis) and Gram-negative bacteria (Escherichia coli, 
Pseudomonas aeruginosa and Klebsiella pneumonia).  The compounds were most effective 
against the Gram positive bacteria, B. subtilis followed by S. aureus and a single strain of the 
Gram negative E. coli (ATCC 25922).  Difluorination on the phenyl ring was shown to 
enhance antibacterial activity and fluorine substitution at the 6-position was shown to be best 
for antibacterial activity.  In comparison to tetracycline, the activity indices of the fluorinated 
styrylchromones ranged from 0.50 to 0.75 against B. subtilis.  The compounds may not be 
able to act as antibacterials alone, but may be able to enhance the antibacterial action of other 
antibiotic compounds by acting synergistically with them. 
 
In addition, the 3-hydroxy-2,4-pentadien-1-one intermediates were tested for their antioxidant 
activity by the 2,2-diphenyl-1-pycryl-hydrazyl (DPPH) radical scavenging assay and Ferric 
Reducing Power assay (FRAP) since these compounds contained a free hydroxyl group at the 
3-position.The prepared library of compounds were ideal to assess whether or not the 
deactivating fluorine atoms on the phenyl ring were better at promoting hydrogen or electron 
transfer to free radicals than the activating methoxylated derivatives.  All the methoxylated 
analogues showed better activity thanthe fluorinated analogues and comparable to that of 
ascorbic acid. 
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The crystal structures of two of the 2-styrylchromones, the 2'-fluoro-2-styrylchromone and 
the 6-fluoro-2-styrylchromone show the geometry and absolute structure of the molecules so 
that all the 2-styrylchromone structures could be fashioned around this.  Suitable crystals for 
X-Ray analysis were also obtained for three of the cinnamate esters and their absolute 
structures were also determined by X-Ray crystallography to study the dihedral angles and 
geometry of the different functional groups.  It was found that the two aromatic rings were 
almost perpendicular to each other and during the transformation of the cinnamate ester to the 
2-styrylchromone, the molecule becomes almost planar. 
 
In addition a complete NMR study of all the intermediates and target molecules are also 
presented here to provide a basis for identification of similar derivatives.  The unambiguous 
assignments of the protons and carbon atoms are provided as well as intricate couplings 
between fluorine and hydrogen as well as fluorine and carbon.  NMR assignments were made 
with the aid of HSQC and HMBC data as well as the coupling constants of the different 
proton and carbon resonances. 
 
Limitations and future work 
1) The yields of some of the 2-styrylchromones, in particular A5b (62%), A5e (45%) and A5i 
(55%) were comparatively low compared to the other styrylchromones with yields of 
between 70 and 90%.  The methodology will need to be modified in order to optimize these 
yields. 
2) 2-Styrylchromones with fluorination at multiple sites on the aromatic rings as well as other 
positions on the skeleton such as the 2 double bond and the , double bond linking the 
chromone skeleton to the phenyl ring.  This can be followed by QSAR and computational 
studies to enable further modification and drug design. 
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3) Only a few strains of Gram positive and Gram negative bacteria were tested against.  Other 
strains of bacteria can be used to determine the antibacterial activity of the compounds 
against them and thereby determine whether or not the compounds have a broader spectrum 
of antibiotic activity. 
4) Other biological activities on the new compounds could be investigated, for example 
antirihnovirus, anticancer and anti-HIV activity in which related compounds have shown to 
be active against. 
4)  All synthesized 2-styryl chromone compounds can be transformed into 
1) dienes using Diels-Alder reactions; 
2) pyrazolines with the reaction of diazomethane; 
3) 1,2,3-triazoles by bromination followed by reaction with sodium azide. 
Further computational and biological activity of these analogues can also be carried out to 
determine whether or not these derivatives can provide leads to be developed into drugs 
against pathogenic and other disorders for example, antibacterial, anti-cancer and anti-HIV 
drugs. 
 
7.2. The 2-thioimidazole dicarboxylates 
Seven fluorinated derivatives of diethyl-2-(benzylthio)-2,3-dihydro-1H-imidazole-4,5-
dicarboxylate (a-g) as well as a nitro and chloro derivative (h-i) were prepared in five steps 
from glycine, ethyl formate, diethyl oxalate, potassium thiocyanate and substituted benzyl 
bromides.  The synthesized compounds exhibited concentration dependent anti-platelet 
aggregation activity on both the thrombin and ADP induced platelet aggregation. The 4-nitro 
and 4-fluoro compounds exhibited the highest activity from the compounds tested, with 
estimated IC50 values of 0.40 and 0.35mg/mL for the thrombin-induced and ADP-induced 
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platelet aggregation, respectively, and further modifications to the structures of these 
compounds may lead to better anti-platelet aggregation activity. 
 
In addition, the crystal structure of 2-mercapto-4,5-imidazoledicarboxylate is presented to 
provide an insight into the structural geometry of the molecule. 
 
Limitations and future work 
1) The library of fluorinated analogues synthesised is rather limit and more fluorinated and 
other halides analogues ofdiethyl-2-(benzylthio)-2,3-dihydro-1H-imidazole-4,5-
dicarboxylateswould need to be synthesized to provide a more comprehensive study of the 
anti-platelet activity of these types of compounds.  This can also be followed by QSAR and 
computational studies to enable further modification and drug design. 
2) Other types of antiplatelet aggregation such as epinephrineinduced platelet aggregation can 
also be used to provide a more comprehensive study on the antiplatelet activity. 
4) Other types of biological activities could also be investigated for example antibacterial, 
anti-fungal, anticancer, anti-HIV activity. 
5)  The substitution of benzyl halides in the 2-mercapto-4,5-imidazoledicarboxylate at the 
sulphur and nitrogen atoms with the reaction of 2 moles of  benzyl halides can also be carried 
out.   These synthesized compounds can be screened for biological assays such as 
antibacterial, anti-fungal, anticancer, anti-HIV activity and anti-TB in addition to anti-platelet 
activity. 
 
In general, the work described here provides a platform for structural elucidation and 
biological activity of two classes of compounds, the 2-styrylchromones and 2-thioimidazoles.  
Other projects and ideas can be generated from this work for future studies. 
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Appendix-1 
A1-1  X-ray Crystallographic data of 6-fluoro-2-styrylchromone discussed in Chapter 2 
Crystal data 
  C17H11FO2 F(000) = 1104 
Mr = 266.26 Dx = 1.388 Mg m
-3 
Monoclinic, C2/c Mo Kα radiation, λ = 0.71073 Å 
a = 28.505 (3) Å Cell parameters from 9566 reflections 
b = 5.6688 (6) Å θ = 1.5–28.3° 
c = 16.4254 (16) Å µ = 0.10 mm-1 
β = 106.189 (2)° T = 173 K 
V = 2548.9 (5)  Å3 Plate, yellow 
Z = 8 0.29 × 0.12 × 0.04 mm 
 
Data collection 
  Bruker Kappa Duo Apex II Diffractometer 3158 independent reflections 
Radiation source: fine-focus sealed tube 2023 reflections with I > 2σ(I) 
graphite Rint = 0.042 
0.5° φ scans and ω scans θmax = 28.3°, θmin = 1.5° 
Absorption correction: multi-scan  
SADABS (Sheldrick, 1997) 
h = -38→30 
Tmin = 0.972, Tmax = 0.996 k = -7→7 
9566 measured reflections l = -21→21 
 
Refinement 
  Refinement on F2 Primary atom site location: structure-invariant 
direct methods 
Least-squares matrix: full Secondary atom site location: difference Fourier 
map 
R[F2 > 2σ(F2)] = 0.044 Hydrogen site location: inferred from 
neighbouring sites 
wR(F2) = 0.112 H-atom parameters constrained 
S = 1.03 w = 1/[σ2(Fo
2) + (0.0479P)2 + 0.4765P]   
where P = (Fo
2 + 2Fc
2)/3 
3158 reflections (∆/σ)max < 0.001 
181 parameters ∆ρmax = 0.25 e Å
-3 




Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2) 
 x y z Uiso*/Ueq 
F1 0.19366 (4) 0.82319 (19) 0.54681 (7) 0.0519 (3) 
O1 0.06955 (4) 0.18317 (19) 0.55091 (7) 0.0342 (3) 
O2 0.01028 (4) 0.61778 (17) 0.34986 (7) 0.0297 (3) 
C1 0.05660 (5) 0.6599 (3) 0.40109 (10) 0.0265 (3) 
C2 0.08052 (6) 0.8553 (3) 0.38023 (10) 0.0306 (4) 
H2 0.0651 0.9503 0.3326 0.037* 
C3 0.12675 (6) 0.9085 (3) 0.42960 (11) 0.0326 (4) 
H3 0.1438 1.0409 0.4167 0.039* 
C4 0.14798 (6) 0.7659 (3) 0.49835 (11) 0.0329 (4) 
C5 0.12538 (5) 0.5722 (3) 0.51941 (10) 0.0308 (4) 
H5 0.1412 0.4777 0.5669 0.037* 
C6 0.07855 (5) 0.5164 (3) 0.46957 (9) 0.0259 (3) 
C7 0.05199 (5) 0.3101 (3) 0.48845 (10) 0.0269 (3) 
C8 0.00474 (5) 0.2732 (3) 0.42952 (10) 0.0280 (3) 
H8 -0.0135 0.1379 0.4361 0.034* 
C9 -0.01448 (5) 0.4231 (3) 0.36549 (10) 0.0273 (3) 
C10 -0.06285 (6) 0.4126 (3) 0.30549 (10) 0.0302 (4) 
H10 -0.0717 0.5343 0.2643 0.036* 
C11 -0.09557 (6) 0.2443 (3) 0.30442 (10) 0.0304 (4) 
H11 -0.0861 0.1220 0.3453 0.036* 
C12 -0.14486 (5) 0.2297 (3) 0.24620 (10) 0.0275 (3) 
C13 -0.17421 (6) 0.0354 (3) 0.25122 (11) 0.0347 (4) 
H13 -0.1624 -0.0808 0.2937 0.042* 
C14 -0.22019 (6) 0.0106 (3) 0.19511 (11) 0.0405 (4) 
H14 -0.2396 -0.1230 0.1989 0.049* 
C15 -0.23795 (6) 0.1789 (3) 0.13365 (12) 0.0388 (4) 
H15 -0.2694 0.1604 0.0947 0.047* 
C16 -0.20992 (6) 0.3747 (3) 0.12883 (11) 0.0367 (4) 
H16 -0.2224 0.4919 0.0871 0.044* 
C17 -0.16400 (6) 0.4009 (3) 0.18424 (10) 0.0319 (4) 






Atomic displacement parameters (Å2) 
 U11 U22 U33 U12 U13 U23 
F1 0.0329 (6) 0.0591 (7) 0.0561 (7) -0.0176 (5) 0.0000 (5) 0.0023 (6) 
O1 0.0361 (7) 0.0309 (6) 0.0326 (6) -0.0006 (5) 0.0047 (5) 0.0067 (5) 
O2 0.0273 (6) 0.0302 (6) 0.0300 (6) -0.0038 (4) 0.0053 (5) 0.0043 (5) 
C1 0.0243 (8) 0.0282 (8) 0.0284 (8) -0.0017 (6) 0.0094 (6) -0.0041 (6) 
C2 0.0341 (9) 0.0274 (8) 0.0323 (9) 0.0000 (7) 0.0128 (7) 0.0006 (7) 
C3 0.0337 (9) 0.0298 (8) 0.0382 (9) -0.0062 (7) 0.0164 (7) -0.0037 (7) 
C4 0.0250 (8) 0.0378 (9) 0.0353 (9) -0.0053 (7) 0.0073 (7) -0.0055 (7) 
C5 0.0271 (8) 0.0340 (8) 0.0306 (9) 0.0006 (7) 0.0070 (7) 0.0010 (7) 
C6 0.0252 (8) 0.0264 (8) 0.0279 (8) 0.0011 (6) 0.0104 (6) -0.0016 (6) 
C7 0.0288 (8) 0.0247 (7) 0.0282 (8) 0.0011 (6) 0.0093 (7) -0.0007 (6) 
C8 0.0284 (8) 0.0244 (7) 0.0312 (8) -0.0039 (6) 0.0083 (7) -0.0001 (6) 
C9 0.0286 (8) 0.0266 (8) 0.0273 (8) -0.0032 (6) 0.0089 (7) -0.0013 (6) 
C10 0.0324 (9) 0.0318 (8) 0.0258 (8) 0.0000 (7) 0.0070 (7) 0.0024 (7) 
C11 0.0328 (9) 0.0288 (8) 0.0277 (8) -0.0002 (7) 0.0055 (7) 0.0005 (7) 
C12 0.0283 (8) 0.0276 (8) 0.0269 (8) -0.0008 (6) 0.0079 (6) -0.0040 (6) 
C13 0.0398 (10) 0.0303 (8) 0.0338 (9) -0.0050 (7) 0.0101 (7) 0.0024 (7) 
C14 0.0372 (10) 0.0379 (10) 0.0464 (11) -0.0131 (8) 0.0115 (8) -0.0064 (8) 
C15 0.0230 (8) 0.0463 (10) 0.0427 (10) -0.0025 (7) 0.0022 (7) -0.0078 (8) 
C16 0.0296 (9) 0.0351 (9) 0.0423 (10) 0.0054 (7) 0.0048 (8) 0.0042 (8) 
C17 0.0271 (8) 0.0272 (8) 0.0397 (10) -0.0004 (6) 0.0066 (7) 0.0012 (7) 
 
Geometric parameters (Å, º) 
F1—C4 1.3626 (18) C9—C10 1.455 (2) 
O1—C7 1.2388 (17) C10—C11 1.331 (2) 
O2—C9 1.3722 (17) C10—H10 0.9500 
O2—C1 1.3742 (18) C11—C12 1.465 (2) 
C1—C6 1.388 (2) C11—H11 0.9500 
C1—C2 1.393 (2) C12—C13 1.399 (2) 
C2—C3 1.375 (2) C12—C17 1.402 (2) 
C2—H2 0.9500 C13—C14 1.383 (2) 
C3—C4 1.383 (2) C13—H13 0.9500 
C3—H3 0.9500 C14—C15 1.379 (2) 
C4—C5 1.366 (2) C14—H14 0.9500 
C5—C6 1.394 (2) C15—C16 1.383 (2) 
C5—H5 0.9500 C15—H15 0.9500 
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C6—C7 1.472 (2) C16—C17 1.378 (2) 
C7—C8 1.438 (2) C16—H16 0.9500 
C8—C9 1.345 (2) C17—H17 0.9500 
C8—H8 0.9500   
C9—O2—C1 118.79 (12) C8—C9—C10 127.32 (14) 
O2—C1—C6 122.25 (13) O2—C9—C10 110.24 (13) 
O2—C1—C2 116.11 (13) C11—C10—C9 124.50 (15) 
C6—C1—C2 121.64 (14) C11—C10—H10 117.8 
C3—C2—C1 118.96 (15) C9—C10—H10 117.8 
C3—C2—H2 120.5 C10—C11—C12 126.16 (15) 
C1—C2—H2 120.5 C10—C11—H11 116.9 
C2—C3—C4 118.84 (15) C12—C11—H11 116.9 
C2—C3—H3 120.6 C13—C12—C17 118.01 (14) 
C4—C3—H3 120.6 C13—C12—C11 119.09 (14) 
F1—C4—C5 119.01 (14) C17—C12—C11 122.89 (14) 
F1—C4—C3 117.83 (14) C14—C13—C12 120.80 (15) 
C5—C4—C3 123.15 (15) C14—C13—H13 119.6 
C4—C5—C6 118.42 (15) C12—C13—H13 119.6 
C4—C5—H5 120.8 C15—C14—C13 120.23 (15) 
C6—C5—H5 120.8 C15—C14—H14 119.9 
C1—C6—C5 118.97 (14) C13—C14—H14 119.9 
C1—C6—C7 119.61 (13) C14—C15—C16 119.83 (15) 
C5—C6—C7 121.41 (14) C14—C15—H15 120.1 
O1—C7—C8 124.01 (14) C16—C15—H15 120.1 
O1—C7—C6 121.54 (14) C17—C16—C15 120.43 (16) 
C8—C7—C6 114.45 (13) C17—C16—H16 119.8 
C9—C8—C7 122.38 (14) C15—C16—H16 119.8 
C9—C8—H8 118.8 C16—C17—C12 120.69 (15) 
C7—C8—H8 118.8 C16—C17—H17 119.7 
C8—C9—O2 122.41 (13) C12—C17—H17 119.7 
C9—O2—C1—C6 -2.0 (2) O1—C7—C8—C9 175.63 (15) 
C9—O2—C1—C2 177.80 (13) C6—C7—C8—C9 -3.6 (2) 
O2—C1—C2—C3 179.27 (14) C7—C8—C9—O2 2.4 (2) 
C6—C1—C2—C3 -0.9 (2) C7—C8—C9—C10 -175.80 (15) 
C1—C2—C3—C4 0.0 (2) C1—O2—C9—C8 0.6 (2) 
C2—C3—C4—F1 -179.45 (14) C1—O2—C9—C10 179.04 (13) 
C2—C3—C4—C5 0.6 (2) C8—C9—C10—C11 -1.6 (3) 
F1—C4—C5—C6 179.65 (14) O2—C9—C10—C11 -179.98 (14) 
C3—C4—C5—C6 -0.4 (2) C9—C10—C11—C12 178.81 (15) 
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O2—C1—C6—C5 -179.09 (14) C10—C11—C12—C13 177.46 (16) 
C2—C1—C6—C5 1.1 (2) C10—C11—C12—C17 -1.5 (3) 
O2—C1—C6—C7 0.5 (2) C17—C12—C13—C14 1.7 (2) 
C2—C1—C6—C7 -179.26 (13) C11—C12—C13—C14 -177.36 (15) 
C4—C5—C6—C1 -0.4 (2) C12—C13—C14—C15 -0.6 (3) 
C4—C5—C6—C7 179.95 (14) C13—C14—C15—C16 -0.8 (3) 
C1—C6—C7—O1 -177.13 (14) C14—C15—C16—C17 1.0 (3) 
C5—C6—C7—O1 2.5 (2) C15—C16—C17—C12 0.2 (3) 
C1—C6—C7—C8 2.2 (2) C13—C12—C17—C16 -1.5 (2) 





A1-2   X-ray crystallographic data of diethyl 2-mercapto-4,5-imidazoledicarboxylate 
discussed in Chapter 3 
Crystal data 
C9H12N2O4S Z = 2 
Mr = 244.27 F(000) = 256 
Triclinic, P¯ 1 Dx = 1.455 Mg m
-3 
a = 7.0493 (11) Å Mo Kα radiation, λ = 0.71073 Å 
b = 8.7173 (13) Å Cell parameters from 4511 reflections 
c = 9.6955 (14) Å θ = 2.5–27.6° 
α = 79.246 (3)° µ = 0.29 mm-1 
β = 85.918 (3)° T = 173 K 
γ = 72.348 (3)° Block, yellow 
V = 557.71 (14)  Å3 0.12 × 0.09 × 0.04 mm 
 
Data collection 
  Bruker Kappa Duo Apex II Diffractometer 1804 reflections with I > 2σ(I) 
Radiation source: fine-focus sealed tube Rint = 0.019 
graphite θmax = 27.6°, θmin = 2.5° 
0.5° φ scans and ω scans h = -9→9 
4511 measured reflections k = -10→11 
2536 independent reflections l = -12→6 
 
Refinement 
  Refinement on F2 Primary atom site location: structure-invariant 
direct methods 
Least-squares matrix: full Secondary atom site location: difference Fourier 
map 
R[F2 > 2σ(F2)] = 0.039 Hydrogen site location: inferred from 
neighbouring sites 
wR(F2) = 0.095 H atoms treated by a mixture of independent 
and constrained refinement 
S = 1.01 w = 1/[σ2(Fo
2) + (0.0445P)2 + 0.0908P]   
where P = (Fo
2 + 2Fc
2)/3 
2536 reflections (∆/σ)max = 0.001 
155 parameters ∆ρmax = 0.29 e Å
-3 




Hydrogen-bond geometry (Å, °) 
D—H···A D—H H···A D···A D—H···A 
N1—H1···O2i 0.969(9) 1.861(11) 2.827(2) 175(2) 
N2—H2···S1ii 0.969(16) 2.325(16) 2.863(17) 171.4(14) 
Symmetry codes: (i)1-x, 2-y,1-z (ii)1-x,1-y,2-z 
 
Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2) 
 x y z Uiso*/Ueq 
S1 0.37160 (8) 0.75878 (6) 0.93291 (5) 0.03030 (16) 
O1 0.7302 (2) 0.64790 (16) 0.34320 (13) 0.0290 (3) 
O2 0.6430 (2) 0.89175 (16) 0.41091 (14) 0.0339 (4) 
O3 0.8677 (3) 0.33164 (17) 0.50149 (15) 0.0443 (4) 
O4 0.7538 (2) 0.22686 (15) 0.70863 (14) 0.0309 (3) 
N1 0.5218 (3) 0.76635 (19) 0.66774 (16) 0.0253 (4) 
H1 0.472 (3) 0.8844 (4) 0.644 (3) 0.053 (7)* 
N2 0.5817 (2) 0.52084 (18) 0.78242 (16) 0.0246 (4) 
H2 0.589 (3) 0.4323 (19) 0.8609 (16) 0.047 (7)* 
C1 0.8803 (3) 0.5941 (3) 0.1230 (2) 0.0371 (5) 
H1A 1.0005 0.5267 0.1744 0.056* 
H1B 0.9180 0.6424 0.0295 0.056* 
H1C 0.7957 0.5259 0.1136 0.056* 
C2 0.7690 (3) 0.7267 (2) 0.2012 (2) 0.0326 (5) 
H2A 0.8490 0.8015 0.2052 0.039* 
H2B 0.6421 0.7907 0.1541 0.039* 
C3 0.6693 (3) 0.7456 (2) 0.4355 (2) 0.0251 (4) 
C4 0.6260 (3) 0.6650 (2) 0.57731 (19) 0.0242 (4) 
C5 0.4932 (3) 0.6795 (2) 0.79443 (19) 0.0237 (4) 
C6 0.6649 (3) 0.5081 (2) 0.64964 (19) 0.0235 (4) 
C7 0.7739 (3) 0.3490 (2) 0.6079 (2) 0.0274 (4) 
C8 0.8552 (3) 0.0614 (2) 0.6809 (2) 0.0334 (5) 
H8A 0.9982 0.0485 0.6599 0.040* 
H8B 0.7953 0.0409 0.5995 0.040* 
C9 0.8312 (4) -0.0562 (3) 0.8103 (2) 0.0411 (6) 
H9A 0.8951 -0.0372 0.8894 0.062* 
H9B 0.8935 -0.1685 0.7944 0.062* 
H9C 0.6891 -0.0399 0.8317 0.062* 
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Atomic displacement parameters (Å2) 
 U11 U22 U33 U12 U13 U23 
S1 0.0400 (3) 0.0221 (3) 0.0246 (3) -0.0043 (2) 0.0043 (2) -0.00341 
(19) 
O1 0.0423 (9) 0.0231 (7) 0.0204 (7) -0.0089 (6) 0.0016 (6) -0.0029 (5) 
O2 0.0468 (10) 0.0184 (7) 0.0308 (8) -0.0048 (6) 0.0084 (7) -0.0019 (6) 
O3 0.0597 (12) 0.0273 (8) 0.0348 (9) -0.0010 (7) 0.0154 (8) -0.0039 (7) 
O4 0.0385 (9) 0.0173 (7) 0.0328 (8) -0.0047 (6) 0.0075 (6) -0.0034 (6) 
N1 0.0324 (10) 0.0193 (8) 0.0220 (8) -0.0057 (7) 0.0007 (7) -0.0018 (7) 
N2 0.0299 (10) 0.0175 (8) 0.0234 (8) -0.0043 (7) 0.0010 (7) -0.0009 (7) 
C1 0.0405 (14) 0.0378 (12) 0.0318 (11) -0.0088 (10) 0.0040 (10) -0.0095 (9) 
C2 0.0437 (14) 0.0300 (11) 0.0222 (10) -0.0098 (10) 0.0016 (9) -0.0023 (8) 
C3 0.0254 (11) 0.0214 (10) 0.0259 (10) -0.0045 (8) -0.0010 (8) -0.0021 (8) 
C4 0.0281 (11) 0.0195 (9) 0.0240 (10) -0.0058 (8) 0.0004 (8) -0.0036 (7) 
C5 0.0268 (11) 0.0196 (9) 0.0240 (10) -0.0063 (8) -0.0030 (8) -0.0015 (8) 
C6 0.0256 (11) 0.0204 (9) 0.0235 (9) -0.0059 (8) -0.0005 (8) -0.0027 (8) 
C7 0.0296 (12) 0.0226 (10) 0.0278 (10) -0.0054 (8) -0.0005 (8) -0.0033 (8) 
C8 0.0358 (13) 0.0205 (10) 0.0424 (12) -0.0051 (9) 0.0025 (10) -0.0087 (9) 
C9 0.0481 (15) 0.0223 (11) 0.0489 (14) -0.0072 (10) -0.0032 (11) -0.0007 (10) 
 
Geometric parameters (Å, º) 
S1—C5 1.6846 (19) C1—H1A 0.9800 
O1—C3 1.311 (2) C1—H1B 0.9800 
O1—C2 1.466 (2) C1—H1C 0.9800 
O2—C3 1.210 (2) C2—H2A 0.9900 
O3—C7 1.194 (2) C2—H2B 0.9900 
O4—C7 1.338 (2) C3—C4 1.478 (3) 
O4—C8 1.468 (2) C4—C6 1.371 (2) 
N1—C5 1.354 (2) C6—C7 1.482 (3) 
N1—C4 1.376 (2) C8—C9 1.500 (3) 
N1—H1 0.969 (2) C8—H8A 0.9900 
N2—C5 1.357 (2) C8—H8B 0.9900 
N2—C6 1.386 (2) C9—H9A 0.9800 
N2—H2 0.969 (2) C9—H9B 0.9800 
C1—C2 1.490 (3) C9—H9C 0.9800 
C3—O1—C2 115.53 (15) C6—C4—C3 136.79 (17) 
C7—O4—C8 115.51 (14) N1—C4—C3 116.42 (16) 
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C5—N1—C4 111.18 (16) N1—C5—N2 104.98 (16) 
C5—N1—H1 124.0 (15) N1—C5—S1 125.61 (14) 
C4—N1—H1 124.8 (15) N2—C5—S1 129.41 (14) 
C5—N2—C6 111.05 (15) C4—C6—N2 106.01 (16) 
C5—N2—H2 122.0 (14) C4—C6—C7 131.34 (17) 
C6—N2—H2 126.9 (14) N2—C6—C7 122.64 (16) 
C2—C1—H1A 109.5 O3—C7—O4 124.86 (18) 
C2—C1—H1B 109.5 O3—C7—C6 125.41 (18) 
H1A—C1—H1B 109.5 O4—C7—C6 109.72 (16) 
C2—C1—H1C 109.5 O4—C8—C9 107.26 (16) 
H1A—C1—H1C 109.5 O4—C8—H8A 110.3 
H1B—C1—H1C 109.5 C9—C8—H8A 110.3 
O1—C2—C1 107.03 (16) O4—C8—H8B 110.3 
O1—C2—H2A 110.3 C9—C8—H8B 110.3 
C1—C2—H2A 110.3 H8A—C8—H8B 108.5 
O1—C2—H2B 110.3 C8—C9—H9A 109.5 
C1—C2—H2B 110.3 C8—C9—H9B 109.5 
H2A—C2—H2B 108.6 H9A—C9—H9B 109.5 
O2—C3—O1 124.89 (18) C8—C9—H9C 109.5 
O2—C3—C4 120.18 (18) H9A—C9—H9C 109.5 
O1—C3—C4 114.91 (16) H9B—C9—H9C 109.5 
C6—C4—N1 106.78 (16)   
C3—O1—C2—C1 166.83 (18) N1—C4—C6—N2 0.0 (2) 
C2—O1—C3—O2 0.5 (3) C3—C4—C6—N2 178.9 (2) 
C2—O1—C3—C4 178.54 (17) N1—C4—C6—C7 -178.9 (2) 
C5—N1—C4—C6 -0.1 (2) C3—C4—C6—C7 0.0 (4) 
C5—N1—C4—C3 -179.22 (18) C5—N2—C6—C4 0.0 (2) 
O2—C3—C4—C6 -166.9 (2) C5—N2—C6—C7 179.09 (18) 
O1—C3—C4—C6 14.9 (4) C8—O4—C7—O3 -0.8 (3) 
O2—C3—C4—N1 11.9 (3) C8—O4—C7—C6 -179.90 (17) 
O1—C3—C4—N1 -166.28 (18) C4—C6—C7—O3 8.0 (4) 
C4—N1—C5—N2 0.1 (2) N2—C6—C7—O3 -170.9 (2) 
C4—N1—C5—S1 -179.75 (15) C4—C6—C7—O4 -172.9 (2) 
C6—N2—C5—N1 -0.1 (2) N2—C6—C7—O4 8.3 (3) 




A1-3   X Ray crystallographic data of 2-Acetylphenyl-(2E)-3-(4-fluorophenyl)acrylate 
discussed in Chapter 6, subchapter 6.1 
Crystal data 
  C17H13FO3 F(000) = 1184 
Mr = 284.27 Dx = 1.373 Mg m
-3 
Monoclinic, C2/c Mo Ka radiation, l = 0.71073 Å 
a = 26.574 (1) Å Cell parameters from 6005 reflections 
b = 6.3883 (3) Å q = 3.1–27.5° 
c = 19.3304 (6) Å m = 0.10 mm-1 
b = 123.037 (2)° T = 173 K 
V = 2751.01 (19)  Å3 Plate, colourless 
Z = 8 0.26 × 0.23 × 0.09 mm 
 
Data collection 
  Nonius Kappa CCD  
diffractometer 
2201 reflections with I > 2σ(I) 
Radiation source: fine-focus sealed tube Rint = 0.021 
graphite θmax = 27.5°, θmin = 3.1° 
1.2° φ scans and ω scans h = -33→34 
6005 measured reflections k = -8→8 
3150 independent reflections l = -25→24 
 
Refinement 
  Refinement on F2 Primary atom site location: structure-invariant 
direct methods 
Least-squares matrix: full Secondary atom site location: difference Fourier 
map 
R[F2 > 2s(F2)] = 0.041 Hydrogen site location: inferred from 
neighbouring sites 
wR(F2) = 0.115 H-atom parameters constrained 
S = 1.05 w = 1/[s2(Fo
2) + (0.0612P)2 + 0.6743P]   
where P = (Fo
2 + 2Fc
2)/3 
3150 reflections (D/s)max < 0.001 
191 parameters Dρmax = 0.18 e Å
-3 




Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2) 
 x y z Uiso*/Ueq 
F1 0.04188 (4) 1.49324 (13) 0.22111 (6) 0.0580 (3) 
O1 0.26072 (5) -0.02536 (18) 0.16114 (6) 0.0556 (3) 
O2 0.16132 (4) 0.49823 (13) 0.02908 (6) 0.0379 (2) 
O3 0.06857 (4) 0.41188 (17) -0.00442 (7) 0.0522 (3) 
C1 0.25590 (7) 0.3344 (3) 0.18081 (9) 0.0512 (4) 
H1A 0.2225 0.3695 0.1867 0.077* 
H1B 0.2633 0.4515 0.1548 0.077* 
H1C 0.2921 0.3074 0.2354 0.077* 
C2 0.24038 (6) 0.1439 (2) 0.12848 (8) 0.0377 (3) 
C3 0.19990 (5) 0.1519 (2) 0.03588 (7) 0.0315 (3) 
C4 0.19941 (6) -0.0253 (2) -0.00725 (8) 0.0369 (3) 
H4 0.2241 -0.1415 0.0228 0.044* 
C5 0.16398 (6) -0.0351 (2) -0.09234 (9) 0.0430 (4) 
H5 0.1643 -0.1569 -0.1203 0.052* 
C6 0.12814 (7) 0.1330 (2) -0.13652 (8) 0.0447 (4) 
H6 0.1039 0.1274 -0.1951 0.054* 
C7 0.12732 (6) 0.3091 (2) -0.09597 (8) 0.0418 (3) 
H7 0.1026 0.4247 -0.1265 0.050* 
C8 0.16273 (6) 0.3169 (2) -0.01042 (8) 0.0327 (3) 
C9 0.11003 (6) 0.5312 (2) 0.02865 (8) 0.0337 (3) 
C10 0.11450 (6) 0.72268 (19) 0.07306 (8) 0.0339 (3) 
H10 0.1496 0.8069 0.0972 0.041* 
C11 0.06885 (6) 0.7778 (2) 0.07935 (8) 0.0346 (3) 
H11 0.0355 0.6853 0.0548 0.042* 
C12 0.06392 (6) 0.96377 (19) 0.11951 (7) 0.0321 (3) 
C13 0.01102 (6) 0.9974 (2) 0.11673 (8) 0.0379 (3) 
H13 -0.0204 0.8971 0.0906 0.045* 
C14 0.00350 (6) 1.1745 (2) 0.15135 (8) 0.0418 (3) 
H14 -0.0326 1.1971 0.1493 0.050* 
C15 0.04946 (6) 1.3164 (2) 0.18860 (8) 0.0388 (3) 
C16 0.10298 (6) 1.2888 (2) 0.19487 (8) 0.0385 (3) 
H16 0.1344 1.3885 0.2226 0.046* 
C17 0.10980 (6) 1.1118 (2) 0.15972 (8) 0.0360 (3) 
H17 0.1464 1.0903 0.1629 0.043* 
 
Atomic displacement parameters (Å2) 
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 U11 U22 U33 U12 U13 U23 
F1 0.0663 (6) 0.0476 (5) 0.0611 (6) -0.0033 (4) 0.0354 (5) -0.0236 (4) 
O1 0.0560 (7) 0.0582 (7) 0.0411 (6) 0.0116 (5) 0.0191 (5) 0.0104 (5) 
O2 0.0366 (5) 0.0330 (5) 0.0456 (5) -0.0029 (4) 0.0234 (4) -0.0093 (4) 
O3 0.0453 (6) 0.0485 (6) 0.0693 (7) -0.0152 (5) 0.0354 (6) -0.0258 (5) 
C1 0.0492 (9) 0.0627 (10) 0.0346 (8) -0.0076 (7) 0.0183 (7) -0.0089 (7) 
C2 0.0314 (7) 0.0486 (8) 0.0358 (7) -0.0011 (6) 0.0201 (6) -0.0001 (6) 
C3 0.0303 (6) 0.0351 (7) 0.0331 (7) -0.0026 (5) 0.0200 (5) -0.0011 (5) 
C4 0.0397 (7) 0.0348 (7) 0.0413 (8) 0.0037 (6) 0.0254 (6) 0.0013 (6) 
C5 0.0512 (9) 0.0416 (8) 0.0440 (8) -0.0030 (7) 0.0311 (7) -0.0103 (7) 
C6 0.0468 (8) 0.0541 (9) 0.0317 (7) -0.0014 (7) 0.0205 (6) -0.0045 (7) 
C7 0.0437 (8) 0.0426 (8) 0.0361 (7) 0.0060 (6) 0.0199 (6) 0.0037 (6) 
C8 0.0346 (7) 0.0305 (7) 0.0366 (7) -0.0031 (5) 0.0217 (6) -0.0039 (5) 
C9 0.0348 (7) 0.0327 (7) 0.0334 (7) 0.0005 (6) 0.0183 (6) 0.0001 (5) 
C10 0.0355 (7) 0.0296 (7) 0.0341 (7) -0.0025 (5) 0.0174 (6) -0.0019 (5) 
C11 0.0352 (7) 0.0305 (7) 0.0344 (7) -0.0032 (5) 0.0165 (6) -0.0030 (5) 
C12 0.0352 (7) 0.0295 (7) 0.0283 (6) 0.0002 (5) 0.0151 (5) -0.0001 (5) 
C13 0.0340 (7) 0.0377 (7) 0.0372 (7) -0.0044 (6) 0.0164 (6) -0.0086 (6) 
C14 0.0366 (7) 0.0463 (8) 0.0408 (8) 0.0010 (6) 0.0199 (6) -0.0080 (6) 
C15 0.0492 (8) 0.0322 (7) 0.0313 (7) 0.0017 (6) 0.0196 (6) -0.0063 (6) 
C16 0.0424 (8) 0.0332 (7) 0.0343 (7) -0.0080 (6) 0.0172 (6) -0.0048 (6) 
C17 0.0377 (7) 0.0338 (7) 0.0364 (7) -0.0026 (6) 0.0201 (6) -0.0015 (6) 
 
Geometric parameters (Å, º) 
F1—C15 1.3600 (15) C7—C8 1.3878 (18) 
O1—C2 1.2195 (17) C7—H7 0.9500 
O2—C9 1.3748 (16) C9—C10 1.4614 (17) 
O2—C8 1.3993 (15) C10—C11 1.3310 (19) 
O3—C9 1.1982 (16) C10—H10 0.9500 
C1—C2 1.490 (2) C11—C12 1.4636 (17) 
C1—H1A 0.9800 C11—H11 0.9500 
C1—H1B 0.9800 C12—C13 1.3937 (18) 
C1—H1C 0.9800 C12—C17 1.3972 (18) 
C2—C3 1.5048 (19) C13—C14 1.3835 (18) 
C3—C8 1.3869 (18) C13—H13 0.9500 
C3—C4 1.4014 (18) C14—C15 1.369 (2) 
C4—C5 1.381 (2) C14—H14 0.9500 
C4—H4 0.9500 C15—C16 1.371 (2) 
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C5—C6 1.379 (2) C16—C17 1.3814 (19) 
C5—H5 0.9500 C16—H16 0.9500 
C6—C7 1.378 (2) C17—H17 0.9500 
C6—H6 0.9500   
C9—O2—C8 116.42 (9) O3—C9—O2 121.72 (12) 
C2—C1—H1A 109.5 O3—C9—C10 127.06 (12) 
C2—C1—H1B 109.5 O2—C9—C10 111.22 (11) 
H1A—C1—H1B 109.5 C11—C10—C9 119.26 (12) 
C2—C1—H1C 109.5 C11—C10—H10 120.4 
H1A—C1—H1C 109.5 C9—C10—H10 120.4 
H1B—C1—H1C 109.5 C10—C11—C12 127.80 (12) 
O1—C2—C1 119.47 (12) C10—C11—H11 116.1 
O1—C2—C3 118.28 (12) C12—C11—H11 116.1 
C1—C2—C3 122.25 (12) C13—C12—C17 118.24 (12) 
C8—C3—C4 117.21 (11) C13—C12—C11 119.00 (11) 
C8—C3—C2 126.11 (11) C17—C12—C11 122.76 (12) 
C4—C3—C2 116.67 (11) C14—C13—C12 121.07 (12) 
C5—C4—C3 121.63 (13) C14—C13—H13 119.5 
C5—C4—H4 119.2 C12—C13—H13 119.5 
C3—C4—H4 119.2 C15—C14—C13 118.25 (13) 
C6—C5—C4 119.62 (13) C15—C14—H14 120.9 
C6—C5—H5 120.2 C13—C14—H14 120.9 
C4—C5—H5 120.2 F1—C15—C14 118.60 (13) 
C7—C6—C5 120.20 (12) F1—C15—C16 118.28 (12) 
C7—C6—H6 119.9 C14—C15—C16 123.12 (12) 
C5—C6—H6 119.9 C15—C16—C17 118.02 (12) 
C6—C7—C8 119.76 (13) C15—C16—H16 121.0 
C6—C7—H7 120.1 C17—C16—H16 121.0 
C8—C7—H7 120.1 C16—C17—C12 121.26 (12) 
C3—C8—C7 121.56 (12) C16—C17—H17 119.4 
C3—C8—O2 119.91 (11) C12—C17—H17 119.4 
C7—C8—O2 118.51 (11)   
O1—C2—C3—C8 164.97 (13) C8—O2—C9—O3 -0.64 (18) 
C1—C2—C3—C8 -14.7 (2) C8—O2—C9—C10 178.87 (10) 
O1—C2—C3—C4 -14.28 (18) O3—C9—C10—C11 0.0 (2) 
C1—C2—C3—C4 166.04 (12) O2—C9—C10—C11 -179.43 (12) 
C8—C3—C4—C5 0.71 (19) C9—C10—C11—C12 -178.78 (11) 
C2—C3—C4—C5 -179.97 (12) C10—C11—C12—C13 177.62 (13) 
C3—C4—C5—C6 0.1 (2) C10—C11—C12—C17 -1.4 (2) 
14 
C4—C5—C6—C7 -0.5 (2) C17—C12—C13—C14 1.26 (19) 
C5—C6—C7—C8 0.0 (2) C11—C12—C13—C14 -177.78 (12) 
C4—C3—C8—C7 -1.21 (18) C12—C13—C14—C15 0.0 (2) 
C2—C3—C8—C7 179.54 (12) C13—C14—C15—F1 178.52 (11) 
C4—C3—C8—O2 -179.87 (11) C13—C14—C15—C16 -1.6 (2) 
C2—C3—C8—O2 0.88 (19) F1—C15—C16—C17 -178.23 (11) 
C6—C7—C8—C3 0.9 (2) C14—C15—C16—C17 1.9 (2) 
C6—C7—C8—O2 179.56 (12) C15—C16—C17—C12 -0.56 (19) 
C9—O2—C8—C3 -109.06 (13) C13—C12—C17—C16 -0.95 (19) 
C9—O2—C8—C7 72.24 (15) C11—C12—C17—C16 178.05 (12) 
 
Hydrogen-bond geometry (Å, º) 
D—H···A D—H H···A D···A D—H···A 
C1—H1B···O2 0.98 2.48 2.8245 (18) 100 
C7—H7···F1i 0.95 2.52 3.2402 (16) 132 
C11—H11···O3 0.95 2.50 2.8415 (16) 101 
C11—H11···O3ii 0.95 2.46 3.3369 (16) 154 
C13—H13···O3ii 0.95 2.45 3.3191 (16) 153 
C16—H16···O1iii 0.95 2.51 3.3590 (17) 149 
C6—H6···Cg1iv 0.95 2.99 3.818 (1) 146 
 
Symmetry codes:  (i) x, -y+2, z-1/2; (ii) -x, -y+1, -z; (iii) -x+1/2, y+3/2, -z+1/2; (iv) x, -y+1, z-1/2. 
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A1-4   X Ray crystallographic data of (E)-2-Acetyl-4-fluorophenyl-3-(4-
fluorophenyl)acrylate 
Crystal data 
  C17H12F2O3 Z = 4 
Mr = 302.27 F(000) = 624 
Triclinic, P¯ 1 Dx = 1.426 Mg m
-3 
a = 7.6510 (9) Å Mo Kα radiation, λ = 0.71073 Å 
b = 12.5610 (14) Å Cell parameters from 7877 reflections 
c = 15.4368 (17) Å θ = 1.7–25.7° 
α = 73.599 (2)° µ = 0.12 mm-1 
β = 81.604 (3)° T = 173 K 
γ = 88.124 (3)° Needle, colourless 
V = 1407.9 (3)  Å3 0.29 × 0.06 × 0.05 mm 
 
Data collection 
  Bruker Kappa Duo Apex II Diffractometer 5294 independent reflections 
Radiation source: fine-focus sealed tube 3362 reflections with I > 2(I) 
graphite Rint = 0.019 
0.5° φ scans and ω scans θmax = 25.7°, θmin = 1.7° 
Absorption correction: multi-scan  
SADABS (Sheldrick, 1997) 
h = -9→9 
Tmin = 0.968, Tmax = 0.994 k = -15→15 
7877 measured reflections l = -18→17 
 
Refinement 
  Refinement on F2 Primary atom site location: structure-invariant 
direct methods 
Least-squares matrix: full Secondary atom site location: difference 
Fourier map 
R[F2 > 2σ(F2)] = 0.042 Hydrogen site location: inferred from 
neighbouring sites 
wR(F2) = 0.114 H-atom parameters constrained 
S = 0.96 w = 1/[ σ 2(Fo
2) + (0.0608P)2]   
where P = (Fo
2 + 2Fc
2)/3 
5294 reflections (∆/σ)max = 0.001 
399 parameters ∆ρ max = 0.21 e Å
-3 




Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2) 
 x y z Uiso*/Ueq 
F1A 0.11548 (18) 0.53403 (10) 0.56787 (8) 0.0547 (4) 
F2A -0.01031 (19) 0.83163 (10) 1.30768 (8) 0.0568 (4) 
O1A -0.2165 (2) 0.87709 (12) 0.77866 (9) 0.0465 (4) 
O2A -0.00539 (17) 0.70018 (10) 0.80883 (8) 0.0295 (3) 
O3A -0.20253 (18) 0.55996 (11) 0.86357 (8) 0.0390 (4) 
C1A -0.1978 (3) 0.99574 (17) 0.62857 (14) 0.0464 (6) 
H1A1 -0.2465 1.0502 0.6600 0.070* 
H1A2 -0.2795 0.9851 0.5884 0.070* 
H1A3 -0.0837 1.0227 0.5922 0.070* 
C2A -0.1727 (2) 0.88770 (16) 0.69741 (13) 0.0332 (5) 
C3A -0.0929 (2) 0.79367 (15) 0.66302 (12) 0.0285 (4) 
C4A -0.0905 (3) 0.79529 (17) 0.57163 (12) 0.0354 (5) 
H4A -0.1375 0.8575 0.5311 0.043* 
C5A -0.0214 (3) 0.70862 (18) 0.53913 (13) 0.0394 (5) 
H5A -0.0213 0.7105 0.4772 0.047* 
C6A 0.0471 (3) 0.61982 (17) 0.59839 (13) 0.0369 (5) 
C7A 0.0514 (3) 0.61431 (16) 0.68805 (13) 0.0344 (5) 
H7A 0.1017 0.5525 0.7274 0.041* 
C8A -0.0195 (2) 0.70130 (15) 0.71936 (11) 0.0269 (4) 
C9A -0.1111 (2) 0.62836 (15) 0.87731 (12) 0.0268 (4) 
C10A -0.1016 (2) 0.64472 (15) 0.96679 (12) 0.0289 (4) 
H10A -0.1516 0.5890 1.0195 0.035* 
C11A -0.0273 (2) 0.73287 (15) 0.97889 (12) 0.0281 (4) 
H11A 0.0272 0.7859 0.9256 0.034* 
C12A -0.0211 (2) 0.75625 (15) 1.06615 (12) 0.0278 (4) 
C13A -0.0902 (3) 0.68239 (16) 1.14934 (12) 0.0325 (5) 
H13A -0.1405 0.6139 1.1501 0.039* 
C14A -0.0864 (3) 0.70771 (17) 1.23050 (13) 0.0377 (5) 
H14A -0.1331 0.6574 1.2871 0.045* 
C15A -0.0132 (3) 0.80762 (17) 1.22748 (13) 0.0364 (5) 
C16A 0.0565 (3) 0.88284 (16) 1.14777 (14) 0.0374 (5) 
H16A 0.1056 0.9513 1.1479 0.045* 
C17A 0.0529 (2) 0.85580 (16) 1.06695 (13) 0.0323 (4) 
H17A 0.1020 0.9062 1.0109 0.039* 
F1B 0.63202 (18) 0.51072 (10) 0.57600 (8) 0.0546 (4) 
17 
F2B 0.50720 (18) 0.83118 (10) 1.29099 (8) 0.0518 (3) 
O1B 0.2986 (2) 0.96987 (12) 0.57913 (10) 0.0550 (4) 
O2B 0.46287 (17) 0.71393 (10) 0.78960 (8) 0.0296 (3) 
O3B 0.32306 (18) 0.54798 (11) 0.85217 (8) 0.0355 (3) 
C1B 0.3017 (3) 0.92016 (17) 0.73712 (13) 0.0394 (5) 
H1B1 0.2488 0.9935 0.7311 0.059* 
H1B2 0.4131 0.9174 0.7619 0.059* 
H1B3 0.2203 0.8632 0.7784 0.059* 
C2B 0.3366 (3) 0.89925 (16) 0.64539 (13) 0.0336 (5) 
C3B 0.4186 (2) 0.79314 (15) 0.63289 (12) 0.0280 (4) 
C4B 0.4413 (3) 0.78131 (17) 0.54416 (13) 0.0361 (5) 
H4B 0.4079 0.8408 0.4962 0.043* 
C5B 0.5097 (3) 0.68733 (17) 0.52390 (13) 0.0398 (5) 
H5B 0.5210 0.6804 0.4636 0.048* 
C6B 0.5611 (3) 0.60369 (16) 0.59420 (13) 0.0367 (5) 
C7B 0.5471 (3) 0.61009 (15) 0.68216 (12) 0.0317 (4) 
H7B 0.5871 0.5515 0.7287 0.038* 
C8B 0.4731 (2) 0.70444 (15) 0.70098 (11) 0.0264 (4) 
C9B 0.3893 (2) 0.62852 (15) 0.86183 (12) 0.0276 (4) 
C10B 0.3977 (2) 0.64876 (15) 0.94982 (12) 0.0295 (4) 
H10B 0.3422 0.5959 1.0029 0.035* 
C11B 0.4767 (2) 0.73519 (15) 0.96133 (12) 0.0288 (4) 
H11B 0.5343 0.7869 0.9081 0.035* 
C12B 0.4830 (2) 0.75797 (15) 1.04916 (12) 0.0283 (4) 
C13B 0.4127 (3) 0.68483 (16) 1.13280 (12) 0.0314 (4) 
H13B 0.3592 0.6172 1.1339 0.038* 
C14B 0.4201 (3) 0.70989 (16) 1.21383 (13) 0.0356 (5) 
H14B 0.3724 0.6602 1.2705 0.043* 
C15B 0.4978 (3) 0.80800 (17) 1.21062 (13) 0.0357 (5) 
C16B 0.5663 (3) 0.88258 (16) 1.13079 (13) 0.0357 (5) 
H16B 0.6172 0.9506 1.1307 0.043* 
C17B 0.5597 (3) 0.85643 (16) 1.04984 (13) 0.0325 (4) 
H17B 0.6086 0.9069 0.9937 0.039* 
 
Atomic displacement parameters (Å2) 
 U11 U22 U33 U12 U13 U23 
F1A 0.0733 (9) 0.0569 (8) 0.0419 (7) 0.0081 (7) -0.0027 (6) -0.0304 (6) 





0.0445 (9) 0.0327 (8) 0.0062 (7) 0.0052 (7) -0.0094 (7) 
O2A 0.0369 (8) 0.0308 (7) 0.0198 (6) -0.0077 (6) -0.0041 (5) -0.0048 (5) 



































































































































0.0008 (9) -0.0053 (8) -0.0089 (8) 
F1B 0.0825 
(10) 
0.0453 (8) 0.0404 (7) 0.0142 (7) -0.0021 (7) -0.0239 (6) 
F2B 0.0790 (9) 0.0516 (8) 0.0336 (7) -0.0002 (7) -0.0119 (6) -0.0240 (6) 
O1B 0.0816 
(12) 
0.0420 (9) 0.0398 (9) 0.0172 (8) -0.0173 (8) -0.0064 (7) 
O2B 0.0409 (8) 0.0281 (7) 0.0211 (6) -0.0042 (6) -0.0051 (6) -0.0082 (5) 
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0.0019 (9) -0.0039 (8) -0.0097 (8) 
 
Geometric parameters (Å, º) 
F1A—C6A 1.355 (2) F1B—C6B 1.355 (2) 
F2A—C15A 1.358 (2) F2B—C15B 1.364 (2) 
O1A—C2A 1.220 (2) O1B—C2B 1.214 (2) 
O2A—C9A 1.358 (2) O2B—C9B 1.375 (2) 
O2A—C8A 1.397 (2) O2B—C8B 1.397 (2) 
O3A—C9A 1.207 (2) O3B—C9B 1.201 (2) 
20 
C1A—C2A 1.495 (3) C1B—C2B 1.497 (3) 
C1A—H1A1 0.9800 C1B—H1B1 0.9800 
C1A—H1A2 0.9800 C1B—H1B2 0.9800 
C1A—H1A3 0.9800 C1B—H1B3 0.9800 
C2A—C3A 1.504 (3) C2B—C3B 1.504 (3) 
C3A—C8A 1.396 (3) C3B—C8B 1.399 (2) 
C3A—C4A 1.403 (2) C3B—C4B 1.404 (3) 
C4A—C5A 1.382 (3) C4B—C5B 1.373 (3) 
C4A—H4A 0.9500 C4B—H4B 0.9500 
C5A—C6A 1.372 (3) C5B—C6B 1.375 (3) 
C5A—H5A 0.9500 C5B—H5B 0.9500 
C6A—C7A 1.371 (3) C6B—C7B 1.371 (3) 
C7A—C8A 1.380 (3) C7B—C8B 1.383 (3) 
C7A—H7A 0.9500 C7B—H7B 0.9500 
C9A—C10A 1.465 (2) C9B—C10B 1.461 (2) 
C10A—C11A 1.332 (3) C10B—C11B 1.326 (3) 
C10A—H10A 0.9500 C10B—H10B 0.9500 
C11A—C12A 1.465 (2) C11B—C12B 1.470 (2) 
C11A—H11A 0.9500 C11B—H11B 0.9500 
C12A—C17A 1.394 (3) C12B—C17B 1.389 (3) 
C12A—C13A 1.397 (2) C12B—C13B 1.400 (3) 
C13A—C14A 1.381 (3) C13B—C14B 1.383 (3) 
C13A—H13A 0.9500 C13B—H13B 0.9500 
C14A—C15A 1.377 (3) C14B—C15B 1.371 (3) 
C14A—H14A 0.9500 C14B—H14B 0.9500 
C15A—C16A 1.370 (3) C15B—C16B 1.365 (3) 
C16A—C17A 1.387 (3) C16B—C17B 1.387 (3) 
C16A—H16A 0.9500 C16B—H16B 0.9500 
C17A—H17A 0.9500 C17B—H17B 0.9500 
C9A—O2A—C8A 117.63 (14) C9B—O2B—C8B 119.28 (14) 
C2A—C1A—H1A1 109.5 C2B—C1B—H1B1 109.5 
C2A—C1A—H1A2 109.5 C2B—C1B—H1B2 109.5 
H1A1—C1A—H1A2 109.5 H1B1—C1B—H1B2 109.5 
C2A—C1A—H1A3 109.5 C2B—C1B—H1B3 109.5 
H1A1—C1A—H1A3 109.5 H1B1—C1B—H1B3 109.5 
H1A2—C1A—H1A3 109.5 H1B2—C1B—H1B3 109.5 
O1A—C2A—C1A 120.50 (18) O1B—C2B—C1B 119.29 (19) 
O1A—C2A—C3A 121.66 (17) O1B—C2B—C3B 118.99 (18) 
C1A—C2A—C3A 117.84 (17) C1B—C2B—C3B 121.72 (17) 
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C8A—C3A—C4A 116.93 (17) C8B—C3B—C4B 116.63 (17) 
C8A—C3A—C2A 122.40 (16) C8B—C3B—C2B 126.54 (16) 
C4A—C3A—C2A 120.66 (17) C4B—C3B—C2B 116.83 (17) 
C5A—C4A—C3A 121.59 (19) C5B—C4B—C3B 122.72 (18) 
C5A—C4A—H4A 119.2 C5B—C4B—H4B 118.6 
C3A—C4A—H4A 119.2 C3B—C4B—H4B 118.6 
C6A—C5A—C4A 118.47 (18) C4B—C5B—C6B 117.43 (18) 
C6A—C5A—H5A 120.8 C4B—C5B—H5B 121.3 
C4A—C5A—H5A 120.8 C6B—C5B—H5B 121.3 
F1A—C6A—C7A 117.96 (19) F1B—C6B—C7B 117.93 (18) 
F1A—C6A—C5A 119.38 (18) F1B—C6B—C5B 118.78 (17) 
C7A—C6A—C5A 122.65 (19) C7B—C6B—C5B 123.28 (19) 
C6A—C7A—C8A 117.98 (19) C6B—C7B—C8B 117.96 (18) 
C6A—C7A—H7A 121.0 C6B—C7B—H7B 121.0 
C8A—C7A—H7A 121.0 C8B—C7B—H7B 121.0 
C7A—C8A—C3A 122.35 (17) C7B—C8B—O2B 118.74 (16) 
C7A—C8A—O2A 118.51 (16) C7B—C8B—C3B 121.94 (16) 
C3A—C8A—O2A 118.97 (16) O2B—C8B—C3B 119.20 (16) 
O3A—C9A—O2A 122.24 (16) O3B—C9B—O2B 122.89 (16) 
O3A—C9A—C10A 125.13 (17) O3B—C9B—C10B 124.69 (17) 
O2A—C9A—C10A 112.63 (16) O2B—C9B—C10B 112.40 (16) 
C11A—C10A—C9A 124.06 (17) C11B—C10B—C9B 125.09 (17) 
C11A—C10A—H10A 118.0 C11B—C10B—H10B 117.5 
C9A—C10A—H10A 118.0 C9B—C10B—H10B 117.5 
C10A—C11A—C12A 126.50 (17) C10B—C11B—C12B 125.74 (17) 
C10A—C11A—H11A 116.7 C10B—C11B—H11B 117.1 
C12A—C11A—H11A 116.7 C12B—C11B—H11B 117.1 
C17A—C12A—C13A 118.45 (17) C17B—C12B—C13B 118.22 (17) 
C17A—C12A—C11A 119.53 (16) C17B—C12B—C11B 119.13 (17) 
C13A—C12A—C11A 122.01 (17) C13B—C12B—C11B 122.64 (17) 
C14A—C13A—C12A 120.80 (18) C14B—C13B—C12B 120.78 (18) 
C14A—C13A—H13A 119.6 C14B—C13B—H13B 119.6 
C12A—C13A—H13A 119.6 C12B—C13B—H13B 119.6 
C15A—C14A—C13A 118.46 (18) C15B—C14B—C13B 118.60 (18) 
C15A—C14A—H14A 120.8 C15B—C14B—H14B 120.7 
C13A—C14A—H14A 120.8 C13B—C14B—H14B 120.7 
F2A—C15A—C16A 119.04 (18) F2B—C15B—C16B 118.99 (18) 
F2A—C15A—C14A 117.92 (17) F2B—C15B—C14B 118.19 (18) 
C16A—C15A—C14A 123.04 (18) C16B—C15B—C14B 122.82 (18) 
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C15A—C16A—C17A 117.81 (18) C15B—C16B—C17B 118.24 (18) 
C15A—C16A—H16A 121.1 C15B—C16B—H16B 120.9 
C17A—C16A—H16A 121.1 C17B—C16B—H16B 120.9 
C16A—C17A—C12A 121.44 (18) C16B—C17B—C12B 121.33 (18) 
C16A—C17A—H17A 119.3 C16B—C17B—H17B 119.3 
C12A—C17A—H17A 119.3 C12B—C17B—H17B 119.3 
O1A—C2A—C3A—C8A -18.2 (3) O1B—C2B—C3B—C8B 178.79 (18) 
C1A—C2A—C3A—C8A 162.02 (17) C1B—C2B—C3B—C8B -0.8 (3) 
O1A—C2A—C3A—C4A 161.39 (19) O1B—C2B—C3B—C4B -1.9 (3) 
C1A—C2A—C3A—C4A -18.4 (3) C1B—C2B—C3B—C4B 178.46 (18) 
C8A—C3A—C4A—C5A 1.1 (3) C8B—C3B—C4B—C5B 1.3 (3) 
C2A—C3A—C4A—C5A -178.53 (18) C2B—C3B—C4B—C5B -178.04 (18) 
C3A—C4A—C5A—C6A -0.4 (3) C3B—C4B—C5B—C6B -1.6 (3) 
C4A—C5A—C6A—F1A 180.00 (17) C4B—C5B—C6B—F1B -178.85 (18) 
C4A—C5A—C6A—C7A -0.7 (3) C4B—C5B—C6B—C7B 0.0 (3) 
F1A—C6A—C7A—C8A -179.50 (17) F1B—C6B—C7B—C8B -179.33 (17) 
C5A—C6A—C7A—C8A 1.2 (3) C5B—C6B—C7B—C8B 1.8 (3) 
C6A—C7A—C8A—C3A -0.6 (3) C6B—C7B—C8B—O2B -178.01 (17) 
C6A—C7A—C8A—O2A -175.83 (17) C6B—C7B—C8B—C3B -2.1 (3) 
C4A—C3A—C8A—C7A -0.5 (3) C9B—O2B—C8B—C7B -51.3 (2) 
C2A—C3A—C8A—C7A 179.03 (17) C9B—O2B—C8B—C3B 132.62 (17) 
C4A—C3A—C8A—O2A 174.70 (16) C4B—C3B—C8B—C7B 0.6 (3) 
C2A—C3A—C8A—O2A -5.7 (3) C2B—C3B—C8B—C7B 179.89 (18) 
C9A—O2A—C8A—C7A -74.0 (2) C4B—C3B—C8B—O2B 176.51 (16) 
C9A—O2A—C8A—C3A 110.55 (19) C2B—C3B—C8B—O2B -4.2 (3) 
C8A—O2A—C9A—O3A 7.0 (3) C8B—O2B—C9B—O3B -4.6 (3) 
C8A—O2A—C9A—C10A -172.49 (15) C8B—O2B—C9B—C10B 176.77 (15) 
O3A—C9A—C10A—C11A -166.69 (19) O3B—C9B—C10B—C11B 177.12 (19) 
O2A—C9A—C10A—C11A 12.8 (3) O2B—C9B—C10B—C11B -4.2 (3) 
C9A—C10A—C11A—C12A 176.92 (18) C9B—C10B—C11B—C12B 178.60 (18) 
C10A—C11A—C12A—C17A -176.24 (19) C10B—C11B—C12B—C17B -175.23 (18) 
C10A—C11A—C12A—C13A 2.7 (3) C10B—C11B—C12B—C13B 4.0 (3) 
C17A—C12A—C13A—C14A 0.4 (3) C17B—C12B—C13B—C14B -0.3 (3) 
C11A—C12A—C13A—C14A -178.47 (19) C11B—C12B—C13B—C14B -179.46 (18) 
C12A—C13A—C14A—C15A 0.2 (3) C12B—C13B—C14B—C15B 0.0 (3) 
C13A—C14A—C15A—F2A 179.92 (18) C13B—C14B—C15B—F2B -178.91 (18) 
C13A—C14A—C15A—C16A -0.2 (3) C13B—C14B—C15B—C16B 0.8 (3) 
F2A—C15A—C16A—C17A 179.56 (17) F2B—C15B—C16B—C17B 178.38 (17) 
C14A—C15A—C16A—C17A -0.3 (3) C14B—C15B—C16B—C17B -1.3 (3) 
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C15A—C16A—C17A—C12A 0.9 (3) C15B—C16B—C17B—C12B 1.0 (3) 
C13A—C12A—C17A—C16A -1.0 (3) C13B—C12B—C17B—C16B -0.3 (3) 




A1-5   X Ray crystallographic data of (E)-2-acetylphenyl-3-(4-methoxyphenyl)acrylate 
Crystal data 
  C18H16O4 Dx = 1.328 Mg m-3 
Mr = 296.31 Mo Kρradiation, λ = 0.71073 Å 
Orthorhombic, Pbca Cell parameters from 25075 reflections 
a = 7.7165 (2) Å θ = 3.0–28.3° 
b = 14.2736 (3) Å  µ= 0.09 mm-1 
c = 26.9200 (6) Å T = 173 K 
V = 2965.03 (12)  Å3 Block, colourless 
Z = 8 0.53 × 0.42 × 0.27 mm 




  Bruker Kappa Duo Apex II Diffractometer 3677 independent reflections 
Radiation source: fine-focus sealed tube 3217 reflections with I > 2(I) 
graphite Rint = 0.029 
0.5° φ scans and ω scans θmax = 28.3°, θmin = 3.0° 
Absorption correction: multi-scan  
SADABS (Sheldrick, 1997) 
h = -10→10 
Tmin = 0.952, Tmax = 0.975 k = -19→18 
25075 measured reflections l = -35→27 
 
Refinement 
 Refinement on F2 Primary atom site location: structure-invariant 
direct methods 
Least-squares matrix: full Secondary atom site location: difference 
Fourier map 
R[F2 > 2σ(F2)] = 0.037 Hydrogen site location: inferred from 
neighbouring sites 
wR(F2) = 0.098 H-atom parameters constrained 
S = 1.02 w = 1/[σ2(Fo
2) + (0.049P)2 + 1.0541P]   
where P = (Fo
2 + 2Fc
2)/3 
3677 reflections (∆/σ)max < 0.001 
201 parameters ∆ρmax = 0.34 e Å
-3 





Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2) 
 x y z Uiso*/Ueq 
O1 0.45244 (11) 0.49905 (6) 0.17391 (3) 0.0320 (2) 
O2 0.31420 (10) 0.36157 (5) 0.11532 (3) 0.02206 (17) 
O3 0.08890 (11) 0.40232 (6) 0.16382 (3) 0.02668 (18) 
O4 0.08027 (12) 0.79216 (6) -0.08812 (3) 0.0316 (2) 
C1 0.70962 (15) 0.45828 (8) 0.21663 (4) 0.0268 (2) 
H1A 0.7392 0.5243 0.2113 0.040* 
H1B 0.8004 0.4185 0.2024 0.040* 
H1C 0.7001 0.4461 0.2523 0.040* 
C2 0.54008 (13) 0.43694 (7) 0.19193 (4) 0.0199 (2) 
C3 0.48195 (13) 0.33652 (7) 0.19053 (4) 0.0182 (2) 
C4 0.53877 (14) 0.27337 (7) 0.22689 (4) 0.0209 (2) 
H4 0.6162 0.2942 0.2520 0.025* 
C5 0.48361 (15) 0.18071 (7) 0.22675 (4) 0.0235 (2) 
H5 0.5215 0.1390 0.2520 0.028* 
C6 0.37317 (15) 0.14911 (7) 0.18966 (4) 0.0244 (2) 
H6 0.3365 0.0856 0.1894 0.029* 
C7 0.31599 (14) 0.21011 (7) 0.15289 (4) 0.0224 (2) 
H7 0.2412 0.1885 0.1273 0.027* 
C8 0.36909 (13) 0.30272 (7) 0.15393 (4) 0.0189 (2) 
C9 0.17167 (14) 0.41441 (7) 0.12636 (4) 0.0201 (2) 
C10 0.13112 (14) 0.48570 (7) 0.08915 (4) 0.0224 (2) 
H10 0.0347 0.5253 0.0956 0.027* 
C11 0.21787 (14) 0.49999 (8) 0.04699 (4) 0.0228 (2) 
H11 0.3106 0.4585 0.0396 0.027* 
C12 0.18128 (14) 0.57483 (7) 0.01116 (4) 0.0219 (2) 
C13 0.26580 (14) 0.57645 (8) -0.03460 (4) 0.0233 (2) 
H13 0.3456 0.5279 -0.0424 0.028* 
C14 0.23633 (14) 0.64739 (8) -0.06925 (4) 0.0234 (2) 
H14 0.2952 0.6471 -0.1002 0.028* 
C15 0.11985 (14) 0.71846 (8) -0.05791 (4) 0.0232 (2) 
C16 0.03313 (16) 0.71780 (8) -0.01233 (4) 0.0284 (2) 
H16 -0.0471 0.7661 -0.0046 0.034* 
C17 0.06367 (16) 0.64736 (8) 0.02136 (4) 0.0273 (2) 
H17 0.0039 0.6478 0.0522 0.033* 
C18 0.16381 (17) 0.79671 (9) -0.13536 (4) 0.0323 (3) 
H18A 0.2895 0.8005 -0.1306 0.048* 
26 
H18B 0.1236 0.8523 -0.1533 0.048* 
H18C 0.1357 0.7404 -0.1546 0.048* 
 
Atomic displacement parameters (Å2) 
 U11 U22 U33 U12 U13 U23 
O1 0.0287 (4) 0.0192 (4) 0.0482 (5) 0.0000 (3) -0.0077 (4) 0.0055 (3) 
O2 0.0245 (4) 0.0243 (4) 0.0173 (3) 0.0045 (3) 0.0001 (3) 0.0035 (3) 
O3 0.0249 (4) 0.0304 (4) 0.0247 (4) 0.0038 (3) 0.0033 (3) 0.0055 (3) 
O4 0.0373 (5) 0.0314 (4) 0.0262 (4) 0.0107 (4) 0.0059 (3) 0.0111 (3) 
C1 0.0255 (5) 0.0235 (5) 0.0313 (5) -0.0027 (4) -0.0040 (4) -0.0026 (4) 
C2 0.0207 (5) 0.0187 (4) 0.0201 (4) -0.0002 (4) 0.0028 (4) -0.0005 (4) 
C3 0.0179 (4) 0.0172 (4) 0.0194 (4) 0.0014 (4) 0.0023 (4) 0.0002 (3) 
C4 0.0218 (5) 0.0214 (5) 0.0195 (5) 0.0023 (4) -0.0010 (4) 0.0001 (4) 
C5 0.0278 (5) 0.0203 (5) 0.0225 (5) 0.0036 (4) 0.0016 (4) 0.0042 (4) 
C6 0.0284 (5) 0.0170 (5) 0.0277 (5) -0.0010 (4) 0.0037 (4) 0.0004 (4) 
C7 0.0228 (5) 0.0223 (5) 0.0220 (5) -0.0011 (4) -0.0003 (4) -0.0028 (4) 
C8 0.0195 (5) 0.0201 (5) 0.0171 (4) 0.0028 (4) 0.0022 (4) 0.0020 (3) 
C9 0.0199 (5) 0.0203 (5) 0.0201 (5) -0.0008 (4) -0.0036 (4) -0.0003 (4) 
C10 0.0224 (5) 0.0224 (5) 0.0223 (5) 0.0028 (4) -0.0038 (4) 0.0017 (4) 
C11 0.0226 (5) 0.0229 (5) 0.0229 (5) 0.0017 (4) -0.0039 (4) 0.0019 (4) 
C12 0.0227 (5) 0.0226 (5) 0.0204 (5) -0.0002 (4) -0.0027 (4) 0.0026 (4) 
C13 0.0217 (5) 0.0243 (5) 0.0240 (5) 0.0026 (4) -0.0003 (4) 0.0012 (4) 
C14 0.0230 (5) 0.0278 (5) 0.0195 (5) 0.0003 (4) 0.0020 (4) 0.0028 (4) 
C15 0.0249 (5) 0.0236 (5) 0.0210 (5) 0.0010 (4) -0.0016 (4) 0.0040 (4) 
C16 0.0332 (6) 0.0273 (5) 0.0246 (5) 0.0094 (5) 0.0045 (4) 0.0026 (4) 
C17 0.0331 (6) 0.0288 (5) 0.0200 (5) 0.0051 (5) 0.0044 (4) 0.0028 (4) 
C18 0.0354 (6) 0.0347 (6) 0.0268 (6) 0.0044 (5) 0.0053 (5) 0.0121 (5) 
 
Geometric parameters (Å, º) 
O1—C2 1.2160 (13) C7—H7 0.9500 
O2—C9 1.3662 (13) C9—C10 1.4618 (14) 
O2—C8 1.4018 (12) C10—C11 1.3334 (15) 
O3—C9 1.2060 (13) C10—H10 0.9500 
O4—C15 1.3644 (13) C11—C12 1.4667 (14) 
O4—C18 1.4271 (14) C11—H11 0.9500 
C1—C2 1.4988 (15) C12—C13 1.3941 (14) 
C1—H1A 0.9800 C12—C17 1.4038 (15) 
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C1—H1B 0.9800 C13—C14 1.3954 (14) 
C1—H1C 0.9800 C13—H13 0.9500 
C2—C3 1.5023 (14) C14—C15 1.3893 (15) 
C3—C8 1.4008 (14) C14—H14 0.9500 
C3—C4 1.4010 (14) C15—C16 1.3976 (15) 
C4—C5 1.3895 (15) C16—C17 1.3744 (15) 
C4—H4 0.9500 C16—H16 0.9500 
C5—C6 1.3880 (16) C17—H17 0.9500 
C5—H5 0.9500 C18—H18A 0.9800 
C6—C7 1.3902 (15) C18—H18B 0.9800 
C6—H6 0.9500 C18—H18C 0.9800 
C7—C8 1.3843 (14)   
C9—O2—C8 114.38 (8) O2—C9—C10 114.05 (9) 
C15—O4—C18 117.72 (9) C11—C10—C9 125.61 (10) 
C2—C1—H1A 109.5 C11—C10—H10 117.2 
C2—C1—H1B 109.5 C9—C10—H10 117.2 
H1A—C1—H1B 109.5 C10—C11—C12 125.07 (10) 
C2—C1—H1C 109.5 C10—C11—H11 117.5 
H1A—C1—H1C 109.5 C12—C11—H11 117.5 
H1B—C1—H1C 109.5 C13—C12—C17 117.58 (10) 
O1—C2—C1 120.95 (10) C13—C12—C11 120.21 (10) 
O1—C2—C3 121.30 (9) C17—C12—C11 122.20 (10) 
C1—C2—C3 117.75 (9) C12—C13—C14 121.77 (10) 
C8—C3—C4 117.67 (9) C12—C13—H13 119.1 
C8—C3—C2 122.13 (9) C14—C13—H13 119.1 
C4—C3—C2 120.19 (9) C15—C14—C13 119.24 (10) 
C5—C4—C3 120.98 (10) C15—C14—H14 120.4 
C5—C4—H4 119.5 C13—C14—H14 120.4 
C3—C4—H4 119.5 O4—C15—C14 125.22 (10) 
C6—C5—C4 119.96 (9) O4—C15—C16 114.92 (10) 
C6—C5—H5 120.0 C14—C15—C16 119.85 (10) 
C4—C5—H5 120.0 C17—C16—C15 120.14 (10) 
C5—C6—C7 120.23 (10) C17—C16—H16 119.9 
C5—C6—H6 119.9 C15—C16—H16 119.9 
C7—C6—H6 119.9 C16—C17—C12 121.42 (10) 
C8—C7—C6 119.33 (10) C16—C17—H17 119.3 
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C8—C7—H7 120.3 C12—C17—H17 119.3 
C6—C7—H7 120.3 O4—C18—H18A 109.5 
C7—C8—C3 121.81 (9) O4—C18—H18B 109.5 
C7—C8—O2 117.89 (9) H18A—C18—H18B 109.5 
C3—C8—O2 120.20 (9) O4—C18—H18C 109.5 
O3—C9—O2 121.95 (9) H18A—C18—H18C 109.5 
O3—C9—C10 124.00 (10) H18B—C18—H18C 109.5 
O1—C2—C3—C8 25.77 (15) C8—O2—C9—C10 171.05 (9) 
C1—C2—C3—C8 -154.62 (10) O3—C9—C10—C11 -178.81 (11) 
O1—C2—C3—C4 -153.44 (11) O2—C9—C10—C11 1.47 (16) 
C1—C2—C3—C4 26.18 (14) C9—C10—C11—C12 -176.73 (10) 
C8—C3—C4—C5 -0.54 (15) C10—C11—C12—C13 -172.04 (11) 
C2—C3—C4—C5 178.70 (9) C10—C11—C12—C17 8.79 (17) 
C3—C4—C5—C6 1.23 (16) C17—C12—C13—C14 0.28 (16) 
C4—C5—C6—C7 -0.67 (16) C11—C12—C13—C14 -178.93 (10) 
C5—C6—C7—C8 -0.57 (16) C12—C13—C14—C15 0.07 (17) 
C6—C7—C8—C3 1.29 (16) C18—O4—C15—C14 0.47 (17) 
C6—C7—C8—O2 177.74 (9) C18—O4—C15—C16 -179.69 (11) 
C4—C3—C8—C7 -0.73 (15) C13—C14—C15—O4 179.43 (11) 
C2—C3—C8—C7 -179.96 (9) C13—C14—C15—C16 -0.41 (17) 
C4—C3—C8—O2 -177.11 (9) O4—C15—C16—C17 -179.46 (11) 
C2—C3—C8—O2 3.67 (14) C14—C15—C16—C17 0.39 (18) 
C9—O2—C8—C7 97.15 (11) C15—C16—C17—C12 -0.02 (19) 
C9—O2—C8—C3 -86.34 (11) C13—C12—C17—C16 -0.31 (17) 




A1-6   X Ray crystallographic data of 2'-Fluro-2-styrylchromone 
Crystal data 
  C17H11FO2 F(000) = 552 
Mr = 266.26 Dx = 1.395 Mg m
-3 
Monoclinic, P21/c Mo Kρ radiation, λ= 0.71073 Å 
a = 13.0965 (16) Å Cell parameters from 6596 reflections 
b = 4.9113 (5) Å θ = 1.6–28.4° 
c = 19.736 (2) Å µ = 0.10 mm-1 
β = 93.140 (3)° T = 173 K 
V = 1267.5 (2)  Å3 Needle, colourless 
Z = 4 0.23 × 0.03 × 0.03 mm 
 
Data collection 
  Bruker Kappa Duo Apex II Diffractometer 1657 reflections with I > 2(I) 
Radiation source: fine-focus sealed tube Rint = 0.048 
graphite θmax = 28.4°, θmin = 1.6° 
0.5° φ scans and ῳ scans h = -15→17 
6596 measured reflections k = -6→5 
3169 independent reflections l = -26→23 
 
Refinement 
  Refinement on F2 Secondary atom site location: difference Fourier 
map 
Least-squares matrix: full Hydrogen site location: inferred from 
neighbouring sites 
R[F2 > 2σ(F2)] = 0.050 H-atom parameters constrained 
wR(F2) = 0.118 w = 1/[σ2(Fo
2) + (0.0473P)2]   
where P = (Fo
2 + 2Fc
2)/3 
S = 0.98 (∆/λ)max < 0.001 
3169 reflections ∆ρmax = 0.26 e Å
-3 
182 parameters ∆ρ min = -0.19 e Å
-3 
0 restraints Extinction correction: SHELXL, 
Fc*=kFc[1+0.001xFc2λ3/sin(2θ)]-1/4 
Primary atom site location: structure-invariant 
direct methods 




Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2) 
 x y z Uiso*/Ueq 
F1 0.11364 (9) 1.4331 (3) 0.42702 (7) 0.0456 (4) 
O1 0.20328 (10) 0.8161 (3) 0.25042 (7) 0.0298 (4) 
O2 0.41846 (10) 0.3760 (3) 0.15406 (8) 0.0404 (4) 
C1 0.28604 (14) 1.4138 (4) 0.39919 (10) 0.0258 (5) 
C2 0.21127 (15) 1.5275 (4) 0.43779 (10) 0.0295 (5) 
C3 0.22903 (17) 1.7248 (4) 0.48598 (11) 0.0348 (5) 
H3 0.1748 1.7959 0.5107 0.042* 
C4 0.32823 (17) 1.8178 (4) 0.49767 (11) 0.0357 (5) 
H4 0.3428 1.9548 0.5308 0.043* 
C5 0.40641 (16) 1.7112 (4) 0.46114 (11) 0.0348 (5) 
H5 0.4745 1.7747 0.4694 0.042* 
C6 0.38559 (15) 1.5138 (4) 0.41297 (10) 0.0316 (5) 
H6 0.4400 1.4429 0.3883 0.038* 
C7 0.26046 (15) 1.2081 (4) 0.34762 (10) 0.0278 (5) 
H7 0.1902 1.1793 0.3353 0.033* 
C8 0.32877 (15) 1.0576 (4) 0.31657 (10) 0.0278 (5) 
H8 0.3989 1.0871 0.3294 0.033* 
C9 0.30567 (14) 0.8534 (4) 0.26507 (10) 0.0269 (5) 
C10 0.37750 (15) 0.7116 (4) 0.23420 (10) 0.0286 (5) 
H10 0.4474 0.7473 0.2465 0.034* 
C11 0.35339 (15) 0.5077 (4) 0.18327 (10) 0.0288 (5) 
C12 0.24286 (14) 0.4687 (4) 0.16872 (10) 0.0248 (4) 
C13 0.20474 (15) 0.2754 (4) 0.12143 (10) 0.0300 (5) 
H13 0.2510 0.1640 0.0984 0.036* 
C14 0.10117 (16) 0.2454 (4) 0.10802 (11) 0.0355 (5) 
H14 0.0761 0.1145 0.0758 0.043* 
C15 0.03324 (16) 0.4082 (4) 0.14197 (12) 0.0397 (6) 
H15 -0.0382 0.3884 0.1322 0.048* 
C16 0.06783 (15) 0.5964 (4) 0.18916 (11) 0.0348 (5) 
H16 0.0212 0.7054 0.2125 0.042* 
C17 0.17267 (15) 0.6241 (4) 0.20213 (10) 0.0272 (5) 
 
Atomic displacement parameters (Å2) 
 U11 U22 U33 U12 U13 U23 
F1 0.0289 (7) 0.0480 (8) 0.0602 (9) -0.0013 (6) 0.0042 (6) -0.0085 (7) 
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O1 0.0240 (7) 0.0317 (8) 0.0333 (8) -0.0004 (6) -0.0001 (6) -0.0064 (7) 
O2 0.0283 (8) 0.0500 (10) 0.0431 (9) 0.0038 (7) 0.0031 (7) -0.0126 (8) 
C1 0.0302 (11) 0.0218 (10) 0.0250 (11) 0.0008 (8) -0.0024 (8) 0.0046 (9) 
C2 0.0256 (11) 0.0297 (12) 0.0327 (12) -0.0004 (9) -0.0020 (9) 0.0058 (10) 
C3 0.0432 (13) 0.0293 (12) 0.0327 (13) 0.0030 (10) 0.0086 (10) -0.0017 (10) 
C4 0.0525 (15) 0.0289 (12) 0.0254 (12) -0.0042 (10) -0.0007 (10) -0.0022 (10) 
C5 0.0336 (12) 0.0339 (12) 0.0361 (13) -0.0037 (9) -0.0053 (10) -0.0038 (10) 
C6 0.0287 (12) 0.0336 (12) 0.0324 (12) -0.0003 (9) 0.0012 (9) -0.0004 (10) 
C7 0.0266 (11) 0.0266 (11) 0.0298 (11) -0.0041 (9) -0.0030 (8) 0.0022 (9) 
C8 0.0280 (11) 0.0276 (11) 0.0272 (11) -0.0029 (9) -0.0028 (8) 0.0023 (9) 
C9 0.0232 (10) 0.0276 (11) 0.0296 (11) -0.0029 (8) 0.0000 (8) 0.0036 (9) 
C10 0.0249 (11) 0.0317 (11) 0.0291 (12) -0.0042 (9) -0.0005 (9) 0.0012 (9) 
C11 0.0265 (11) 0.0307 (12) 0.0293 (12) 0.0020 (9) 0.0023 (9) 0.0038 (10) 
C12 0.0249 (10) 0.0253 (10) 0.0243 (11) -0.0004 (8) 0.0020 (8) 0.0037 (9) 
C13 0.0340 (12) 0.0283 (11) 0.0280 (12) -0.0008 (9) 0.0033 (9) -0.0011 (9) 
C14 0.0348 (13) 0.0336 (12) 0.0379 (13) -0.0066 (10) -0.0014 (10) -0.0061 (10) 
C15 0.0260 (11) 0.0416 (14) 0.0510 (15) -0.0018 (10) -0.0023 (10) -0.0088 (12) 
C16 0.0253 (11) 0.0343 (12) 0.0448 (14) 0.0009 (9) 0.0025 (10) -0.0079 (10) 
C17 0.0290 (11) 0.0258 (11) 0.0269 (11) -0.0018 (9) 0.0017 (9) -0.0006 (9) 
 
Geometric parameters (Å, º) 
F1—C2 1.366 (2) C8—C9 1.448 (3) 
O1—C9 1.369 (2) C8—H8 0.9500 
O1—C17 1.384 (2) C9—C10 1.343 (3) 
O2—C11 1.237 (2) C10—C11 1.442 (3) 
C1—C2 1.390 (3) C10—H10 0.9500 
C1—C6 1.406 (3) C11—C12 1.473 (3) 
C1—C7 1.460 (3) C12—C17 1.389 (3) 
C2—C3 1.369 (3) C12—C13 1.404 (3) 
C3—C4 1.385 (3) C13—C14 1.376 (3) 
C3—H3 0.9500 C13—H13 0.9500 
C4—C5 1.387 (3) C14—C15 1.395 (3) 
C4—H4 0.9500 C14—H14 0.9500 
C5—C6 1.375 (3) C15—C16 1.371 (3) 
C5—H5 0.9500 C15—H15 0.9500 
C6—H6 0.9500 C16—C17 1.390 (3) 
C7—C8 1.335 (3) C16—H16 0.9500 
C7—H7 0.9500   
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C9—O1—C17 118.68 (15) C10—C9—C8 123.57 (18) 
C2—C1—C6 115.30 (18) O1—C9—C8 113.93 (17) 
C2—C1—C7 121.23 (18) C9—C10—C11 122.99 (18) 
C6—C1—C7 123.47 (19) C9—C10—H10 118.5 
F1—C2—C3 118.06 (18) C11—C10—H10 118.5 
F1—C2—C1 117.38 (18) O2—C11—C10 123.91 (18) 
C3—C2—C1 124.56 (19) O2—C11—C12 122.41 (18) 
C2—C3—C4 118.1 (2) C10—C11—C12 113.68 (17) 
C2—C3—H3 120.9 C17—C12—C13 117.83 (17) 
C4—C3—H3 120.9 C17—C12—C11 120.34 (18) 
C3—C4—C5 120.1 (2) C13—C12—C11 121.83 (18) 
C3—C4—H4 119.9 C14—C13—C12 120.75 (19) 
C5—C4—H4 119.9 C14—C13—H13 119.6 
C6—C5—C4 120.1 (2) C12—C13—H13 119.6 
C6—C5—H5 119.9 C13—C14—C15 119.6 (2) 
C4—C5—H5 119.9 C13—C14—H14 120.2 
C5—C6—C1 121.8 (2) C15—C14—H14 120.2 
C5—C6—H6 119.1 C16—C15—C14 121.13 (19) 
C1—C6—H6 119.1 C16—C15—H15 119.4 
C8—C7—C1 124.71 (18) C14—C15—H15 119.4 
C8—C7—H7 117.6 C15—C16—C17 118.51 (19) 
C1—C7—H7 117.6 C15—C16—H16 120.7 
C7—C8—C9 125.90 (19) C17—C16—H16 120.7 
C7—C8—H8 117.1 O1—C17—C12 121.81 (17) 
C9—C8—H8 117.1 O1—C17—C16 116.06 (17) 
C10—C9—O1 122.50 (18) C12—C17—C16 122.13 (19) 
C6—C1—C2—F1 -178.85 (16) C9—C10—C11—O2 179.6 (2) 
C7—C1—C2—F1 2.0 (3) C9—C10—C11—C12 -0.4 (3) 
C6—C1—C2—C3 0.5 (3) O2—C11—C12—C17 -179.08 (19) 
C7—C1—C2—C3 -178.62 (18) C10—C11—C12—C17 0.9 (2) 
F1—C2—C3—C4 179.05 (18) O2—C11—C12—C13 1.1 (3) 
C1—C2—C3—C4 -0.3 (3) C10—C11—C12—C13 -178.86 (18) 
C2—C3—C4—C5 -0.1 (3) C17—C12—C13—C14 1.1 (3) 
C3—C4—C5—C6 0.3 (3) C11—C12—C13—C14 -179.08 (18) 
C4—C5—C6—C1 -0.1 (3) C12—C13—C14—C15 -0.2 (3) 
C2—C1—C6—C5 -0.3 (3) C13—C14—C15—C16 -0.7 (3) 
C7—C1—C6—C5 178.82 (19) C14—C15—C16—C17 0.7 (3) 
C2—C1—C7—C8 -168.4 (2) C9—O1—C17—C12 0.3 (3) 
C6—C1—C7—C8 12.5 (3) C9—O1—C17—C16 -179.66 (17) 
33 
C1—C7—C8—C9 -179.67 (18) C13—C12—C17—O1 178.85 (17) 
C17—O1—C9—C10 0.3 (3) C11—C12—C17—O1 -0.9 (3) 
C17—O1—C9—C8 -179.59 (16) C13—C12—C17—C16 -1.2 (3) 
C7—C8—C9—C10 178.4 (2) C11—C12—C17—C16 179.04 (18) 
C7—C8—C9—O1 -1.8 (3) C15—C16—C17—O1 -179.73 (19) 
O1—C9—C10—C11 -0.2 (3) C15—C16—C17—C12 0.3 (3) 
C8—C9—C10—C11 179.63 (18)   
 
Hydrogen-bond geometry (Å, °) 
D—H···A D—H H···A D···A D—H···A 
C7—H7···O1 0.95 2.46 2.791(2) 100 
 














































































































































































































































































































































































































